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SUMMARY 
 
The congenital sodium diarrhea is a very rare genetic disease. Children affected by this 
condition suffer from a severe diarrhea characterized by watery stools with a high fecal loss 
of sodium and bicarbonates, resulting in hyponatremic dehydration and metabolic acidosis. 
Genetic analyses have identified mutations in the Spint2 gene as a cause of this disease. 
The spint2 gene encodes a transmembrane serine protease inhibitor expressed in various 
epithelial tissues including the gastro-intestinal tract and renal tubules. The physiological role 
of Spint2 is completely unknown. In addition, physiological partners of Spint2 are still to be 
identified and the mechanism of inhibition by Spint2 remains elusive. Therefore, the aim of 
this project was to get insights about the function and the role of Spint2 in the context of the 
congenital sodium diarrhea in order to better understand the pathophysiology of diarrheas and 
maybe identify new therapeutic targets.  
A functional assay in Xenopus oocytes identified the membrane-bound serine proteases 
CAP1 and Tmprss13 as potential targets of Spint2 because both proteases were no longer 
inhibited by the mutant Spint2 Y163C that has been associated with the congenital diarrhea. 
Further functional and biochemical experiments suggested that the inhibition of Tmprss13 by 
Spint2 occurs though a complex interaction between both proteins. 
The effects of membrane-bound serine proteases on the Na
+
-H
+
 exchanger NHE3, 
which has been proposed to be involved in the pathogenesis of the congenital sodium 
diarrhea, were also tested. A specific cleavage of NHE3 by the membrane-bound serine 
protease Tmprss3 was observed in biochemical experiments.  
Unfortunately, the physiological relevance of these results could not be assessed in vivo 
since the conditional Spint2 knockout mouse model that we generated showed a reduction in 
Spint2 expression of only 50% and displayed no phenotype. 
Briefly, this work provides two new potential partners of Spint2 and emphasizes a 
putative regulation of NHE3 by membrane-bound serine proteases. Further work done in 
animal models and cell lines is required to assess the physiological relevance of these results 
and to obtain additional data about Spint2 and the congenital diarrhea. 
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RÉSUMÉ 
 
La diarrhée congénitale de sodium est une maladie génétique très rare. Les enfants 
touchés par cette maladie présentent une diarrhée aqueuse sévère accompagnée d’une perte 
fécale de sodium et bicarbonates causant une déshydratation hyponatrémique et une acidose 
métabolique. Des analyses génétiques ont identifié des mutations du gène Spint2 comme 
cause de cette maladie. 
Le gène Spint2 code pour un inhibiteur de sérine protéase transmembranaire exprimé 
dans divers épithéliums tels que ceux du tube digestif ou des tubules rénaux. Le rôle 
physiologique de Spint2 n’est pas connu. De plus, aucun partenaire physiologique de Spint2 
n’a été identifié et le mécanisme d’inhibition par Spint2 nous est peu connu. Le but de ce 
projet est donc d’obtenir de plus amples informations concernant la fonction et le rôle de 
Spint2 dans le contexte de la diarrhée congénitale de sodium, cela afin de mieux comprendre 
la physiopathologie des diarrhées et peut-être d’identifier de nouvelles cibles thérapeutiques. 
Un test fonctionnel dans les ovocytes de Xenopus a identifié les sérine protéases 
transmembranaires CAP1 et Tmprss13 comme potentielles cibles de Spint2 dans la mesure où 
ces deux protéases n’étaient plus bloquées par le mutant de Spint2 Y163C qui est associé avec 
la diarrhée congénitale de sodium. Des expériences fonctionnelles et biochimiques plus 
poussées suggèrent que l’inhibition de Tmprss13 par Spint2 est le résultat d’une interaction 
complexe entre ces deux protéines. 
Les effets des sérine protéases transmembranaires sur l’échangeur Na+-H+ NHE3, qui 
pourrait être impliqué dans la pathogenèse de la diarrhée congénitale de sodium ont aussi été 
testés. Un clivage spécifique de NHE3 par la sérine protéase transmembranaire Tmprss3 a été 
observé lors d’expériences biochimiques. 
Malheureusement, la pertinence physiologique de ces résultats n’a pas pu être évaluée 
in vivo, étant donné que le modèle de souris knockout conditionnel de Spint2 que nous avons 
créé ne montrait une réduction de l’expression de Spint2 que de 50% et aucun phénotype. 
En résumé, ce travail met en évidence deux nouveaux partenaires possibles de Spint2, 
ainsi qu’une potentielle régulation de NHE3 par des sérine protéases transmembranaires. Des 
expériences supplémentaires faites dans des modèles animaux et lignées cellulaires sont 
requises pour évaluer la pertinence physiologique de ces données et pour obtenir de plus 
amples informations au sujet de Spint2 et de la diarrhée congénitale de sodium. 
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ABBREVIATIONS 
AE-1 Anion exchanger 1 
AIDS acquired immunodeficiency syndrome 
BPTI bovine pancreatic trypsin inhibitor (also known as aprotinin) 
cAMP cyclic adenosine monophosphate 
CAP channel activating protease 
CFTR cystic fibrosis transmembrane conductance regulator 
cGMP cyclic guanosine monophosphate 
CMTI cucurbita maxima trypsin inhibitor 
DPPIV dipeptidyl peptidase IV 
DRA down-regulated in colonic adenomas 
DSS dextran sodium sulfate 
ENaC epithelial sodium channel 
ENS enteric nervous system 
ES cells embryonic stem cells 
GC-C guanylate cyclase C receptor 
GPI glycophosphatidylinositol 
GUCY2C guanylate cyclase C receptor 
HAI hepatocyte growth factor activator inhibitor 
HGF hepatocyte growth factor 
HGFA hepatocyte growth factor activator 
HIV human immunodeficiency virus 
INFγ interferon γ 
MDCK Madin-Darbey canine kidney (cells) 
NBC-1 Na
+
-HCO3
-
 cotransporter 
NHE Na
+
-H
+
-exchanger 
NK2CL Na
+
-K
+
-2Cl
—
cotransporter 
OMSVP3 third domain of silver pheasant ovomucoid inhibitor (Kazal-type) 
ORT oral rehydration therapy 
PAT-1 putative anion transporter 1 
RCL reactive center loop 
SBTI soybean trypsin inhibitor 
SGLT1 Na
+
-couple glucose transporter, member 1 
Slc solute carrier 
SSI Subtilisin inhibitor 
Tmprss transmembrane protease, serine 
TNFα tumor necrosis factor α 
VIP vasoactive intestinal peptide 
8 
 
INTRODUCTION 
 
PROLOGUE ABOUT SALT AND WATER BALANCE 
 
Complex living organisms such as the human body are composed of a huge number of 
cells (about 10
14
 for the human body). These cells not only live on their own but also interact 
with each other to form tissues, organs and finally systems, each having a specific role. From 
the level of the cells to the level of the systems, biological processes are tightly regulated to 
permit life. The control of all these parameters is called homeostasis and remarkably occurs 
even though the external environment surrounding complex living organisms varies a lot (e.g. 
changes in temperature, variable access to food and water, presence of other complex living 
organisms and microorganisms). This external world was called “milieu extérieur” by the 
French physiologist Claude Bernard, in opposite to the “milieu intérieur”, in which the cells 
of the human body live.  
An adult with a body weight of 70 kg is made of 60% of water, namely 42 liters. Two-
third (28 liters) of this volume is present within the cells: this is the intracellular fluid volume. 
One third (14 liters) is outside the cells: this is the extracellular fluid volume, which is 
subdivided in blood plasma (3 liters) and interstitial fluid (11 liters). Although, both the 
intracellular and extracellular fluid volumes have a similar osmolality (290 mOsm), their 
composition is different. In particular, cells have a high K
+
 concentration and low Na
+
 and Cl
-
 
concentrations, whereas low K
+
 concentration and high Na
+
 and Cl
-
 concentrations are found 
in extracellular fluid. All these parameters are vital and are thus tightly regulated. The 
regulation of extracellular fluid volume is achieved by controlling the total body content of 
NaCl (the main electrolytes), whereas extracellular osmolality is regulated via the control of 
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total body water content. These phenomena constitute the salt and water balance or 
homeostasis. 
Water / sodium homeostasis involves different organs, such as the gastro-intestinal tract, 
the central nervous system, endocrine glands, the lung, the skin and the kidney. By 
modulating the output of salt and water, the kidney plays a pivotal role in salt and water 
balance. Consequently, diseases of the kidney usually lead to disturbances of extracellular 
fluid that may be life-threatening. 
The gastrointestinal tract is the organ where the food and water intake occurs and thus, 
also contributes importantly in the maintenance of salt and water balance. As for the kidney, 
diseases involving the gut can lead to severe disorders of water and electrolytes homeostasis. 
For instance, diarrhea is a major cause of death in the world, notably in children from 
developing countries, and a very common symptom in industrial countries. In spite of this, 
mechanisms of electrolytes and water transports in the gut and their regulation are still 
incompletely understood.  
 
 
1. INTESTINAL ION TRANSPORT 
 
1.1. General considerations 
Unless otherwise specified, data of the following chapters come from the sources (1-5) and the textbook Medical Physiology, Boron and 
Boulpaep, 2nd updated edition, 2012, Saunders. 
 
Fluid absorption takes place in the small intestine and in the colon. Although the 
average fluid intake is around 1.5 to 2 L/day, these organs absorb up to 10 L of fluid every 
day. As shown in figure 1, they also have to reabsorb fluid that has been secreted along the 
entire digestive tract, namely 1.5 L/day of saliva, 2.0 L/day of gastric secretion, 1.5 L/day of 
pancreatic secretion and 0.5 L/day of bile secretion. The small intestine itself, but also the 
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colon can secrete fluid that must be reabsorbed. Most of fluid is (re)absorbed by the small 
intestine (6.5 L/day), while remaining fluid is (re)absorbed by the colon. Finally, only 0.1 
L/day is excreted with the feces. These numbers highlight the considerable capacity of 
intestinal tissues to transport water. Interestingly, water transport is entirely a passive process, 
whereas intestinal epithelial cells actively transport Na
+
 and Cl
-
. This solute movement then 
drives fluid movement. 
 
Figure 1: Fluid balance in the gastro-intestinal tract (from Boron and Boulpaep, Medical Physiology, 2nd updated edition, 
2012) 
1.2. Na
+
 absorption 
Na
+
 absorption in the small intestine and colon occurs via three different mechanisms: 
(1) nutrient-coupled Na
+
 absorption, (2) electroneutral NaCl absorption and (3) electrogenic 
Na
+
 absorption. In each case, the Na-K-pump on the basolateral side of epithelial cells, which 
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actively pumps 3 Na
+
 ions out of the cell and 2 K
+
 ions into the cells, is the driving force for 
Na
+
 entry in the apical side of epithelial cells. 
 
1.2.1. Nutrient-coupled Na
+
 absorption (figure 2) 
First described in the 1960s (6), nutrient-coupled absorption is an important mechanism 
of Na
+
 absorption directly after a meal. Its contribution between periods of food intake is of 
limited importance. Sugars, amino acids and other nutrients transport is coupled to Na
+
 
absorption. A classic example is glucose-coupled Na
+
 absorption mediated by SGLT 
(Na/glucose cotransporter), which is followed osmotically by water absorption (7). Nutrient-
coupled Na
+
 absorption mainly occurs in jejunum. Because such transport remains intact 
during diarrheal disease, oral rehydration therapy (ORT) contains sugar, salt and water so 
that, in spite of active fluid secretion in the gut, sufficient salt and water absorption can occur 
by stimulating glucose-couple Na
+
 transport. ORT constitutes a major progress in the 
management of diarrhea around the world (8). 
 
 
Figure 2: Nutrient-coupled Na
+
 absorption (from Boron and Boulpaep, Medical Physiology, 2nd updated edition, 2012) 
 
1.2.2. Electroneutral NaCl absorption 
Na
+
 absorption is also possible in the absence of nutrients as first shown in the 1970s 
(9,10). This uptake is mediated by the Na-H exchangers NHE2 and NHE3 (11), both localized 
in apical membrane of intestinal epithelial cells (see discussion of NHE3 later). This 
transport, which couples Na
+
 entry into enterocytes to proton secretion into the intestinal 
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lumen, is stimulated in the duodenum and jejunum by HCO3
-
 rich secretion from the pancreas 
(figure 3). In other parts of the small intestine and colon, Na-H exchange is coupled to Cl-
HCO3 exchange, resulting in electroneutral NaCl absorption (figure 4). 
 
 
Figure 3: Na-H exchange (from Boron and Boulpaep, Medical Physiology, 2nd updated edition, 2012) 
 
 
Figure 4: Parallel Na-H and Cl-HCO3 exchange (from Boron and Boulpaep, Medical Physiology, 2nd updated edition, 2012) 
 
1.2.3. Electrogenic Na
+
 absorption 
Electrogenic Na
+
 absorption is exclusively found in the distal part of the colon. In this 
process, epithelial sodium channels ENaC mediate the entry of Na
+
 from the apical side of 
colonic epithelial cells (figure 5). ENaC is a Na
+
-selective ion channel responsible for 
transepithelial Na
+
 transport particularly in renal distal tubules, distal colon and lung (12,13). 
As in other tissues, electrogenic Na
+
 absorption is also regulated by the mineralocorticoid 
hormone aldosterone. 
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Figure 5: electrogenic Na
+
 absorption (from Boron and Boulpaep, Medical Physiology, 2nd updated edition, 2012) 
 
1.3. Cl
-
 absorption 
Cl
-
 absorption either occurs in a passive manner driven by the negatively charged lumen 
generated by nutrient-coupled and electrogenic Na+ absorption as seen in the jejunum and 
distal colon or via Cl-HCO3 exchangers working alone or in parallel with Na-H exchangers 
(figure 6). Two Cl-HCO3 exchangers mediate most of Cl
-
 absorption at the intestine brush 
border membrane: Slc26a3 and Slc26a6 (solute carrier family members 26a3 and 26a6 
respectively). Slc26a3, first identified in the colon, is also known as DRA (down regulated in 
colonic adenomas) because of its low expression in such tumors (14). Slc26a6, also named 
PAT-1, was discovered via data mining (15). Both exchangers are widely expressed along the 
small intestine and colon (16-18), with a higher abundance in duodenum and colon for 
Slc26a3 and duodenum, jejunum and ileum for Slc26a6. They both play a significant role in 
Cl
-
 absorption, mainly in duodenum and jejunum, as demonstrated by studies in knockout 
mice (16,19-21). In addition to its role in the proximal part of the small intestine, Slc26a3 also 
plays a role in the colon. The importance of this transporter is highlighted by the fact that 
recessive loss-of-function mutations in the SLC26A3 gene have been identified in children 
presenting a congenital chloride diarrhea (22). Although Slc26a3 and Slc26a6 have similar 
contributions in Cl
-
 absorption (minor differences exist), Slc26a3 deficiency is more severe, 
probably because of its role in distal colon. 
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Figure 6: Cl
-
 absorption (from Boron and Boulpaep, Medical Physiology, 2nd updated edition, 2012). Although not shown in this 
figure, Cl-HCO3 exchange also occurs in duodenum and jejunum (1). 
 
1.4. Cl
-
 secretion 
For a long time, intestinal tissues have been considered to exclusively perform an 
absorptive task. Studies done during cholera outbreaks during the 1950-1960s have changed 
this concept (23-25), showing notably that supernatant of Vibrio cholerae culture instilled into 
rabbit ileum provokes a strong secretion of fluid. Experiments done in Ussing chambers 
clarified the pathophysiological mechanism of secretory diarrhea due to Vibrio cholerae and 
thus, with further molecular studies, provided a more comprehensive model of fluid secretion 
by intestinal epithelia (26-28). This model involves a chloride channel localized at the apical 
cell surface that allows secretion of Cl
-
 ions into the intestinal lumen, basolateral membrane 
K+ channels that repolarize the cell and a basolateral membrane NaK2Cl transporter that 
mediates Cl
-
 entry into the enterocytes (figure 7). CFTR (for cystic fibrosis transmembrane 
conductance regulator) is the apical Cl
-
 channel mentioned above. This channel first cloned in 
1989 (29) is well known for its role in the genetic disease cystic fibrosis, which is 
characterized by meconium ileus and constipation, recurrent pulmonary infections with 
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progressive parenchymal destruction, pancreatic insufficiency and liver failure; disorders that 
are all consequences of abnormal Cl
-
 transport in the intestine, lung, pancreas and liver 
respectively (30). By increasing adenylate cyclase activity and thus intracellular cAMP levels, 
cholera toxin not only stimulates CFTR-mediated Cl
-
 secretion but also inhibits Na-H 
exchangers-mediated Na
+
 absorption (26,27,31,32). Regulation of Na
+
 and Cl
-
 transport is 
further discussed in the next chapter. 
 
 
Figure 7: Cl
-
 secretion (from Boron and Boulpaep, Medical Physiology, 2nd updated edition, 2012). 
 
1.5. Regulation of intestinal Na
+
 and Cl
-
 transport 
This chapter sums up various aspects of the regulation of intestinal Na
+
 and Cl
-
 
transport. In intestinal epithelial cells, intracellular levels of Ca
2+
, cAMP and cGMP, and 
gluco- and minrealocorticoids all modulate ion transport either by changing the number of 
transporters at the cell surface and/or by modifying their intrinsic activity. In particular, 
increased Ca
2+
, cAMP and cGMP intracellular levels leads to both a stimulation of Cl
-
 
secretion and an inhibition of electroneutral NaCl absorption (26,31,33-35). The main targets 
of these modulating pathways are CFTR and NHE3 respectively (3,36). How Cl-HCO3 
exchangers are regulated is poorly known.  
Based on immunohistochemical analyses, absorption is thought to mainly occur in the 
villous enterocytes, whereas secretion takes place in cryptic cells of the small intestine (37). 
This distinction is less clear in the colon, raising the possibility that some overlap does exist 
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and that a same cell might display(re-)absorptive and secretive capacity via molecular 
complexes involving NHE3, CFTR Slc26a3 and Slc26a6 (1). 
The common cellular modulators of ion intestinal transport at the level of intestinal 
epithelial cells described above are all controlled by higher systems via an increasing list of 
active molecules (table 1): (1) the endocrine / paracrine system, (2) the neuroenteric system 
and (3) the immune system. 
 
Table 1: Intestinal active molecules. Taken from (2). 
 
1.5.1 The endocrine / paracrine system 
The adrenal glands can release the mineralocorticoid hormone aldosterone in response 
to dehydration and volume contraction and the glucocorticoid hormone cortisol in response to 
stress. In distal colon, aldosterone binds its receptor and stimulates electrogenic Na
+
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absorption (3). Cortisol increases NHE3-mediated electroneutral Na
+
 absorption (38) but also 
activates SGLT1 and thus glucose-coupled Na
+
 absorption (39). 
Numerous endocrine cells, called enterochromaffin cells (EC cells), are found all along 
the gastrointestinal tract. They produce molecules that modulate ion transport via a paracrine 
effect. As an example, they secrete guanylin and uroguanylin in the intestinal lumen in 
response to salt intake. These short peptides bind an apical receptor for guanylate cyclase 
(GC-C) in epithelial cells; this increases cGMP levels leading through stimulation of Cl
-
 
secretion through CFTR (40-42). Interestingly, the heat-stable toxin of E.Coli that causes 
travellers’diarrhea acts through the same mechanism (figure 8). Recently, one gain of function 
mutation and two loss of function mutations in the GC-C gene have been reported in patients 
with chronic diarrhea and meconium ileus respectively (43,44) (see later). The GC-C receptor 
may also have other intestinal functions such as modulation of the intestinal barrier and 
inflammation, and regulation of epithelial cell proliferation and apoptosis (45,46). 
Interestingly, extra-intestinal roles for this receptor have been proposed in renal electrolytes 
handling, satiety and metabolic syndrome, and attention deficiency and hyperactive behaviour 
(47-49). 
 
Figure 8: Mechanism of action of heat-stable E.Coli enterotoxin (STa). STa binds the GC-C receptor 
increasing cGMP levels and activating Cl- channels such as CFTR. Taken from (2) 
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1.5.2 The neuroenteric system 
The gastrointestinal tract possesses a complex intrinsic nervous system called enteric 
nervous system (ENS). ENS is composed of two plexi, the myenteric plexus and the 
submucosal plexus. In particular, it has nerves that release factors with ion transport 
modulating activity on epithelial cells. Examples of such modulators include acetylcholine 
and vasoactive intestinal peptide (VIP), which inhibit electroneutral NaCl absorption and 
stimulate Cl
-
 secretion, via the muscarinic M3 receptors (Ca
2+
 as a second messenger) and the 
VIP receptors (via cAMP) respectively (50). 
 
1.5.3. The immune system 
The immune system is able to release active molecules that regulate ion transport in 
epithelial cells. For instance, mast cells secrete histamine, which has secretory and anti-
absorptive effects on epithelial cells probably indirectly through cholinergic enteric nerves 
(51). Cytokines secreted by T cells such as tumor necrosis factor α (TNFα) and interferon γ 
(INFγ) may also inhibit electroneutral NaCl absorption and increase Cl- secretion (52,53). 
 
 
2. DIARRHEA 
 
Diarrhea is a very frequent disease around the world. According to the World Health 
Organization (www.who.int), 1.5 million children die every year because of diarrhea and 
about 2 billion of diarrheal diseases are diagnosed every year. Fortunately, most cases are 
self-limited and can be treated by conservative means, namely rehydration. However, in some 
cases, diarrhea may be intractable and may persist for a long time. 
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From the patient’s point of view, diarrhea may be defined by the excretion of loose 
stools to watery stools, by an increase in stool mass and/or by an increase in stool frequency. 
More strictly, diarrhea is defined as a stool mass higher than 200-250 g/day, even though the 
passage of loose / watery stools more than three times a day is used in clinical practice.  
Diarrhea occurs when the absorptive capacity of the small intestine and colon, although 
normally very efficient (up to 15 liters/day of fluid and 5 liters/day respectively), is 
overwhelmed or when intestinal motility is altered. Acute diarrhea lasts several days, whereas 
chronic diarrhea persists for weeks, months or years. Depending on the causal mechanism, 
diarrheal diseases can be classified into 5 groups (Robbins Basic Pathology, 7
th
 edition, 
Kumar, Cotran and Robbins, 2005): 
1) Secretory diarrhea: Intestinal fluid secretion exceeds absorption even during fasting. 
For instance, infection of the intestinal epithelial cells by viruses or bacteria can 
provoke a secretory diarrhea because of damages within the epithelium or of 
production of toxins by the microorganisms that activate fluid secretion or block 
fluid absorption (e.g Cholera toxin or E.coli toxin). 
2) Osmotic diarrhea: Unabsorbed molecules exert osmotic forces driving fluid 
movement towards the intestinal lumen. This happens for example when taking 
lactulose to treat hepatic encephalopathy, Mg
2+
 containing antacids or purgative 
agents. 
3) Exudative diarrhea: Several bacteria or parasites such as Salmonella may cause 
extensive destruction of the mucosa resulting in purulent, bloody diarrhea. This also 
occurs with inflammatory bowel diseases (Crohn’s disease and ulcerative colitis). 
4) Malabsorption: Diarrhea occurs because of the presence of unabsorbed nutrients and 
fat in the intestinal lumen, e.g. due to a lack of digestive enzymes (pancreatic 
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insufficiency or genetic enzymatic defects), defective bile secretion, reduced 
intestinal surface area, lymphatic obstruction… 
5) Altered motility: Increased motility as seen in hyperthyroidism for example may 
reduce the intestinal retention time necessary for absorptive processes. 
 
Of course, multiple mechanisms may be present within the same individual. Thus, 
diarrheas are also grouped depending on the etiology of the diarrhea; e.g. infectious diarrhea, 
endocrine diarrhea, inflammatory diarrhea, neoplasia-induced diarrhea, drug-induced 
diarrhea… 
 
 
3. CONGENITAL DIARRHEAL DISORDERS AND FAMILIAL 
DIARRHEA SYNDROMES 
 
3.1. General considerations 
Congenital diarrheal disorders and familial diarrhea syndromes form a heterogeneous 
group of diarrheas sharing one common feature; they are all due to a known or putative gene 
defect (54,55). Although very rare, these pathologies are particularly interesting because they 
point out genes playing important roles in the gastrointestinal tract and thus provide in turn 
the possibility to better understand intestinal physiology and the pathophysiological 
mechanisms of more frequent intestinal diseases. In addition, studying such diseases may 
allow the identification of new pharmacological targets leading to the design of new drugs. 
Clinical presentation can vary from a very severe and intractable diarrhea starting out 
immediately after birth (sometimes with prenatal onset), threatening life because of massive 
dehydration, alterations in pH, various metabolic disorders and failure to thrive, to milder 
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diarrhea appearing only later in life. The management of the disease depends on the genetic 
etiology; intravenous fluid replacement might be the only treatment in most cases, whereas 
some diarrheas can be treated by theoretically “simple” but practically complicated means 
such as removal of lactose from the diet in the case of congenital lactase deficiency (56) or 
pancreatic enzyme replacement for enterokinase deficiency (57). Interestingly, some 
spontaneous improvement, as children grow, has been reported for example in enterokinase 
deficiency suggesting that compensatory mechanisms may appear later in life or that some 
gene is important only during infancy and its function becomes no longer necessary during 
childhood or adult state (58). 
Berni Canani et al have recently proposed to classify congenital diarrheal disorders into 
4 categories (see also figure 9) (54): 
1) Disorders with defects of digestion, absorption, and transport of nutrients and 
electrolytes. This category is further subdivided in: 
  - disaccharidase deficiencies: e.g. congenital lactase deficiency (59) 
  - ion and nutrient transport defects: e.g. congenital sodium diarrhea (60,61) 
  - pancreatic insufficiencies: e.g. enterokinase deficiency (58) 
  - lipid trafficking defects: e.g. chylomicron retention disease (62,63) 
2) disorders with defects of enterocyte differentiation and polarization: e.g microvillous 
inclusion disease (63) 
3) disorders with defects of enteroendocrine cells differentiation: e.g. enteric 
anendocrinosis (64) 
4) disorders with defects of modulation of intestinal immune response: e.g. IPEX = 
immune dysregulation polyendocrinopathy (65). 
 
Multiple congenital diarrheal disorders and familial diarrhea syndromes have been 
described and the list of such diseases is increasing rapidly, due to recent progress made in 
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molecular genetic tools. Therefore, it is not possible to review all of them. In the next chapter, 
the congenital sodium diarrhea, which is the main topic of this work, will be considered in 
details. Because of their close connection to this disease and/or to NaCl transport in the gut, 
the congenital chloride diarrhea, the glucose-galactose malabsorption and a recent familial 
diarrheal syndrome related to mutations in the GUCY2C gene will also be discussed. 
 
 
Figure 9: Mechanisms involved in the pathogenesis of congenital diarrheas. From (54) 
 
3.2. Congenital chloride diarrhea 
This rare secretory diarrhea was first reported in 1945 (66,67). The disease is 
characterized by a chronic, very profuse diarrhea with a specific faecal loss of chloride 
(>90mmol/l) resulting in severe dehydration, hypochloremic and hypokaliemic metabolic 
alkalosis that may threaten life unless treated with intravenous rehydration and salt 
substitution. Poorly treated patients may present impaired renal function and nephrocalcinosis 
(68). Other problems related to this diarrhea include intestinal inflammation, hyperuricemia, 
inguinal hernias, spermatoceles, and male subfertility (69,70). Mutations in the Slc26A3 gene 
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have first been identified in Finnish patients in 1996 (22). This gene, also known as DRA (for 
Down-Regulated in Adenoma), encodes a chloride-bicarbonate exchanger that play an 
important role in NaCl (re)absorption throughout the gut but mainly in ileum and large 
intestine (71). More than 50 different mutations of this gene have been reported so far, all 
predicting to lead to a loss of function of the exchanger (72). Slc26A3 deficient mice display 
a phenotype similar to the congenital chloride diarrhea, with high chloride content diarrhea, 
body weight loss, dehydration and hypochloremia (16). 
 
3.3. Glucose-galactose malabsorption 
Glucose-galactose malabsorption was first reported in 1963 (73). This disease is 
characterized by a severe watery diarrhea in newborns. Removal of lactose, glucose and 
galactose from the diet results in a complete cessation of all symptoms, whereas diarrhea 
resumes upon reintroduction of those sugar molecules in the diet. Turk et al identified in a 
family with members affected by the glucose-galactose malabsorption one loss of function 
mutation in the SGLT1 gene, which had been cloned two years before (74-76). SGLT1 
encodes a Na/Glucose co-transporter that is responsible for glucose-coupled Na+ transport in 
intestinal and renal tissues (7). 
 
3.4. Familial diarrhea syndrome and mutation of GUCY2C 
A group of Norwegian physicians has recently identified one family with 32 adult 
members suffering from a familial diarrhea syndrome (43). In opposite to congenital diarrheal 
disorders that are usually transmitted as autosomal recessive traits and are characterized by 
very severe diarrhea affecting infants, the transmission of this syndrome was autosomal 
dominant. Affected members of this family presented a mild chronic diarrhea associated with 
diverse intestinal problems such as irritable bowel syndrome, Crohn’s disease, episodes of 
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bowel obstruction and esophagitis. One common gain of function mutation in the GUCY2C 
gene was detected in those patients. The GUCY2C gene encodes a transmembrane guanylate 
cyclase receptor expressed in epithelial intestinal cells (46). The heat stable toxin of E.Coli 
STa is a super agonist of this receptor and leads to secretory diarrhea by activating fluid 
secretion and inhibiting fluid absorption via an increase in cGMP levels. Endogneous ligands 
of this receptor include guanylin and uroguanylin that are secreted by epithelial intestinal cells 
into the lumen but also into the blood (45). Interestingly, recessive loss of function mutations 
of GUCY2C associated with meconium ileus have also been recently identified in 2 Bedouin 
families living in the desert (44). Therapeutic drug that targets this receptor are developed or 
are currently being tested in clinical trials for their efficacy to treat constipation or diarrhea 
(77,78).  
 
 
4. THE CONGENITAL SODIUM DIARRHEA 
 
4.1. Description and pathophysiology 
The congenital sodium diarrhea is a rare congenital secretory diarrhea first described in 
1985 (79,80). Only few cases have been reported in the literature (60,81-85).The diarrhea is 
characterized by a prenatal onset of disease with polyhydramnios, followed immediately after 
birth by large amounts of watery stools and faecal loss of sodium and HCO3
-
. Newborns 
suffer from hyponatremic dehydration with hypotension, secondary hyperaldosteronism and 
metabolic acidosis. 
The management consists in parenteral nutrition, but patients die in the first year of life 
because of recurrent catheter-related infections or of liver failure due to parenteral nutrition. 
Anatomic defects or abnormalities are excluded by radiological examinations and no 
25 
 
anatomo- or histopathological changes are observed except for some mild villous atrophy 
with slight crypt hyperplasia that are probably due to long term parenteral nutrition. Electron 
microscopy shows in villous cells lipid-negative vacuoles and membranous whorls in clear 
vacuoles, mitochondria and lysosomes (figure 10). Müller et al proposed that these changes 
may represent apical membrane breakdown products caused by instability and/or disordered 
configuration of a sodium/proton exchanger protein (60). Infectious and auto-immune origins 
for this diarrhea are excluded. Endocrine causes are also ruled out because of normal 
plasmatic levels of thyroid hormones, thyroid-stimulating hormone, vasoactive intestinal 
peptide, calcitonin, gastrin, and prostaglandin E2. 
 
 
Figure 10: Morphology of jejunal mucosa of a patient with the congenital sodium diarrhea. (A) Light 
microscopy image of sections of jejunal mucosa showing abnormal crypt hyperplastic and villous atrophy, in 
which villus height equals crypt depth. (B) Transmission electron microscopic image of villous columnar 
epithelium showing marked vacuolation with slightly mounded apical membranes. (C) Transmission electron 
microscopic image of a villus tip epithelial cell from jejunal mucosa showing distinct membranous whorls within 
clear vacuoles (arrowhead), lysosomal bodies (arrow), and swollen mitochondria (m). From (60). 
 
Affected children may also display dysmorphologic features such as choanal atresia, 
anal atresia, corneal erosions and hypertelorism (figure 11). These changes associated with 
the sodium diarrhea constitute a syndromic form of the congenital sodium diarrhea. (61) 
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Figure 11: Facial characteristics of patients with the congenital sodium diarrhea. Note hypertelorism, long 
philtrum, sparse hair, and photophobia. From (61) 
 
Jejunal perfusion studies in one patient and Na
+
-transport analysis in brush border 
membrane vesicles of jejunal biopsies from two patients affected by the congenital sodium 
diarrhea showed a huge decrease in proton-gradient-dependent Na
+
 uptake, whereas Na
+
-
stimulated glucose uptake was normal, suggesting an important defect in Na-H-exchange in 
intestinal tissues (80,81). 
 
4.2. Mutations in the Spint2 gene 
In 2000, Müller et al reported a family of consanguineous descent in Austria with 5 
children affected by the congenital sodium diarrhea (figure 12) and concluded that the disease 
was not related to mutations in the genes encoding Na-H-exchangers known to be expressed 
in the gut, namely NHE1, NHE2 and NHE3 (60). More recently, this same laboratory has 
identified one common mutation in the Spint2 gene in the patients of this Austrian family 
(61). They also report 4 other mutations in several other families with members having the 
congenital sodium diarrhea.  
 
Figure 12: Pedigree of the congenital sodium diarrhea family. from (61) 
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Spint2 mutations associated with the congenital sodium diarrhea were detected in a 
splice acceptor site (c.593.1G A) and in splice donor sites (c.337+2T C, c.553+2T A), 
which probably provoke an aberrant splicing and the loss of normal gene expression. Another 
mutation was identified in a highly conserved region of the protein (Y163C), which might 
hinder the correct folding of the protein or decrease the activity of the reactive site (figure 13). 
A fifth mutation involves the start codon and probably abolishes the expression of Spint2. 
Although not clearly demonstrated, these mutations are expected to result in a loss of function 
of Spint2.  
 
 
Figure 13: Conservation of the SPINT2 p.Y163C mutation. (A) Alignment of multiple human Kunitz 
domains from different proteins. The mutated tyrosine is invariantly conserved within the highly conserved 
catalytic Kunitz domain.(B) Alignment of known and predicted SPINT2 orthologs shows high evolutionary 
conservation of this mutated tyrosine residue. From (61) 
 
Interestingly, mutations of Spint2 were associated with the syndromic form of the 
congenital sodium diarrhea, given that all patients affected exhibited the dysmorphologic 
features mentioned above. Patients that only suffer from the congenital sodium diarrhea alone 
do not have any mutations in the Spint2 gene. Mutations in the NHE8 gene encoding for a 
Na
+
/H
+
 exchanger, which might be important in Na
+
 handling in the gut in early life, have 
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recently been ruled out in those patients (86). How mutations of Spint2 result in the 
congenital sodium diarrhea or a dysmorphologic phenotype is completely unknown. 
 
 
5. SPINT2 
 
5.1. Definition 
The spint2 gene encodes a serine protease inhibitor of Kunitz-type 2, also called HAI-2 
for Hepatocyte Growth Factor Activator Inhibitor-2, placental bikunin or kop for Kunitz 
domain containing protein overexpressed in pancreatic cancer. Its cloning or protein isolation 
was reported in 1997 from three different origins: (1) pancreatic cancer tissues, (2) a cDNA 
placental library and (3) from the condition medium of the human stomach carcinoma cell 
line MKN45 (87-89). 
Spint2 is a protein that is 252 amino acid long and weighs around 30-35 kD.  
It has the following structure (figure 14):  
- 1 signal peptide on the N-terminus (Signal peptides are found in proteins that are targeted to the endoplasmic 
reticulum and eventually destined to be either secreted/extracellular/periplasmic/etc., retained in the lumen of the endoplasmic reticulum, of 
the lysosome or of any other organelle along the secretory pathway or to be I single-pass membrane proteins. Source: www.uniprot.org) 
 
 - 2 Kunitz domains, which are 60 amino acid long domains, with a characteristic highly 
conserved spacing of six cysteine residues forming three disulfide bonds, responsible for the 
inhibition of trypsin-like serine proteases. 
- one 24 amino acid long hydrophobic segment at the C-terminal end as a putative 
transmembrane domain . 
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Figure 14: Schematic structure of the Spint2 protein. From (87,90) 
 
5.2 Tissue distribution and expression of Spint2 
Strong Spint2 mRNA expression is detected by Northern blot analyses in human 
placenta, kidney, pancreas, prostate, testis, thyroid and trachea with milder expression in 
thymus, ovary, small intestine, colon, lung and brain (87-89). In mouse, strong mRNA 
expression was seen in stomach, duodenum, jejunum, ileum, colon, liver, kidney, testis, 
ovary, and placenta, with weak expression in heart and esophagus, but no expression in brain 
(91). 
Two isoforms have been described: a long isoform which consists in the full length 
inhibitor with its two Kunitz domains and a shorter isoform that lacks the N-terminal part 
Kunitz domain (91). At the mRNA level, the long isoform is the main isoform in human 
tissues whereas the small isoform is more predominant in mouse tissues. Recently, a mouse 
model with the LacZ gene inserted in the locus encoding Spint2 and thus driven by the 
promoter of Spint2 has been generated (92). -galactosidase activity, supposed to reflect 
Spint2 protein expression, could then be shown in different epithelia including in kidney 
(mainly in the distal part of the renal tubules but also weakly in proximal tubules), 
gallbladder, sebaceous glands and hair follicles, trachea and bronchi/bronchioles, bladder, 
uterus, seminal glands and thymus. In the gut, activity was found in the small intestine and 
colon, both in cryptic and villous/surface cells (although villous expression was weaker) and 
also in goblet cells. Surprisingly, in pancreas, -galactosidase activity was only detected in 
endocrine cells of islets of Langerhans but not in exocrine acinar cells. Finally, activity was 
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also seen in brain and ovary but not in liver, salivary glands, heart, skeletal muscle, spleen, 
vessels, mammary gland, oral cavity and esophagus. Globally, the tissue distribution of 
Spint2 is very similar to Spint1 and CAP3 expression (92). 
The subcellular localization of Spint2 has been studied only in the Caco-2 cell line, 
which consists in epithelial cells of colonic carcinoma origin. In those cells, grown on filter as 
monolayers, endogenous Spint2 protein expression is thought to be mainly intracellular 
although it can be detected at the apical membrane (93). 
 
5.3. Function of Spint2 
The function of Spint2 has been assessed only in cell-free in vitro assays using soluble 
recombinant proteins, so far. Spint2 has been to be a powerful inhibitor of several proteases 
including trypsin, plasmin, plasma kallikrein, pancreatic kallikrein, tissue kallikrein, HGFA 
(hepatocyte growth factor activator), chymotrypsin, factor XIa, but is a poor inhibitor of 
factors VIIa, IXa, Xa, XIIa (88,94). These proteases that are rather non-specific or involved in 
blood coagulation are likely not related to the congenital sodium diarrhea. Both domains 
present a similar inhibition capacity, although the first domain shows a small decrease 
capacity to block kallikrein and factor XIa. Qin et al generated mutants of Spint2 in which the 
P1 arginine residue of the reactive site of each Kunitz domain (see later) was mutated to a 
leucine residue (90). The mutation in the first Kunitz domain R48L significantly decreases the 
inhibitory activity of Spint2 on HGFA whereas the homologous mutation in the second 
Kunitz domain R143L was similar to the wild-type form of Spint2, suggesting that the first 
inhibitory domain of Spint2 is important for HGFA inhibition. These data were obtained 
using the human long isoform of Spint2 that has two Kunitz domains. Interestingly, the major 
mouse form of Spint2 that lacks the first Kunitz domain is also able to potently inhibit HGFA, 
as does a mouse construct with both Kunitz domains (95). Still in cell-free assays, Spint2 was 
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shown to be also a powerful inhibitor of the membrane bound-serine proteases Tmprss1 (also 
known as hepsin), CAP3 (also known as matriptase), CAP1 (also known as prostasin), 
Tmprss13 and matriptase-2 (92,96-99). Regarding the inhibition of CAP3, the first Kunitz 
domain of Spint2 seems to be more important than the second domain since the R48L mutant 
binds less efficiently to CAP3 than Spint2 wild-type and mutant R143L (93).  
 
5.4. Spint2 and cancers 
Spint2 may act as a tumor suppressor gene in medulloblastomas (100), gastric cancers 
(101), uterine leyomyosarcoma (102), prostate cancers (103), endometrial cancer (104), 
gliomas (105), hepatocellular carcinomas (106), renal cell carcinomas (107-109), breast 
cancers (110,111) cervical cancers (112) and ovarian cancers (113). In almost all these 
studies, low Spint2 expression was associated with poor clinical outcome. As a putative 
mechanism, it has been proposed that Spint2 might have, depending on the cancer cell line, 
anti-proliferative, pro-apoptotic, anti-migratory and anti-invasiveness properties presumably 
by regulating the HGF/met pathway via the inhibition of HGFA but also of CAP3 and 
Tmprss1 (114). The first inhibitory domain of Spint2 was shown to be more important than 
the second domain to mediate inhibition of migration and invasiveness of SMMC-7721 
hepatocellular cancer cells (114). In contradiction to all studies mentioned above, one study 
showed that high Spint2 expression was associated with breast tumor aggressiveness (115). It 
is important to note that most of these studies report correlative findings and the role of Spint2 
has been assessed only in vitro cancer cell lines via its overexpression. Furthermore, some 
studies are based on immunohistochemistry experiments done on tumor biopsies, although no 
good antibodies against Spint2 for such applications seem to be available (92). Experiments 
done in Spint2 KO or Spint2 transgenic mice are clearly required to confirm the role of Spint2 
in carcinogenesis. 
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5.5. Spint2 in mouse models 
Spint2 knockout mice show have a lethal phenotype in utero (116) due to early defects 
during the gastrulation stage, hypoplasia of the placental labyrinth with loss of epithelial 
polarity and reduction in vessels number, and non-closure of the neural tube as seen in figure 
15 (117). 
 
Figure 15: Constitutive Spint2 KO mice display embryonic defects: (left panel) abnormal clefting of the 
epiblast near the embryonic/extraembryonic junction (arrow) in KO embryo (right) compared to WT embryo 
(left), (middle panel) histological sections showing placental labyrinth hypoplasia (middle layer) in KO animals 
(lower image) compared to WT animals (upper image) and (right panel) defects of neural tube closure in KO 
embryos (left) compared to WT embryos (right). From (116,117) 
 
This model can be rescued by disrupting the st14 gene encoding the membrane-bound 
serine protease CAP3, indicating that Spint2 controls crucial proteolytic pathways essential 
for embryonic development (117). Additional proteases are involved in such pathways since 
non-closure of the neural tube was still seen in Spint2
-/-
, st14
-/-
 double knockout mice, albeit at 
a lower frequency. Embryonic lethality of Spint2 knockout mice can also be avoided when 
the activity of the membrane-bound serine protease CAP1 is strongly decreased as seen in the 
Frizzy mice that have a point mutation in the CAP1 gene that reduces its function (118,119). 
Globally, these rescue experiments indicate that there is a genetic interaction between Spint2, 
CAP3 and CAP1 during development in utero. Whether the Spint2 protein directly interacts 
with CAP3 or CAP1 in cells remains unknown.  
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5.6. Putative roles of Spint2 in vivo 
A role of Spint2 in idiopathic pulmonary fibrosis has been proposed based on a work 
done in fibroblasts (120). Compared to fibroblasts from healthy donors, lung fibroblasts from 
patients with idiopathic pulmonary fibrosis display decreased HGFA expression and activity 
(HGFA has a protective effect in animal models of lung pulmonary fibrosis), which is 
associated with an increase in Spint2 expression.  
A recombinant truncated form of Spint2, lacking the transmembrane domain, potently 
decreases sodium transport when applied on primary cultures of human bronchial epithelial 
cells obtained from healthy subjects or from cystic fibrosis patients (121). This effect, also 
seen with serine protease inhibitor aprotinin but not with soybean trypsin inhibitor (SBTI) and 
alpha1-antitrypsin, can be reversed upon treatment with trypsin. Similarly, the same construct 
of Spint2 attenuated tracheal potential difference in vivo in trachea of guinea pigs (122,123). 
It has been recently proposed that Spint2 could play a role in liver fibrosis occurring 
after cholangiopathies such as biliary atresia (124). This is based on the observation that 
Spint2 expression at the mRNA levels and at the protein level is increased in biliary atresia 
livers and in other cholangiopathies. This occurs in reactive cells of portal areas. Further 
experiments done on primary culture of fetal liver cells showed that several inflammatory 
molecules such as TNF-α and TGF-β increase Spint2 expression and that Spint2 enhances 
fibrotic processes and affects hepatic differentiation possibly by inhibiting HGFA. 
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6. SPINT1/HAI-1 
 
6.1. Definition 
Spint1, better known under the name of HAI-1 for Hepatocyte Growth Factor Activator 
Inhibitor type 1 because of its isolation from a gastric cancer cell line based on its capacity to 
inhibit HGFA, is a homologous protein of Spint2 (125). HAI-1 has also two Kunitz domains 
that are responsible for serine protease inhibition and a putative transmembrane domain, but it 
is a longer protein (513 amino acids) than Spint2 and it has a LDL-receptor-like domain 
between both Kunitz domains (figure 16). The percentage of homology of the two Kunitz 
domain of Spint2 and HAI-1 is 54% and 36% respectively (87).  
 
 
Figure 16: Schematic structure of the HAI-1 protein. TM=transmembrane domain. From (125). 
 
6.2. Tissue distribution, expression and function of HAI-1 
The tissue distribution of HAI-1 is very similar to Spint2 (92,125). At the subcellular 
level, HAI-1 is expressed predominantly on the basolateral membrane of epithelial cells and 
its expression is increased in injured or regenerative epithelia (126,127). In cell-free in vitro 
assay, HAI-1 inhibits HGFA and trypsin (125,128). The first kunitz domain of HAI-1 seems 
to be responsible for the inhibition of HGFA (128). Other proteases inhibited by HAI-1 
include Tmprss1, CAP1, Tmprss13, HAT (97,99,129,130). 
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6.3. Interaction HAI-1-CAP3 
HAI-1 also inhibits CAP3 in cell free assay and a complex CAP3-HAI-1 has been 
isolated in human milk, suggesting that HAI-1 is a physiologic inhibitor of CAP3 (131). 
Again, the first Kunitz domain of HAI-1 is likely responsible for this inhibition (132). In 
addition, several studies suggest that HAI-1 is necessary for the activation CAP3 (133-135) 
and it has been proposed that HAI-1 might transport CAP3 from the basolateral membrane to 
the apical membrane (136), where it might mediate the secretion of CAP3.  
 
6.4. HAI-1 knockout mouse models 
HAI-1 knockout mice display embryonic lethality due to failed placental development 
and function (137,138). As for Spint2, this model can be rescued by disrupting the CAP3 
gene (139). A highly hypomorphic mouse model of HAI-1 also avoid the embryonic lethality 
issue but these mice display strong growth retardation and die 16 days after birth (140). In 
particular, HAI-1 hypomorphic mice develop scaly skin with diminished barrier function due 
to altered filaggrin processing (figure 17). 
 
Figure 17: Scaly skin of hypomorphic HAI-1 mice. From (112) 
 
As for the placental failure, the postnatal mortality of HAI-1 mice can be totally rescued 
by knocking down the CAP3 gene (141). Similar rescue can be obtained with a hypomorphic 
mutation in the CAP1 gene (119). It is still unclear how HAI-1, CAP1 and CAP3 interact at 
the protein level. A putative cascade involving HAI-1, CAP1 and CAP3 has been proposed 
based on experiments performed in primary cultures of human keratinocytes or with Caco-2 
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cells. Here, CAP1 might be activated by CAP3, whose activity would be controlled by HAI-1 
(142,143). In contrast to this model, Szabo et al suggested that in placental cells CAP1 
activates CAP3 (119).  
A HAI-1 gut-specific knockout mouse model has been generated using Cre-mediated 
recombination driven by the villin promoter (144). These mice are normal on gross 
examination but show in cryptic cells of their proximal colon mild alterations such as cryptic 
architecture modifications, increased apoptosis and enhanced permeability. They are also 
more sensitive to DSS-induced colitis. 
As other putative roles of HAI-1, it has been shown that, in vivo, HAI-1 (but not 
Spint2) is increased in regenerative intestinal epithelium after chemical-induced colitis (145). 
Like Spint2, HAI-1 may act also as a suppressor tumor gene in many cancer cell types (146) 
and may also play a role in the pathogenesis of lung fibrosis (147).  
 
 
7. PROTEASES AND THEIR INHIBITORS 
 
7.1 General considerations about proteases 
Unless otherwise specified, data of these chapters come from the following sources (148-154) and the textbook Biochemistry, Berg, 
Tymoczko and Stryer, 5th edition, 2002, W.H. Freeman. 
 
Proteases are enzymes responsible for the catalytic breakdown of peptide bonds; a 
process called proteolysis. Their role in biological processes is very large. Proteases are 
involved in unspecific protein degradation, which is not only important at the level of the 
entire organism to obtain free amino acids from dietary proteins or peptides, but also at the 
cellular level to remove proteins that are no longer used and recycle amino acids for the 
synthesis of new proteins.  
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In addition to these effects, proteases have multiple other biological functions in which 
they only cleave their substrates at specific regions and in a tightly controlled manner; a 
process called limited proteolysis. Limited proteolysis is responsible for the activation or 
inactivation of enzymes, transcription factors, hormones and other proteins and peptides. For 
example, hormones and enzymes might be translated first in an inactive form called 
prohormones and proenzymes. Then, proteolytic removal of a short part of these immature 
molecules leads to their activation. This is the case for insulin or trypsin for instance that are 
synthesized as proinsulin or trypsinogen. Limited proteolysis may also occur in a cascade 
where one protease cleaves and activates another protease, which in turn cleaves and activates 
a third protease. This continues until the final effector is activated as seen in the coagulation 
cascade. Many important biological and physiological processes are regulated by limited 
proteolysis: cell proliferation and cell death, various signalling pathways, complement 
system, blood coagulation, fibrinolysis, immune system, tissue remodelling, wound healing, 
development … 
Because of this large diversity, proteases play an important role in diseases and are thus 
the targets of classical drugs such as inhibitors of the angiotensin-converting-enzyme used to 
treat hypertension and cardiovascular disease, inhibitors of coagulation factors for thrombosis 
or HIV protease inhibitors in the treatment of AIDS (149). Much effort is made towards the 
discovery of new therapeutics targeting proteases (155). 
The human genome encodes 578 proteases ((156) / www.sitedegradome.uniovi.es), 
which are divided in subgroups according to their catalytic mechanism: 
- aspartic proteases (21 members): e.g pepsin and renin. 
- cysteine proteases (161): e.g. caspases 
- metalloproteases (191): e.g matrix metalloprotease such as collagenases 
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- serine proteases (178): e.g. trypsin, chymotrypsin, membrane-bound serine 
proteases 
- threonine proteases (27): e.g proteasome subunits. 
 
7.2. Mechanisms of proteolysis 
Substrate cleavage by chymotrypsin has been extensively studied and represents a good 
example of proteolysis by a serine protease. Cleavage of the peptide bond occurs in a small 
cleft of the rather spherical chymotrypsin called the active site. This active site contains three 
amino acids that are critical for proteolysis: serine at position 195, histidine at position 57 and 
aspartic acid at position 102. These amino acids form the so-called catalytic triad. Briefly, 
figure 18a shows that the histidine residue, with the help of the aspartate residue, deprotonates 
the hydroxyl group of the serine residue. The highly reactive serine makes a nucleophilic 
attack of the carbonyl carbon atom of the substrate and form with the latter a transient 
covalent bond to form the acyl-enzyme intermediate. Then hydrolysis occurs, releasing the 
cleaved substrate and regenerating the enzyme (figure 18a). 
Cysteine proteases use a similar mechanism but here a cysteine residue is responsible 
for the nucleophilic attack of the peptide bond (no aspartic acid residue is involved in this 
reaction) (figure 18b). Aspartic proteases and metalloproteases use two aspartic acids residues 
and a metal ion (usually zinc) respectively in their active site to activate a molecule of water, 
which in turn performs the nucleophilic attack on the substrate (figure 18c and d). 
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Figure 18: Mechanisms of proteolytic activity of serine (a), cysteine (b), aspartic (c) and metalloproteases 
(d). See text for explanations. From (157) 
 
Chymotrypsin cleaves peptides bonds after amino acids residues such as tryptophan, 
tyrosine, phenylalanine (all are large hydrophobic residues), whereas trypsin cleaves after 
arginine or lysine. This specificity is related to the presence of a pocket, called S1 pocket, into 
which such residues can fit (figure 19). Further substrate specificity can be achieved by the 
presence, within the active site of the protease, of subsites that have to accommodate with 
side chain residues of the substrate located around the scissile bond. Such residues are labeled 
P1, P2, P3 and so forth or P’1, P’2, P’3 depending on their localization on the amino-terminal 
or carboxy-terminal side, respectively, of the scissile bond. Likewise, corresponding subsites 
in the protease are labeled S1, S2, S3 or S’1, S’2, S’3 (figure 20). 
 
Figure 19: S1 pocket of Chymotrypsin. From Biochemistry, Berg, Tymoczko and Stryer, 5th edition, 2002, W.H. Freeman 
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Figure 20: Schematic representation of a protein substrate binding to a protease. From (149) 
 
7.3. General consideration about protease inhibitors 
Excessive proteolytic activity might result in deleterious effects in tissues and cells. To 
avoid this problem, several mechanisms of defense exist. First, proteases are sometimes 
confined in very restricted and specialized area. For instance, cellular proteases involved in 
protein degradation are localized in lysosomes or proteasomes (158,159). Second, proteases 
are translated as inactive enzymes called zymogens. Zymogens are then converted in a 
controlled manner into active proteases by other proteases or sometimes via auto-activation 
(figure 21). A third line of defense consists in the inhibition of proteases by inhibitors (figure 
21). 
  
Figure 21: Regulation of protease activity by inhibitors. From (149) 
 
Paradoxically, natural protease inhibition is performed only by proteins, except in some 
microorganisms, which can produce small non-peptidic compounds with the capacity to 
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inhibit proteases. The human genome is estimated to encode 156 protease inhibitors ((156) / 
www.sitedegradome.uniovi.es). This is clearly less than the numbers of genes encoding 
proteases (578, see above). One explanation for this difference would be that inhibitors are 
able to block multiple proteases. Alternatively, new inhibitors are to be found or already 
known proteins might have the capacity to inhibit proteolytic activity in addition to their 
initial function. 
 
7.4. Classifications of serine protease inhibitors 
Although it is clear that protease inhibitors avoid uncontrolled and thus excessive 
proteolysis, their physiological role in a more specific sense is poorly known. Indeed, most 
inhibitors where discovered and isolated based on their capacity to inhibit well-known 
proteases such as trypsin, chymotrpysin, elastase or subtilisin. The “true” physiological 
targets of most inhibitors remain to be found. Because of this lack, classification of protease 
inhibitors has been generating a lot of confusion in the field.  
Laskowski and Kato were the first to propose a system to order protease inhibitors 
(148). Based on extensive homology, they introduced eight different families, whose name is 
the name of the most studied protease inhibitor of that family (e.g. Streptomyces subtilisin 
inhibitor family) or the name of the scientist who discovered it (e.g. Kunitz, Kazal or 
Bowman-Birk inhibitors). As an example, Kunitz inhibitors, first crystalized in 1945 by 
Moses Kunitz (160), are made of inhibitory domains of 58 amino acids that are higly stable 
(even to boiling) and show a conserved sequence and structure. In particular, the Kunitz 
consensus has 6 conserved cysteines that make three disulfides bonds in a specific manner 
(figure 22) with the P1 residue (scissile bond) close to the second cysteine (figure 23). 
Today, around 78 families are listed in the Peptidase database MEROPS (161). These 
families are defined by homology in amino acid sequence. This database also groups protease 
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inhibitors into clans based on similarities in their tertiary structure. As mentioned in the 
database, « a clan of peptidase inhibitors contains all the modern-day inhibitors that have 
arisen from a single evolutionary origin of inhibitors ». One clan can include several families 
and one family may not belong to a clan. In spite of this broad diversity, common 
characteristics related to structure and function can be found, leading to a limited number of 
inhibition mechanisms.  
 
Figure 22: Alignment of the amino acid sequence of the Kunitz domains of Spint2 (=HAI-2) with human 
homologous protein sequences (HAI-1, APP for Amyloid βA4 protein, APPH for Amyloid-like protein 2, IαTI 
for Inter-α-tryspin inhibitor, TFPI forTissue factor pathway inhibitor). The consensus sequence is shown at the 
bottom with the 6 conserved cysteines. From (87) 
 
 
Figure 23: Kunitz domains of Spint2: (a) Amino-acid residues in the Spint2 sequence surrounding the reactive 
sites (arrow) of the two Kunitz-domains (1, 2). (b) Scheme of the presumed topological structure of the disulfide 
bonds (solid circle, a half cystine residue; arrow, presumed reactive site). From (89). 
 
7.5. Mechanisms of protease inhibition 
7.5.1. General considerations 
Proteases can be classified, based on the mechanism of proteolysis, into serine, cysteine, 
metallo-, aspartic and threonine proteases. Accordingly, protease inhibitors usually block 
specifically one of these classes of proteases. However, there are exceptions to this rule; for 
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instance, serpins (described later) can inhibit not only serine proteases but also cysteine 
proteases.  
The region of the inhibitor that blocks protease activity is called the reactive site. From 
a general point of view, inhibition of the protease active site is achieved by the docking of the 
inhibitor reactive site, which can consist in defined structural elements such as a binding loop 
or an amino- or carboxy terminal ends of a protein (or both). This way, substrates can no 
longer have access to the active site of the protease.  
Serine proteases inhibitors form the most studied family. Mechanistically, three 
different types of serine protease inhibitors can be distinguished that will be described in 
further detail in the next chapter: 
- canonical inhibitors 
- non-canonical inhibitors 
- serpins. 
 
7.5.2. Canonical inhibition 
The canonical mechanism also called standard mechanism was first described by 
Laskowski and Kato (148). Most serine proteases inhibitors, including Kunitz-type inhibitors, 
use this mechanism. They interact with the target protease in a substrate-like and non-covalent 
manner. In fact, inhibitors serve as a substrate for the protease. Their reactive site should thus 
fit the active site and subsites of the protease. A nomenclature similar to real substrates 
(mentioned above) can be used to characterize the reactive site of inhibitors containing the 
peptide bond that can be cleaved by protease (e.g. scissile bond and subsites P1, P2, P3 / P’1, 
P’2, P’3) (see figure 23). However, in contrary to substrates, inhibitors form highly stable 
complexes with the proteases, and the scissile bond (between P1 and P’1) is cleaved very 
slowly. The reaction can be defined as follow: 
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where E is the enzyme (protease), I the inhibitor, EI the stable protease-inhibitor complex and 
I* the modified inhibitor whose scissile bond has been cleaved. kon and k
*
on are respective 
association rate constants and koff and k
*
off are respective dissociation rate constants. kcat and 
k
*
cat are the respective catalytic rate constants that indicate how much substrate (in mol) is 
converted into product per second per mole of enzyme. Several things are important to 
mention about this reaction: 
- both the Michaelis-Menten constant Km=(koff+kcat)/kon and the catalytic rate constant 
kcat are extremly low. In spite of this, the ratio kcat/Km is high indicating that I is a 
good substrate for E. In other words, the affinity of the inhibitor for the protease is 
very high but the efficiency of the protease to cleave the inhibitor is very low. 
- the reaction is reversible. I* can react with E and the cleaved peptide bond can be 
re-synthesized. I* is very similar to I, except for minor modifications around the 
scissile bond. The ratio I/I* is near unity, indicating that I and I* form a complex 
with E with similar efficiency. 
 
7.5.3. Structure of canonical inhibitors 
Canonical inhibitors have a large variability in their global structure, which may 
comprise  sheets,  helices or a mix of both, and usually contain disulfide bonds. This 
scaffold structure accounts for the multiple families described among serine protease 
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inhibitors such as Kunitz-type inhibitors, Kazal-type inhibitors or Bowman-Birk inhibitors. 
However, they share a common feature: the binding loop. This segment includes the scissile 
bond and interacts with the active site of the protease. In spite of the very diverse amino acid 
sequences, the binding loops of different inhibitors from different families display a strikingly 
similar canonical conformation characterized by a convex loop, complementary to the 
concave active site of the protease. Figure 24 shows the conserved binding loop despite the 
high variability of the scaffolding domain in several canonical inhibitors from different 
families. Figure 25 is a superimposition of the P3-P’3 segments of binding loops of OMSVP3 
(ovomucoid inhibitor of Kazal-type), SSI (subtilisin inhibitor) and BPTI (bovine pancreatic 
trypsin inhibitor also known as aprotinin, Kunitz-type) inhibitors. The binding loop is a rather 
flexible segment in free inhibitors but become very rigid upon binding with the target 
protease. Minimal conformational changes take place upon formation of the enzyme-inhibitor 
complex; this is described as the classical lock and key interaction. The conformation of the 
binding loop is the results of disulfide bonds, hydrogen bonds and hydrophobic interactions 
occurring between residues both from the loop and the scaffold. For instance, inhibitors of 
Kunitz–type have 6 conserved cysteines forming disulfide bonds in a very specific manner. 
Interestingly, one study has shown that a mutant of BPTI with almost all residues in the 
binding loop mutated to alanines was still able to display a canonical binding loop, although 
less structured than the wild-type loop, and to interact with trypsin (162). This highlights the 
important role played by the inhibitor scaffold in the generation of the binding loop. 
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Figure 24: Representative set of canonical inhibitor structures. Binding loop and P1 side chain residue are 
marked in red, secondary-structure elements are colored in blue (β sheets) and green (α helices), disulfide bonds 
are in yellow. Name of inhibitor family (in bold) and name of representative are indicated. From (151) 
 
 
 
Figure 25: Superimposition of main chain P3-P3 of binding loops of: OMSVP3, light gray; SSI, gray; 
BPTI, dark gray. From (151) 
 
The P1 residue of the binding loop is fully exposed in all inhibitors and interacts tightly 
with the S1 pocket of the protease. Its nature is therefore important for protease inhibition 
specificity. Arg and Lys residues confer specificity towards trypsin-like proteases, Tyr, Phe, 
Trp, Leu and Met residues towards chymotrypsin-like proteases and Ala and Ser towards 
elastase-like proteases respectively. Thus, mutating this P1 key residue does not necessarily 
abolish the inhibition activity but rather changes the substrate specificity. Since the subsites 
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(P2, P3, P’2, P’3 and so forth) are also important for proper function of the binding loop, P1 
mutant inhibitors may still exhibit significant inhibition activity. 
 
7.5.4. Examples of canonical inhibition 
I) Complex trypsin-CMTI1 inhibitor 
Figure 26 shows, as an example of canonical inhibition, the interaction between trypsin 
and CMTI1 inhibitor (Potato I family). Trypsin is the larger protein seen in the upper part of 
the complex with its active site in the bottom bound to the small inhibitor CMTI (lower part 
of the complex). The canonical binding loop and the P1 side chain residue are depicted in red. 
The interaction is shown in further detail in figure 27. Here, P3 to P’3 residues of the binding 
loop interact with the active site of trypsin. In particular, P1-P3 residues (Arg5-Cys3) form an 
anti-parallel  sheet with residues 214-216 of the protease. In addition, the P1 residue (Arg5) 
is in close contact with the oxygen atom from the hydroxyl group of catalytic Ser195. 
 
Figure 26: Complex Trypsin-CMTI. From (151) 
 
 
48 
 
Figure 27: Schematic representation of canonical inhibition based on the structure of the CMTI I-trypsin 
complex. The inhibitor [dark gray, residues marked as (I)] binds to the protease [light gray, residues marked as 
(E)] in a manner similar to that of a typical substrate. Several characteristic interactions are shown: (i) 
antiparallel b sheet formed between residues P1-P3 of the inhibitor and residues 214–216 of the protease; (ii) 
sub-van der Waals contacts between Ser195 Og and P1 carbonyl carbon. From (151) 
 
II) Complex HGFA-Kunitz domain 1 of HAI-1 
The complex formed by the serine protease Hepatocyte Growth Factor Activator HGFA 
and the first inhibitory domain of Kunitz-type of HAI-1 (Hepatocyte Growth Factor Activator 
Inhibitor-1), an inhibitor homologous to Spint2 is shown in figure 28 (163,164). In Fig.28A, 
the first Kunitz domain of HAI-1 is in purple with side chains in magenta, and the catalytic 
domain of HGFA is in beige with is active site in orange. This complex follows the rules of 
canonical inhibition. HAI-1 residues P1 R260, C259-C283 and R258 make contacts with 
subsites S1 (S195), S2 and S4 of HGFA in a substrate-like manner, forming an anti-parallel  
sheet. In Fig28 B and C, all residues (in green) of HGFA (catalytic H57 and S195 are in 
yellow) that interact with residues of HAI-1 (side chains in blue) are shown. The P1 residue 
R260 of the first domain of HAI-1 (KD1) is highly exposed to allow deep insertion into the 
S1 pocket. 
 
Figure 28: Interaction of HGFA protease domain with HAI-1-derived Kunitz domain 1 (KD1). (A) KD1 
(magenta) interacts with HGFA (beige) in a substrate-like manner by occupying subsites S4, S2 and S1 (in 
orange) with Arg258, Cys259–Cys283, and Arg260 (P1 residue), respectively (side chains in blue). The binding 
region is delineated by the dotted line, and corresponds to the green surface in (B). (B) Open book representation 
of the HGFA–KD1 interaction. Residues on HGFA (green) and KD1 (blue) with an atom within 4.0Å of the 
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other protein (=binding region) are indicated. KD1 uses the protruding P1 Arg260 for insertion into the deep S1 
pocket. The catalytic His57 and Ser195 are also within 4.0Å of KD1 and are in yellow. From (163). 
 
III) Complex CAP3-Aprotinin 
A final example of canonical inhibition is represented in figure 29, which shows the 
interaction between the catalytic domain of the membrane-bound serine protease matriptase 
(in red), also known as CAP3, with the bovine pancreatic trypsin inhibitor aprotinin (BPTI, 
Kunitz-type) in blue. The classical contacts between P3-P1 residues of the binding loop 
(Pro13I and Ly15I) with the S1 pocket and subsites can be easily recognized. Moreover, this 
structure also shows a secondary binding segment (Gly36I-Arg39I). The presence of this 
additional binding segment indicates that protease-substrate or protease-inhibitor interactions 
involve more residues than those of the binding loop. This may add more specificity in such 
interactions. 
 
Figure 29: Section of the complex formed between Aprotinin (blue color) and CAP3 (red-orange). See text 
for description. From (165) 
 
7.5.5. Non-canonical inhibition 
Beside the canonical inhibition, some serine proteases can also be inhibited via a non-
canonical mechanism. This is the case for selective thrombin inhibitors such as hirudin or 
ornithodorin. The anticoagulant properties of hirudin have been known for a long time. This 
65 amino acid long peptide was isolated from salivary gland of medicinal leech and shown to 
be a powerful inhibitor of thrombin (166). The crystal structure of the thrombin-hirudin 
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complex solved in 1990 shows that the N-terminal part of hirudin is inserted into the narrow 
cleft of the active site of thrombin, partially blocking it by forming a parallel  sheet 
(167,168). In addition to this contact, hirudin makes a second contact via its long C-terminal 
tail with the exosite of thrombin usually recognized by fibrinogen (figure 30); this further 
hinders substrates to have access to the active site. Ornithodorin, isolated form a blood 
sucking soft tick, is a two-domain inhibitor. Although a canonical inhibition of thrombin 
would be anticipated since the structure of these two domains resemble to BPTI inhibitor 
(Kunitz-type), their binding loops are a bit distorted (169). Thus, they inhibit thrombin via a 
non-canonical mechanism similar to hirudin. The N-terminal domain binds the active site, 
while the C-terminal domain binds the fibrinogen recognition exosite. 
 
 
Figure 30: Structure of thrombin and thrombin-inhibitor complexes. A, The active site of the thrombin 
molecule is highlighted in yellow; the binding site is located at the base of the cleft. Adjacent to the binding site 
is the apolar binding site for fibrinogen. Exosites I and II are located on opposite sides of the thrombin molecule. 
Exosite I functions as a substrate docking site, enhancing the affinity of the interaction between thrombin and 
fibrinogen. Exosite II binds to heparin. B, Thrombin bound to the bivalent direct thrombin inhibitor hirudin. The 
C-terminus tail of hirudin binds to exosite I and the N-terminus partly obstructs the active site. After binding, 
bivalirudin is cleaved by the thrombin active site, which partly restores thrombin activity. C, Thrombin bound to 
a univalent, small-molecule direct thrombin inhibitor. Univalent direct thrombin inhibitors (argatroban, 
melagatran, dabigatran) fit into the cleft on thrombin and bind to both the active and apolar sites. From (166) 
 
7.5.6. Mechanism of inhibition used by serpins 
Serpins stands for serine proteases inhibitors. They form a large family of inhibitors 
with more than 1500 members identified in various species (170). The name might lead to 
some confusion by implying that all serine protease inhibitors are serpins, which is not the 
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case. Serpins constitute a well-defined family among other families of serine protease 
inhibitors (e.g. canonical inhibitors). Moreover, serpins can also block other types of 
proteases such as cysteine proteases (171). Unlike others serine protease inhibitors, which are 
usually small proteins, serpins are large inhibitors of about 350-500 amino acids. Examples of 
serpins in human include antithrombinIII, 2-antiplasmin and 1-antitrpysin, which play 
important roles in the coagulation cascade, fibrinolysis and lung physiology respectively 
(172). 
Their mechanism of inhibition is also different from the canonical inhibition (173). The 
process is irreversible as opposed to canonical inhibitors, which form thermodynamically 
stable but reversible complexes with their targets. The initial contact between serpin and 
enzyme is similar to canonical inhibitors based on a binding loop (called the reactive center 
loop RCL) inserted into the active site of the protease (figure 31). Then, the enzyme attacks 
the P1-P’1 peptide bond of the serpin to form an acyl-enzyme intermediate. At this point, 
unlike the very rigid canonical inhibitors, which exhibit little conformational changes, serpins 
fully incorporate the cleaved RCL into the core domain (  sheet A) and the covalently bound 
protease undergoes a pole-to-pole movement related to the inhibitor. In this complex, the 
inhibitor remains mostly intact. This is not the case for the protease, which is deformed over 
one third of its structure, including the catalytic site. 
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Figure 31: Mechanism of trypsin inhibition by the serpin α1-antitrypsin. Ribbon depictions of native α1-
antitrypsin with trypsin aligned above it in the docking orientation (left), and of the complex showing the 71Å 
shift of the P1 methionine of α1-antitrypsin, with full insertion of the cleaved reactive-centre loop into the A-
sheet (right). Regions of disordered structure in the complexed trypsin are shown as interrupted coils projected 
from the native structure of trypsin. Red, α1-antitrypsin β-sheet A; yellow, reactive-centre loop; green ball-and-
stick, P1 Met; cyan, trypsin (with helices in magenta for orientation); red ball-and-stick, active serine 195. from 
(173) 
 
 
8. MEMBRANE-BOUND SERINE PROTEASES AS POTENTIAL 
PARTNERS OF SPINT2 
 
8.1. General considerations 
Spint2 is an inhibitor of serine protease that contains a transmembrane domain. Putative 
partners of Spint2 could thus belong to a recently identified new subfamily of serine proteases 
composed of 20 members, called membrane-bound (or membrane-anchored) serine proteases 
(174). All these proteases share a similar catalytic domain of the S1 peptidase family (same as 
trypsin) and can have several accessory domains in the stem region (figure 32). They can be 
classified into two groups based on their membrane anchorage. Proteases have either a 
transmembrane domain in the C-terminus (as for tryptase-γ1) or are anchored to the 
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membrane via GPI-anchor (as for prostasin and testsin). They are known as type-I 
transmembrane proteases. Alternatively, proteases have a transmembrane domain located on 
the N-terminus. They are called type-II transmembrane serine proteases. This group can be 
further phylogenetically divided into four smaller groups. 
 
 
Figure 32: The human complement of membrane-anchored serine proteases. The single serine protease 
domain of tryptase γ1, prostasin, and testisin is attached to the membrane by a C-terminal type I transmembrane 
domain or glycophosphatidylinositol (GPI) anchor. Type II transmembrane serine proteases are attached to the 
membrane by a signal anchor (SA) located close to the N terminus. The stem region between the SA and the C-
terminal serine protease domain contains an assortment of domains including low-density lipoprotein receptor 
class A (LDLA); sea urchin sperm protein, enteropeptidase, and agrin (SEA); Cls/Clr, urchin embryonic growth 
factor, and bone morphogenic protein-1 (CUB); meprin, A5 antigen, and receptor protein phosphatase μ 
(MAM); frizzled; and group A scavenger receptor. From (174) 
 
 
8.2. Physiological role of membrane-bound serine proteases 
Some of these proteases have been shown to be involved in various physiological 
processes. For instance, CAP1/prostasin and CAP3/matriptase play an important role in the 
maintenance of the epidermal barrier integrity (175-177) and, only for CAP3, in intestinal 
barrier integrity (178,179). They are also known, with Tmprss3 and CAP2/Tmprss4 to 
regulate ENaC activity in vitro (47,180,181), although in vivo implication of membrane-
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bound serine proteases in the regulation of ENaC has only been shown for CAP1 so far 
(118,182). Physiological roles have been defined for Tmprss3 and Tmprss1/hepsin in auditory 
development and deafness (183-185), for Corin in the processing of proANP to ANP in heart 
(186) and in remodeling of spiral arteries in placenta (187), for Tmprss6/matriptase-2 in iron 
metabolism (188), for Tmprss15/Enterokinase in the intestinal activation of pancreatic 
tryspinogen into trypsin (58), and for testisin in fertility (189). All these data are inferred from 
experiments done in knockout mice. Human mutations have been reported for CAP3, 
Tmprss3, Tmprss6 and Tmprss15 leading to autosomal recessive ichtyosis with hypotrichosis, 
hearing loss, iron-refractory iron-deficiency anemia and intestinal enterokinase deficiency 
with diarrhea and hypoproteinemic edema respectively (58,183,188,190). No biological role 
has been defined for Tryptase γ1, Tmprss11d/HAT, Tmprss11e/DESC1, Tmprss11a, 
Tmprss11f/HAT-like4, Tmprss11b/HAT-like5, Tmprss2, Tmprss4, Tmprss13/MSPL, 
Tmprss5/Spinesin, Tmprss7/Matriptase-3 and Tmprss9/Polyserase-1. Moreover, no 
phenotype could be ascribed to Tmprss2, Tmprss11a or Tmprss11d knockout mice (191,192).  
 
8.3 Membrane-bound serine proteases and Spint2 
In vitro, Spint2 is a potent inhibitor of Tmprss1, CAP3, CAP1, Tmprss13 and 
matriptase-2 (92,96-99). Similar findings were found for HAI-1 who inhibits Tmprss1, CAP1, 
Tmprss13 and HAT (97,99,129,130). In particular, indirect evidence suggests that HAI-1 
seems to be a physiological inhibitor of CAP3 since a complex CAP3-HAI-1 could be 
purified form human milk (131). In addition, in vivo studies performed in mice indicate 
genetic interactions between CAP1, CAP3, HAI-1 and Spint2 (see chapters about Spint2 and 
HAI-1). Briefly, the embryonic lethality of Spint2 and HAI-1 knockout mice can be rescued 
by the disruption of the CAP1 or CAP3 genes and the postnatal lethality of HAI-1 
hypormorphic can be rescued by knocking down CAP3. These experiments demonstrate that 
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membrane-bound serine proteases, as well as membrane-bound serine protease inhibitors, 
play an important role in embryogenesis, fetal and placental development, and support that 
Spint2 and HAI-1 are inhibitors of membrane-bound serine proteases. In spite of these data, it 
is still unknown whether and how these proteins interact with each other in vivo. 
 
 
9. NHE3 AS A CANDIDATE GENE IN THE CONGENIAL 
SODIUM DIARRHEA 
 
9.1. General considerations 
NHE3 is one of the nine isoforms of Na-H-exchangers that belongs to the mammal 
SLC9 family (193). This exchanger mediates the transport of one Na
+
 ion into the cell and 
one proton out of the cell. NHE3 is abundantly located on the plasma membrane of intestinal 
epithelial cells (duodenum, jejunum, ileum, proximal colon) and tubular cells of the kidney 
(proximal tubule and thick ascending limb) (11). At the subcellular level, it is found at the 
plasma level but also has juxtanuclear localization. NHE3 cycles from one region to the other 
in a tightly regulated manner (194).  
 
9.2. Physiological role of NHE3 
NHE3 is a major actor in Na
+
 (re)absorption in the gastro-intestinal tract and in the 
kidney (11,195). NHE3 knockout mice show a phenotype very similar to the congenital 
sodium diarrhea, although the diarrhea is milder (196). These mice display absorptive defects 
fluid and bicarbonates in intestine and kidney, and consequently suffer from a mild diarrhea 
with alkaline stools and enlarged small intestine and colon, metabolic acidosis and 
hypotension. As compensatory mechanisms, aldosterone is increased, as is ENaC (epithelial 
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sodium channel) activity and H-K-ATPase mRNA expression. In the kidney, proximal fluid 
and bicarbonate absorption is reduced, whereas renin and AE1 (Cl-HCO3 exchanger) mRNA 
expression is increased. These mice die quickly when fed with a low salt diet (197,198) and 
also suffer from spontaneous colitis (199). In the intestine, NHE3 is functionally linked to the 
Cl-HCO3 exchangers SLC26A3 and SLC26A6 (DRA and PAT-1) to mediate electroneutral 
NaCl absorption (20,21). NHE3 is thus important for sodium absorption in the gut between 
the meals. In the kidney, it plays an important role in NaCl absorption but also bicarbonate 
absorption and ammonium secretion (200). Interestingly, NHE3 is also active when located 
inside the cell where it may mediate acidification of early endosomes (201,202).  
 
9.3. Regulation of NHE3 
The expression, localization and activity of NHE3 are highly regulated by a wide group 
of molecules (table 2). Of note, the second messengers cAMP, cGMP and Ca
2+
 can all 
decrease the abundance of NHE3 at the plasma membrane as well as its intrinsic activity. 
NHE3 is made of N-terminal domain of about 500 amino acids making 11 transmembrane 
domains that is responsible for the exchange of Na
+
 and H
+
 (203) and a large intracellular C 
terminal part, which is required for its regulation. Many molecules have been shown to bind 
this C-terminal loop (figure 33). These are reviewed in detail elsewhere (36,204).  
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Table 2: Molecules that acutely regulate NHE3. From (11) 
 
 
Figure 33: NHE3 regulatory complexes. NHE3 organization including COOH-terminal domains involved in 
acute regulation and binding partners. The NHE3 NH2 and COOH termini are illustrated. Shown above the 
COOH terminus in blue are sites of action of regulatory stimuli defined by the truncations which abolish the 
specific regulatory effects. The direction of the arrow indicates acute stimulation (↑) or inhibition (↓) of NHE3 
activity. Below the COOH terminus in yellow are listed associating proteins and the areas of their binding sites 
on NHE3. From (36) 
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9.4. NHE3 and serine proteases 
Regulation of NHE3 by serine proteases is poorly unknown. Among the various 
regulatory proteins of NHE3, the serine protease dipeptidyl peptidase IV (DPPIV) has been 
shown to bind to NHE3 in Opossum kidney cells (205). This protease is a member of the 
prolyl oligopeptidase family, which specifically cleaved prolyl bonds of small peptides (161). 
It is a membrane-bound serine protease with a broad tissue distribution including the intestine, 
kidney, liver, pancreas, salivary glands and immune organs such as spleen, thymus and lymph 
node (206). DDPIV is well known for its capacity to cleave and inactivate incretin hormones 
glucagon-like peptide-1 (GLP-1) and glucose insulinotropic peptide (GIP) (207). These 
hormones are secreted in the gut after a meal and bind receptors in many organs including in 
pancreas, where they regulate glucose metabolism. Inhibitors of DDPIV are now used as 
therapeutic tools in diabetes mellitus (208). DDPIV play also an important role in immune 
function (206). Regarding NHE3, inhibition of DDPIV reduces NHE3 activity in opossum 
kidney cells (a model of proximal tubular cells) and in proximal tubules of rats (209,210). 
DDPIV inhibitors also decrease blood pressure in young spontaneous hypertensive rats (211). 
This is the sole example of regulation of NHE3 by serine protease and thus an interesting 
partner for Spint2. However, if we assume that Spint2 mutations linked to the congenital 
sodium diarrhea are loss of function mutations, unopposed DDPIV activity would lead to an 
increase in NHE3 activity and thus to Na
+
 hyperabsorption in the gut, not to a diarrhea with a 
Na
+
 loss.  
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AIMS OF THE PROJECT 
 
Mutations in the Spint2 gene, which encodes a transmembrane serine protease inhibitor, 
have been associated with the congenital sodium diarrhea. How Spint2 is involved in the 
pathogenesis of this rare disease is currently unknown and the physiological role of Spint2 
remains elusive.  
Based on the clinical findings of the congenital sodium diarrhea mainly consisting in a 
specific loss of Na
+
 and HCO3
-
 in the stools, and the known jejunal defect in Na-H-exchange, 
we hypothesize that Spint2 may be a novel regulator of ion transport in gastrointestinal 
tissues. Since the congenital chloride diarrhea, with a specific loss of Cl
-
 and H
+
 in the stools 
(a mirror finding of the congenital sodium diarrhea), is due to mutations of the Cl-HCO3 
exchanger Slc26A3 and because NHE3 knockout mouse model phenocopies the congenital 
sodium diarrhea (even though the phenotype is milder), the Na-H-exchanger NHE3 appears 
as a particularly interesting candidate transporter. Loss of function mutations of Spint2 could 
result in the loss of inhibition of a yet unknown target serine protease. The unopposed activity 
of this protease may lead, directly or indirectly via other proteases or substrates, to the 
inhibition of NHE3. In consequence of this inhibition, Na
+
 and HCO3
-
 are poorly 
(re)absorbed throughout the gut, as seen in the congenital sodium diarrhea. 
Spint2 might also regulate other intestinal transporters such as the Cl
- 
channel CFTR or 
the electrogenic Na
+
-HCO3
-
cotransporter NBC1. Increased activity of CFTR, as observed 
during Vibrio Cholerae infections, results in a very severe watery diarrhea with important loss 
Na
+
, Cl
-
, K
+
 and HCO3
-
 (212). NBC1 is responsible for HCO3
-
 reabsorption in renal proximal 
tubules and loss of function mutations of NBC1 have been reported in patients suffering from 
proximal tubular acidosis (213,214). NBC1 KO mice showed profound metabolic acidosis 
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and hyponatremia (215). These mice do not display any diarrhea but intestinal impactions 
(like CFTR knockout mice (216)), suggesting that, in contrary to its role in kidney, NBC1 
plays a role in intestinal anion secretion. Thus, an increase in NBC1 activity might be present 
in congenital sodium diarrhea patients. 
Alternatively, ion transport via the paracellular route could be altered in the congenital 
sodium diarrhea. For instance, mutations in the tight junction forming proteins claudin 16 and 
19 have been reported to cause renal Mg
2+
 wasting in humans (217,218). Other claudins, such 
as claudin-2, -10 and -15 have been shown to mediate specific Na
+
-transport (219-221). 
Interestingly, the membrane-bound serine protease CAP3 has been proposed to regulate 
intestinal barrier in mice via the modulation of claudin-2 expression (179). 
No in vivo targets of Spint2 have been identified so far. As mentioned above, rescue 
experiments in Spint2 knockout mice strongly suggest that the membrane-bound serine 
proteases CAP1 and CAP3 are potential partners of Spint2 (117,119,179). The Spint2 protein 
has a transmembrane domain and there is growing evidence that HAI-1 (the homolog of 
Spint2) is an in vivo partner of CAP3 (222). Thus, we hypothesize that in vivo partners of 
Spint2 may belong to the membrane-bound serine proteases family. Of course, we cannot 
exclude serine proteases from other families as potential targets of Spint2. 
Spint2 has two inhibitory domains of the Kunitz type. How these two domains mediate 
serine protease inhibition is unknown. Answering this question has been difficult since no in 
vivo partners have been attributed to Spint2. In vitro studies suggest that both domains can 
inhibit serine proteases such as trypsin, plasmin, plasma kallikrein, pancreatic kallikrein, 
tissue kallikrein, chymotrypsin, factor XIa (see chapter about Spint2). Using site-directed 
mutagenesis, one study showed that the first domain Kunitz is mainly responsible for the 
inhibition of HGFA (90).  
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Mutations of the Spint2 gene associated with the congenital sodium diarrhea are 
probably loss-of-function mutations. This is based on three observations: 1) the congenital 
sodium diarrhea is transmitted as an autosomal recessive trait, 2) the Spint2 mutant Y163C 
shows a reduced inhibitory activity on trypsin and 3) start codon or intronic mutations of 
Spint2 lead to the absence of Spint2 protein detection when transfected in COS cells (61). 
However, the functional consequences of mutations in the Spint2 gene, particularly the 
Y163C missense mutation, have not been carefully assessed.  
 
The aims of this research project are: 
1) To perform a structure-activity study to determine the impact of the Spint2 
mutation Y163C on its inhibitory activity. This also intends to identify 
partners of Spint2 among the subfamily of membrane-bound serine proteases 
and to provide a better understanding of serine protease inhibition by the two 
Kunitz domains of Spint2. 
Approach: functional assay in Xenopus oocytes to study both functional and 
biochemical interactions between Spint2 and membrane-bound serine proteases. 
 
2) to understand the physiological role of Spint2, mainly assessing its putative 
involvement in the regulation of ion transporters (such as NHE3) in 
gastrointestinal tissues via the inhibition of membrane-bound serine proteases.  
Approaches: 
A) Generation of a Spint2 knockout mouse model and analysis of its 
intestinal phenotype. 
B) Establishment of a polarized intestinal epithelial cell line to study 
the repercussions of Spint2 knock-down and overexpression, and 
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candidate protease overexpression on Na
+
 transport and epithelial 
barrier integrity. 
C) Study of the potential regulation of NHE3 by membrane-bound 
serine proteases in Xenopus oocytes. 
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MATERIAL AND METHODS 
 
cDNA clones. cDNA clones of Tmprss3 and rat NHE3 (wt and mutant E213I) were 
gift from Bernard Rossier (University of Lausanne) and Daniel Fuster (University of Bern) 
respectively. cDNA clones of human CAP1, CAP3, Tmprss2, DPPIV and human NHE3 were 
obtained from the Mammalian Gene Collection (MGC). All cDNA were subcloned into the 
pSD(BS)easy vector (for expression in Xenopus oocytes) or into the pcDNA3.1 vector (for 
expression in Caco-2 cells). A FLAG-tag sequence was added to Spint2 using a single BstEII 
restriction site located in a sequence encoding the region between both Kunitz domains. PCR 
amplification was performed to add a tag HA-tag to NHE3 (rat and human forms, both in C-
terminal part), a GFP tag in the C-terminal part of Spint2, a histidine-tag to CAP3 and 
DPPIV. 
Site directed mutagenesis. Spint2 mutants (R48L, R143L, Y163C) were created 
using the Stratagene's QuickChange protocol. 
cRNAs. pSD(BS)easy plasmids (including α, β, and γ subunits of rat ENaC) were 
linearized using restriction enzymes with single site located after the poly(A) tail and capped 
cRNAs were in vitro synthesized
 
by SP6 polymerase. 
Expression in Xenopus oocytes. Stage V and VI healthy oocytes were isolated from 
ovarian tissue of Xenopus laevis and pressure–injected with 100nl of cRNA solution as 
indicated in the legends of the figures. For the functional assay, ooyctes were injected with 
the α, β and γ rat subunits of ENaC cRNAs (0,11ng of each subunit per oocyte) and with 
cRNAs of membrane-bound serine proteases and Spint2 (wild-type and mutants) as indicated. 
Oocytes were kept at 19° C in a low Na+ (for the functional experiments with ENaC) 
modified Barth solution (MBS) containing (mM):  10 NaCl, 0.82 MgSO4, 0.41 CaCl2, 0.33 
Ca(NO3)2, 80 N-methyl-D-glucamine (NMDG), 2 KCl and 5 HEPES or a normal Na+ (for all 
other experiments experiments) modified Barth solution (MBS) containing (mM): ): 85 NaCl, 
1 KCl, 2.4 NaHCO3, 0.82 MgSO4, 0.41 CaCl2, 0.33 Ca(NO3)2, and 10 HEPES, 4.08 NaOH 
 Electrophysiology. Electrophysiological measurements were made 12 hours after 
injection. The oocytes were studied using the standard
 
two-electrodes voltage clamp 
technique using a Dagan TEV voltage
 
clamp amplifier (Dagan, Minneapolis, MN), the 
Digidata 1322
 
digitizer, and the PClamp 9 data-acquisition and analysis package
 
(Axon 
Instruments, Molecular Devices, Sunnyvale, CA).
 
The two electrodes contained 1 M KCl 
solution. All electrophysiological experiments were performed at room temperature (22 °C). 
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The holding potential was -100 mV. The composition of the perfusion solution was (in
 
mM) 
120 NaCl, 2.5 KCl, 1.8 CaCl2-2H2O, and 10 HEPES-H
+
. Amiloride-sensitive Na
+
 current 
(INa) was defined as the difference between Na
+
 current obtained in the presence (10 μm) and 
in the absence of amiloride. As a positive control for ENaC activation by serine proteases, the 
oocytes were exposed to
 
5 µg/ml trypsin (Sigma-Aldrich Chemie) in the perfusion solution 
for 2-3 minutes.  
22Na uptake in Xenopus oocytes. Non-injected oocytes or NHE3-injected oocytes (taken 3-4 
days after injection) were washed and incubated in a Na
+
-free solution (mM: 100 choline Cl, 
2 KC1, 1 CaCl2, 1 MgCl2, 10 Hepes/Tris, pH 6.8) for 30 mintes at 18°C. Oocytes were then 
transferred in a 
22
Na-uptake solution (mM: 99 choline Cl, 0.5 
22
NaCl, 2 KC1, 1 CaCl2, 1 
MgCl2, 10 Hepes/Tris, pH 7.4) for 30 minutes at 18°C. Uptake was stopped by transferring 
the oocytes in an ice-cold stop solution (mM: 50 choline Cl, 50 NaCl, 2 KC1, 1 CaCl2, 1 
MgCl2, 10 Hepes/Tris, pH 7.4). After extensive washing using the same solution, oocytes 
were lysed in 10% SDS and uptake was measured by scintillation counting. 
Antibodies. Mouse monoclonal anti-Actin and anti-FLAG antibodies are from Sigma 
and were used at a 1:1000 and 1:500 dilutions respectively. Rabbit polyclonal anti-GFP 
antibody is from Sigma and was used at a 1:1000 dilution. Mouse monoclonal anti-HA 
antibody is from Covance and was at a 1:1000: Rabbit polyclonal Anti-His antibody is from 
Rockland and was used at a 1:1000 dilution. This antibody is conjugated to an infrared dye 
IRdye800 that allows protein detection using the Li-Cor® technology. Monoclonal antibodies 
were detected with an anti-mouse IRdye800 or 680 antibody. 
Pull-down assays. 24 hours after injection, oocytes were lysed in lysis buffer (1 % 
triton X-100, 100 mM NaCl, 20 mM Tris-HCl pH 7.5, 10mM Imidazole, 1 mM PMSF and 10 
μg/ml of each Leupeptin, Pepstatin and Aprotinin). Lysates were then vortexed and 
centrifuged for 10 minutes at 12’000rpm. The intermediate phase was withdrawn and a 
sample of each lysate was kept as a control of “total lysate fraction”. The rest of the lysate was 
incubated overnight with 50μl of Nickel-beads (Ni-NTA Agarose, Quiagen). Elution was 
performed with 50μl of 2x SDS-PAGE sample buffer (containing DTT 25mM and EDTA 
50mM). All samples were heated at 95°C for 10 minutes before loading on the SDS-PAGE 
(5-15%). 
Cell surface biotinylation. 24h hours after injection, oocytes were rinsed twice in 
MBS and then incubated in biotinylation buffer (mM: 10 triethanolamine, 150 NaCl, 2 CaCl2, 
pH 9.5) containing 1mg/ml NHS-SS-Biotin (Sigma-Aldrich Chemie) for 15 minutes at 4°C. 
Excess biotin was quenched in quench buffer (mM:192 glycine, 25 Tris-HCl, pH7.5 in MBS) 
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and oocytes were washed twice in MBS. After biotinylation, oocytes were lysed in lysis 
buffer and lysates were incubated with 50µl streptavidin beads overnight at 4°C. Beads were 
washed three times with lysis buffer, twice with a high salt buffer (same as lysis buffer but 
with 500mM NaCl) and once in 50mM Tris-HCl pH7.4 or only three times with lysis buffer 
as indicated. Elution was performed with 50μl of 2x SDS-PAGE sample buffer (containing 
DTT 25mM). All samples were heated at 95°C for 10 minutes before loading on the SDS-
PAGE (5-15%). 
Generation of Spint2 gut-specific and tamoxifen-inducible Knockout mice. 
Embryonic stem cells with one allele of Spint2 trapped by the gene-trap construct 
rsFlipRosaCeo0 were obtained from the German Gene Trap Consortium (GGTC). These cells 
come from the 129P2 (formerly 129/Ola) mouse strain. The presence of the gene trap 
construct in the first allele of Spint2 was verified by PCR analysis and sequencing.  ES cells 
were injected into the blastocoel cavity of C57/BL6-derived blastocysts and implanted into 
pseudopregnant females. Chimeric offsprings were crossed to C57/BL6 mice to obtain 
TRAP/+ mice. We were unable to obtain TRAP/TRAP mice by crossing TRAP/+ mice 
together because of embryonic lethality (see results). The orientation of the gene trap 
construct was inverted by crossing TRAP/+ mice with Gt(ROSA)26Sor-FLPe mice (kindly 
provided by Edith Hummler, University of Lausanne)  to obtain Tinv/+ mice. Tinv/Tinv 
homozygous mice were crossed to Villin-Cre mice (kindly provided by Edith Hummler, 
University Of Lausanne) to obtain gut-specific Spint2 KO mice or to β-actin-Cre-ERtm mice 
(Jackson laboratory) to obtain Tamoxifen-inducible Spint2 KO mice. Genotyping of mice was 
performed by PCR on genomic DNA samples of tail or ear biopsies. The following primers 
were used to detect: 
the spint2 wt allele: 
mgS2_18423F: GAAGTTCTTGGATTTGAGTGTTGG 
mgS2_18821R: CCCACTACCTTCGAAACTCC 
 the Spint2 trapped allele: 
mgS2_18423F: GAAGTTCTTGGATTTGAGTGTTGG 
Cd2R: CAAGTTGATGTCCTGACCCAAG 
the FLPe transgene: 
FLIP_anti: CTCGAGGATAACTTGTTTATTGC 
FLIP_sense: CTAATGTTGTGGGAAATTGGAGC 
 the VillinCre transgene: 
Crevillin_F: GTTCGCAAGAACCTGATGGAC 
Crevillin_R: CTAGAGCCTGTTTTGCACGTT 
 the CreERtm transgene: 
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CAGG_CreERTM_F: CTCTAGAGCCTCTGCTAACC 
CAGG_CreERTM_R: CCTGGCGATCCCTGAACATGTCC 
Quantitative PCR analysis. Total RNA was extracted from mouse tissues using the 
RNeasy kit from Qiagen according to the manufacturer's protocol. 1.5 μg RNA was reverse 
transcribed into cDNA with the M-MLV reverse transcriptase and random primers (Promega). 
RNA was treated with DNAse I (Promega) to remove any possible traces of genomic DNA 
before the cDNA synthesis. The following primers and Taqman probes were used to detect: 
Spint2 cDNA : 
mSpint2_exon3_F: GAATGGAGCCGACTCTTCTG 
mSpint2_exon5_R: GCCTTCGGGACACAGTATTC 
mSpint2_exon4_Probe: AGAAAGCAGAGTGCTGAGGACCTGTCT 
Actin cDNA: 
mActin_exon1_F: GCTTCTTTGCAGCTCCTTCGT 
mActin_exon2_R: CCAGCGCAGCGATATCG 
mActin_exon1-2_Probe: CCCGCCACCAGTTCGCCATG 
 
The qRT-PCR experiments were carried out on an ABI PRISM 7500 equipment (Applied 
Biosystems). PCR was performed in 96-well plates (Applied Biosystems) in 20-μl reactions 
that contained 10 μl of TaqMan Master Mix (Applied Biosystems), 250 nM of probe, 900 nM 
of each primer and 4 μl of cDNA (diluted 25 times). 
Tamoxifen-induced Spint2 ablation treatment. 4 week-old Tinv/Tinv; CreERtm+ or 
Tinv/Tblocked; CreERtm+ mice (and littermates controls negative for the Cre transgene) 
were injected intraperitoneally with Tamoxifen (9mg or 3mg/40g of body weight, SIGMA) in 
peanut oil once day durinfg 4 days or 10 days (see results). 
Metabolic cages. 8 week-old mice were place in individual metabolic cages to 
collect, after three days of adaptation, 24 hour urine and faeces and measure bodyweight 
water and food intake. Mice were fed a normal salt diet (>3.2% Na
+
, Sniff) for days and then 
a low-salt diet (0.18% Na
+
) for three days. At the end of the experiment, Mice were 
anesthetized with isoflurane and blood was collected by retroorbital plexus puncture. Mice 
were then sacrificed to collect tissues for qRT-PCR experiments. Urinary and plasma Na
+
 and 
K
+
 were measured using a flame photometer (Cole-Palmer Instrument). 
Cell culture. Caco-2 cells were kindly provided by Blaise Corthésy (University of 
Lausanne). Cells were grown at 37°C in MEM (Gibco) supplemented with 10% FBS, 10 mM 
HEPES, 1% penicillin/streptomycin, 2mM glutamine, 1mM sodium pyruvate and 0.1% 
transferrin. Cells cultivated to 80% confluency were seeded on Snapwell filters (diameter, 12 
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mm; pore size, 0.4 μm; Corning Costar, Cambridge, MA) at a density of 2.5-3.0 × 105 
cells/cm
2
. The culture medium was changed every 2-3 days. After 3 weeks, the formation of 
monolayers of polarized cells was assessed by measuring the transepithelial electrical 
resistance (TER) using a Millicell-ERS apparatus (Millipore, Bedford, MA). TER values of 
around 350-400 ohms × cm
2 
were usually found. Cells were then washed three times with 
PBS and lysed in RLT-Buffer (from Qiagen RNeasy kit) by pipetting up and down. Before 
PCR-analysis, total RNA was extracted and then in vitro reverse transcribed into cDNA as 
described above. The following primers were used for PCR analyses: 
 
 
Cell transfections. Caco-2 cells grown on plastic were transfected using 
Lipofectamine2000 (Invitrogen) with pcDNA3.1 plasmids encoding Spint2 cDNA with 
FLAG-tag or GFP-tag or shRNA constructs targeting human Spint2 (Thermo Scientific, 
TRCN0000073578, -79, -80, -81 and -82). 48 hours after transfection, membrane preparation 
were performed or cells were lysed to collect total RNA. 
Membrane preparation. All steps were performed at 4°C. Cells grown on plastic in 6 
well-plates were scrapped in 300μl of lysis buffer (100 mM Tris-HCl pH 7.0, 300 mM NaCl, 
10 mM MgCl2, 1 mM PMSF and 10 μg/ml of each Leupeptin, Pepstatin and Aprotinin). 
Lysate were centrifuged at full speed for 30 minutes. The supernatant was kept as the 
cytosolic fraction. Pellets were resuspended in lysis buffer (same buffer as described in the 
pull-down assays section) and centrifuged at full speed for 15 minutes. The supernatant was 
kept as the membrane fraction. Both fractions were then used for SDS-PAGE. 
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RESULTS 
 
1. STRUCTURE-ACTIVITY STUDY OF SPINT2 WILD TYPE 
AND MUTANTS; A FUNCTIONAL ASSAY IN XENOPUS 
OOCYTES 
 
1.1. Functional assay in Xenopus oocytes 
The results of this project are found in a manuscript that is currently being in the 
reviewing process for publication in the Journal of Biological Chemistry (see manuscript at 
the end of this work). 
 
1.2. Complementary data to the functional assay in Xenopus oocytes 
1.2.1. Assessment of the Spint2 R48L and R143L mutations 
Qin et al generated mutants of Spint2 where the P1 residue (reactive site) at position 48 
and 143 in each Kunitz domain is mutated from an arginine into a leucine (90). In cell-free in 
vitro assay using soluble recombinant proteins, the mutant in the first Kunitz domain, Spint2 
R48L, showed a decreased inhibitory activity on HGFA (Hepatocyte Growth Factor Activator 
Inhibitor), whereas the mutant in the second Kunitz domain, Spint2 R143L, was still 
functional, suggesting an important role of the first domain for the inhibition of HGFA. 
Recently, the same mutants have been tested for their inhibitory activity on CAP3 in MDCK 
cells (93). The inhibition was only assessed on the capacity of Spint2 wild-type or mutants to 
“protect” the full length form CAP3 from (auto-?) proteolyitc activation and degradation. In 
this aspect, Spint2 R48L showed a reduced capacity, whereas Spint2 R143L was still able to 
prevent the degradation of CAP3.  
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We assessed both mutants, together with the double mutant in our functional assay in 
Xenopus oocytes. As depicted in figure 1, Spint2 R48L showed a reduced capacity to block 
the activating effect of CAP3 on ENaC. Spint2 R143L displays a slightly decreased inhibitory 
activity although it is statistically significant. A more profound loss of function was seen with 
the double mutant Spint2 R48L/R143L, although its inhibitory capacity was not fully 
abolished. 
 
 
Figure 1: Inhibitory effect of Spint2 R48L and Spint2 R143L on CAP3. Oocytes were injected with 0.11ng 
cRNA of each rENaC subunit, CAP3 and Spint2 (wild-type or mutants) cRNAs as indicated. n≥24 measured 
oocytes. ENaC-mediated sodium currents INa
+
 are measured without (black bars) and with trypsin (5μg/ml) 
perfused extracellularly (white bars) as a positive control for ENaC activation. Left panel shows absolute values 
of INa
+
. Right panel shows relative trypsin-mediated increase in INa
+
 as assessed by diving for each oocytes INa
+ 
after trypsin treatment by INa
+
 before trypsin treatment. Data are means ± SEM. ***, p<0.001, compared to 
ENaC + protease + Spint2 WT respectively after One-way ANOVA followed by Tukey’s multiple comparisons 
test. 
 
We also tested the effect of these mutations of Spint2 on Tmprss2. We did not observe 
any reduction of the inhibitory activity of Spint2 R48L and Spint2 R143L compared to Spint2 
wild-type (figure 2). Only the double mutant Spint2 R48L/R143L showed a clear loss of 
function although it still had some inhibitory activity. These results confirm data from recent 
publications and suggest that the first inhibitory domain of Spint2 is more important for the 
inhibition of CAP3 but not for Tmprss2.  
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Figure 2: Inhibitory effect of Spint2 R48L and Spint2 R143L on Tmprss2. Oocytes were injected with 
0.11ng cRNA of each rENaC subunit, Tmprss2 and Spint2 (wild-type or mutants) cRNAs as indicated. n≥20 
measured oocytes. ENaC-mediated sodium currents INa
+
 are measured without (black bars) and with trypsin 
(5μg/ml) perfused extracellularly (white bars) as a positive control for ENaC activation. Left panel shows 
absolute values of INa
+
. Right panel shows relative trypsin-mediated increase in INa
+
 as assessed by diving for 
each oocytes INa
+ 
after trypsin treatment by INa
+
 before trypsin treatment. Data are means ± SEM. ***, p<0.001, 
compared to ENaC + protease + Spint2 WT respectively after One-way ANOVA followed by Tukey’s multiple 
comparisons test. 
 
We also compared the effect of Spint2 R48L to the effect of the congenital sodium 
diarrhea mutant Y163C on CAP3. Both mutants were tested during same experiments as was 
the double mutant R48L/Y163C. Figure 3 reports, as expected, a similar partial loss of 
function of both mutants with a residual inhibitory activity of about 40%. An additive effect 
of both mutations was observed using the double mutant Spint2 R48L/Y163C but the function 
was not totally abolished. These results imply that, in opposite to previous experiments, both 
domains might play a role in the inhibition of CAP3 by Spint2. 
 
 
Figure 3: Inhibitory effect of Spint2 R48L and Spint2 Y163C on CAP3. Oocytes were injected with 0.11ng 
cRNA of each rENaC subunit, CAP3 and Spint2 (wild-type or mutants) cRNAs as indicated. n≥24 measured 
oocytes. ENaC-mediated sodium currents INa
+ 
are measured without (black bars) and with trypsin (5μg/ml) 
perfused extracellularly (white bars) as a positive control for ENaC activation. Left panel shows absolute values 
of INa
+
. Right panel shows relative trypsin-mediated increase in INa
+
 as assessed by diving for each oocytes INa
+ 
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after trypsin treatment by INa
+
 before trypsin treatment. Data are means ± SEM. *, p<0.05, **, p<0.01, ***, 
p<0.001, compared to ENaC + protease + Spint2 WT respectively after One-way ANOVA followed by Tukey’s 
multiple comparisons test. 
 
 
1.2.2. Dipeptidyl peptidase IV as putative target of Spint2 
Dipeptidyl peptidase IV, DPPIV, is the only serine protease that has been proposed in 
the literature to act as a regulator of the Na-H-exchanger NHE3 (see introduction, chapter 
about NHE3). We tested the potential interaction between DPPIV and Spint2 in our functional 
assay in Xenopus oocytes. DPPIV, although a membrane-bound serine protease, belongs to 
the S9 family and is thus functionally and structurally different from the other membrane-
bound serine protease studied in this project (CAP1, CAP2, CAP3, Tmprss1, Tmprss2, …) 
that belong to S1 family. DPPIV is not able to stimulate the activity of the epithelial sodium 
channel ENaC (figure 4). This makes it difficult to use ENaC as reporter gene to test an 
interaction between DPPIV and Spint2.  
 
Figure 4: Effect of DPPIV on ENaC in Xenopus oocytes. Oocytes were injected with 0.11ng cRNA of each 
rENaC subunit and increasing amount of DPPIV cRNA as indicated. N=8 measured oocytes. ENaC-mediated 
sodium currents INa
+
 are measured without (black bars) and with trypsin (5μg/ml) perfused extracellularly (white 
bars) as a positive control for ENaC activation. 
 
We thus tried to make a competitive assay where ENaC, DPPIV, CAP3 and Spint2 are all co-
injected in oocytes. If Spint2 binds DPPIV with a high affinity, CAP3 should not be inhibited 
anymore by Spint2 and could thus activate ENaC. Figure 5 shows that it is not case, because 
increases in injected DPPIV cRNA amounts did not prevent the inhibition of CAP3 by Spint2 
as seen by the absence of activation of ENaC and its intact sensitivity to trypsin. The gradual 
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decrease in INa
+
 with and without trypsin seen when co-injecting CAP3, Spint2 and DPPIV is 
likely due to a decrease in the translation of ENaC because of a competition for the 
translational machinery. 
 
 
Figure 5: Competition between CAP3 and DPPIV as substrate for Spint2. Oocytes were injected with 
0.11ng cRNA of each rENaC subunit, CAP3, Spint2 and increasing amount of DPPIV cRNAs as indicated. n≥10 
measured oocytes. ENaC-mediated sodium currents INa
+
 are measured without (black bars) and with trypsin 
(5μg/ml) perfused extracellularly (white bars) as a positive control for ENaC activation. 
 
Pull-down experiments were performed to assess biochemically whether DPPIV and 
Spint2 interact. For this purpose a His-tag was introduced in the N- or C-terminal end of 
DPPIV to allow affinity purification of DPPIV using nickel-beads. As positive control, figure 
6A shows the co-purification of Spint2-FLAG with CAP3 that has a His-tag in its N-terminal 
end. In contrary, in the same experiment, Spint2-FLAG could not be co-purified with DPPIV, 
even if DPPIV was affinity-purified using either the His-tag on the N- or C-terminal part 
(figure 6B). All these results from both functional and biochemical experiments suggest that 
Spint2 is not an inhibitor of DPPIV. 
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Figure 6: Biochemical interaction between Spint2 and DDPIV in Xenopus oocytes. A) Western blot 
performed using oocytes coexpressing tagged His-CAP3 and Spint2-FLAG as indicated. B) Western blot 
performed using oocytes coexpressing tagged His-DDPIV and Spint2-FLAG as indicated. Bound fraction 
contains proteins eluted after incubation onto nickel beads. Membranes were blotted with anti-FLAG (red) and 
anti-His (green) antibodies. 
 
 
2. GENERATION OF A SPINT2 KNOCKOUT MOUSE MODEL 
 
2.1. The gene-trap approach 
A constitutive Spint2 mouse model has already been generated using a gene-trap 
approach (116,117). In opposite to the classical gene-targeting approach that specifically 
alters the expression of one selected gene by removing one or more critical exons based on 
homologous recombination (223), the gene-trap approach consists in the random insertion of 
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a gene trap vector construct into the genome of mouse embryonic stem (ES) cells (224). 
When inserted into an intronic or coding region of a gene, this construct is supposed to alter 
the expression of this gene and may even abolish it when present in one of the first introns of 
the gene or in a critical region. 
Spint2 knockout mice unfortunately display embryonic lethality due to early defects 
during the gastrulation stage, abnormal placental labyrinth development and non-closure of 
the neural tube (116,117). To circumvent this issue, we planned to generate a conditional 
knockout mouse model of Spint2 using the Cre/lox technology (225). 
In 2005, Schnütgen et al described two gene trap vector constructs combined with the 
Cre/lox system and generate more than 1000 ES cells clones with one gene trapped by one of 
their constructs, among them the Spint2 gene (226). We thus ordered from the German Gene 
Trap Consortium ES cells with the FlipRosaCeo construct inserted in the first intron of 
Spint2. Figure 7 shows how this construct abolishes gene expression when inserted within the 
first intron of a gene.  
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Figure 7: Conditional gene trap vectors and mechanism of gene inactivation. (A) Schematic representation 
of the retroviral gene trap vectors. LTR, long terminal repeat; frt (yellow triangles) and F3 (green triangles), 
heterotypic target sequences for the FLPe recombinase; loxP (red triangles) and lox511 (purple triangles), 
heterotypic target sequences for the Cre-recombinase; SA, splice acceptor; βgeo, β-galactosidase/neomycin 
phosphotransferase fusion gene; pA, bovine growth hormone polyadenylation sequence; TM, human CD2 
receptor transmembrane domain. (B) Conditional gene inactivation by a SAβgeopA cassette. The SAβgeopA 
cassette flanked by recombinase target sites (RTs) in a FlEx configuration is illustrated after integration into an 
intron of an expressed gene. Transcripts (shown as gray arrows) initiated at the endogenous promoter are spliced 
from the splice donor (SD) of an endogenous exon (here, exon 1) to the SA of the SAβgeopA cassette. Thereby 
the βgeo reporter gene is expressed and the endogenous transcript is captured and prematurely terminated at the 
cassette's pA causing a mutation. In step 1, FLPe inverts the SAβgeopA cassette onto the antisense, noncoding 
strand at either frt (shown) or F3 (not shown) RTs and positions frt and F3 sites between direct repeats of F3 and 
frt RTs, respectively. By simultaneously excising the heterotypic RTs (step 2), the cassette is locked against 
reinversion because the remaining frt and F3 RTs cannot recombine. This inversion reactivates normal splicing 
between the endogenous splice sites, thereby repairing the mutation. Cre-mediated inversion in steps 3 and 4 
repositions the SAβgeopA cassette back onto the sense, coding strand and reinduces the mutation. Note that the 
recombination products of steps 1 and 3 are transient and transformed into the stable products of step 2 and 4, 
respectively. From (226) 
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2.2. Constitutive and conditional Spint2 knockout mice 
We first generated mice having one allele of the Spint2 gene containing the 
FlipRosaCeo gene trap vector construct inserted within the first intron. In this configuration 
(that we called TRAP), the construct is supposed to abolish Spint2 expression because only a 
truncated mRNA and thus protein (made of the first exon of Spint2 and the reporter cassette 
Ceo) is produced when the Spint2 gene is active. No further exons should be expressed since 
the reporter cassette has a polyadenylation signal that terminates transcription prematurely 
(i.e. before transcription of exon 2). When crossing heterozygous mice together, we did not 
observe any mice homozygous for the trapped allele of Spint2 (Spint2 TRAP;TRAP) as 
shown by PCR genotyping in figure 8a. These results indicate that Spint2 expression is 
sufficiently altered to cause embryonic lethality as for the constitutive knockout model 
previously reported. 
As shown in figure 6, recognition sites for the FLPe recombinase and Cre recombinase 
flank the FlipRosaCeo gene trap vector construct. There are two pairs of sites for each 
recombinase. Each pair can only recombine with itself; e.g. LoxP sites cannot recombine with 
Lox51 sites. Moreover, the sites are arranged in a specific manner that blocks the construct in 
its new configuration once recombination mediated by one recombinase has occurred. 
To repair the mutation induced by the presence of the gene trap construct and thus 
rescue the embryonic lethality, TRAP/+ mice were crossed with transgenic mice expressing 
the FLPe recombinase under the Gt(ROSA)26Sor promoter (227). This promoter allows FLPe 
expression in all cells starting already during the preimplantation stage. FLPe-mediated 
recombination inverts the reporter cassette. In this configuration (called inverted trap = inv 
TRAP), the cassette is “inactive” and normal splicing of the Spint2 gene occurs thus repairing 
the mutation and allowing normal Spint2 expression (see Step 2 in figure 7). This step was 
correctly achieved as seen in figure 8b that shows three weaned mice being homozygous for 
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the inverted trapped allele (=inv TRAP), indicating that enough Spint2 expression is restored 
to avoid embryonic lethality. These mice are viable and are on gross examination 
undistinguishable from wild-type mice.  
 
Figure 8: PCR-genotyping. A, Genotyping of pups born from the breeding between heterozygous mice. None 
of the pups are homozygous for the trapped allele (=TRAP, 800bp). WT allele is the product at 400bp. B, 
recombination with the FLPe. Mice no 6,8,13 are homozygous for the inverted trapped allele (Inv. TRAP 
1500bp). 
 
The final step consists in reactivating the mutation to abolish Spint2 expression in 
selected tissues, in our case epithelial cells of the small intestine and colon. We crossed inv 
TRAP / inv TRAP homozygous mice with transgenic mice expressing the Cre recombinase 
driven by the villin promoter. The villin promoter ensures Cre expression only in epithelial 
cells of the small intestine and colon (228). In this step (see Step 3 in figure 7), Cre-mediated 
recombination is supposed to occur only in those cells. This recombination repositions the 
reporter cassette back to its initial orientation. In this configuration, the mutation is 
reactivated and Spint2 expression should be abolished specifically in intestinal epithelial cells. 
Unfortunately, qRT-PCR experiments done using fractions of cells enriched in epithelial cells 
of the ileum (were both Spint2 and Cre expression is supposed to be high) showed that inv 
TRAP homozygous, Villin-Cre positive mice have a similar Spint2 mRNA expression than 
inv TRAP homozygous, Villin-Cre negative mice (figure 9).  
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Figure 9: Spint2 mRNA expression levels in selected organs. Spint2 mRNA expression was assessed in mice 
homozygous for the inverted trapped allele expressing or not the Cre driven by the villin promoter. n=3 mice per 
genotype. Mucosa of the ileum was scrapped to obtain a fraction enriched in epithelial cells and another enriched 
in intestinal wall cells. Ileum was assessed here because both Spint2 and Cre expressions are expected to be 
abundant. 
 
Furthermore, inv TRAP homozygous, Villin-Cre positive mice do not exhibit any 
phenotype on gross examination such as diarrhea. Analyses from experiments done in 
metabolic cages with mice fed a normal salt or a low salt diet do not show any difference 
between inv TRAP homozygous, Villin-Cre positive mice and controls (Table 1). These 
results indicate that the system used here failed to generate a conditional gut-specific Spint2 
knockout mouse model. Mutations in the LoxP and Lox51 sites that are recognized by the Cre 
recombinase were excluded by sequencing (data not shown).  
Metabolic cages Standard diet (4 days) Low salt diet (3 days) 
 Control (n=7) “KO” (n=5) Control (n=7) “KO” (n=5) 
Body weight (g) 27.2 ± 0.43 27.4 ± 1.01 27.4 ± 0.49 27.6 ± 1.16 
Food intake (g/24h/gBW) 0.135 ± 0.006 0.138 ± 0.008 0.124 ± 0.005 0.129 ± 0.005 
Water intake (g/24h/gBW) 0.16 ± 0.01 0.179 ± 0.007 0.167 ± 0.015 0.172 ± 0.005 
Stool (g/24h/gBW) 0.019 ± 0.001 0.021 ± 0.001 0.019 ± 0.001 0.019 ± 0.001 
Urine volume (g/24h/gBW) 0.057 ± 0.006 0.075 ± 0.005 0.054 ± 0.006 0.064 ± 0.007 
Plasma Na+ (mmol/l) N.D. N.D. 147.7 ± 2.4 144.9 ± 1.5 
Plasma K+ (mmol/l) N.D. N.D. 5.1 ± 0.3 4.9 ± 0.1 
Urinary Na+ excretion (μmol/24h/gBW) 7.15 ± 0.75 7.52 ± 0.6 1.47 ± 0.3 1.27 ± 0.3 
Urinary K+ excretion (μmol/24h/gBW) 22.75 ± 2.03 24.89 ± 1.44 35.99 ± 2.03 38.00 ± 2.5 
Table 1: Data of experiments in metabolic cages. 7 inv TRAP/inv TRAP Cre negative (control) mice and 5 
inv TRAP/inv TRAP Cre positive (“KO”) mice were fed first a standard diet (4 days) and then a low salt diet (3 
days). Mice were housed in individual metabolic cages during the whole experiment.  
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Since Villin-Cre-mediated recombination was inefficient, we used another transgenic 
mouse model expressing in every cell-type a tamoxifen-inducible Cre as developed by 
Hayashi and McMahon (called Cre ERTM) (229). Tamoxifen-induction of this Cre driven by 
the β-Actin/CMV enhancer promoter is depicted in figure 10.  
 
 
Figure 10: Mechanism of action of Cre fused to the ligand-binding domain of the estrogen receptor. The 
Cre protein is maintained in the cytoplasm because of its fusion to the estrogen-receptor (ER). Upon tamoxifen 
treatment, CreER translocates into the nucleus where Cre-mediated recombination occurs. From (230) 
 
Inv TRAP homozygous mice were bred with transgenic mice Cre ERTM and 4 weeks old 
pups were treated with tamoxifen (9mg/40g of body weight intraperitoneally) once a day for 4 
days. This time, we observed a 50% decrease in Spint2 mRNA expression in the distal part of 
the small intestine and colon (fig. 11) but on gross examination, these mice showed no 
diarrhea and no weight loss (data not shown). 
 
Figure 11: Spint2 mRNA expression levels in selected organs. Spint2 mRNA expression was assessed in mice 
homozygous for the inverted trapped allele expressing or not the Tamoxifen-inducible Cre driven by the β-Actin 
promoter. Mice were injected i.p. with Tamoxifen (9mg/40g body weight) once a day for 4 days. n=2 mice per 
genotype.  
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Since a 50% decrease is likely insufficient to observe any phenotype, we tried to improve the 
protocol. The tamoxifen-inducible Cre is expressed in every cell including in germ cells 
where Cre-mediated recombination also occurs upon tamoxifen. Thus, it is possible to 
generate heterozygous mice that have one Spint2 allele trapped by the gene-trap construct in 
the inverted position (repaired mutation, Step 2 in figure 7) and the other allele with the 
construct in its initial position (active mutation Step 4 in figure 7). In the latter configuration, 
the construct cannot further recombine because all pairs of homotypic recognition sites for the 
Cre are destroyed (this allele is called Tblock). In such heterozygous mice, only one allele 
should recombine to get both alleles with the gene trap active (Step 4 in figure 1). Tamoxifen 
treatment was increased to 10 days (3mg/40g of body weight). qRT-PCR analyses revealed 
again a 50% reduction in Spint2 mRNA expression in proximal colon and jejunum (figure 
12). Interestingly, Tinv/Tblock heterozygous Cre-negative mice that are supposed to have 
only one functional allele (Tinv) show a similar Spint2 mRNA expression than Tinv/Tinv 
homozygous mice that have two functional alleles, suggesting that the functional allele can 
completely compensate for the reduced or abolished function of the non-functional allele 
(Tblock). This compensation was seen only in the proximal colon and jejunum, but not in the 
kidneys and lungs. In spite of this lack of compensatory mechanisms, no further decrease in 
Spint2 mRNA expression could be obtained in the kidneys and lungs upon tamoxifen 
treatment, suggesting that Cre-mediated recombination is inefficient to obtain a larger 
reduction in Spint2 mRNA expression. In conclusion, the strategy used here based on a gene-
trap approach combined with the Cre/lox system is not suitable to get a gut-specific or a 
tamoxifen-induced Spint2 knockout mouse model.  
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Figure 12: Spint2 mRNA expression levels in selected organs. Spint2 mRNA expression was assessed in mice 
homozygous for the inverted trapped allele or heterozygous (with one trapped blocked allele) expressing or not 
the tamoxifen-inducible Cre driven by the BetaActin promoter. Mice were injected i.p. with tamoxifen (3mg/40g 
body weight) once a day for 10 days.  
 
 
3. AN EPITHELIAL CELL MODEL FOR SPINT2 
 
3.1. Characterization of Caco-2 cells 
Animal models and particularly genetically modified mouse models are very useful 
tools to understand in vivo the physiological role of genes of interest. Since our strategy did 
not allow us to generate a viable Spint2 knockout mouse model, we planned to establish an 
epithelial cell model for Spint2.  
We used the Caco-2 cell line, which is an intestinal epithelial cell line of colonic 
adenocarcinoma origin (231). These cells can be grown on filter where they form monolayers 
of polarized cells resembling villous cell of the small intestine called enterocytes. Caco-2 cells 
were cultured on Snapwells during 3 weeks to obtain monolayers with a transepithelial 
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electric resistance of around 350-400 Ωcm2, which is consistent with recent publications 
(232,233). 
In order to characterize these cells in more detail, mRNA gene expression analysis was 
performed on Caco-2 cells grown on plastic and on filters as a monolayer. Figure 13 shows 
that mRNA of Spint2 and its homolog Spint1 (HAI-1) can be easily detected in those cells. 
Candidate transporters for the congenital sodium diarrhea such as NHE3 and CFTR are also 
expressed. As expected, the mRNA expression of NHE3 increases when the cells differentiate 
into polarized enterocytes on filter. mRNA of several membrane-bound serine proteases such 
as CAP1, CAP3 and Tmprss2 can be detected, but not Tmprss13.  
 
Figure 13: mRNA gene expression analysis in Caco-2 cells. RT-PCR was performed using total RNA 
extracted from Caco-2 cells grown on plastic (upper panel) or on filter to form a monolayer of polarized cells 
(lower panel). Plasmid cDNA of Tmprss13 was used as a control for Tmprss13 amplification. 
 
3.2. Overexpression of Spint2 in Caco-2 cells 
In order to overexpress Spint2 in Caco-2 cells, we generated two tagged constructs of 
Spint2. In one construct, a FLAG-tag was added in the putative extracellular region of Spint2 
between the two Kunitz domains and in the other construct, a GFP-tag was fused to the C-
terminal part of Spint2 (the putative cytosolic region). Both constructs are as functional as the 
wild-type untagged form of Spint2, as assessed by their capacity to inhibit the activating 
effect of CAP1 or CAP3 on the epithelial sodium channel (ENaC) in Xenopus oocytes (figure 
14). Spint2-FLAG and Spint2-GFP cDNA constructs were transfected into Caco-2 cells 
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grown on plastic. Both constructs could be detected at the protein level by western blotting 
after membrane preparation (figure 15). 
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Figure 14: Inhibitory activity of FLAG-tagged and GFP-tagged Spint2 on CAP3 and CAP1 as assessed by 
modulation of ENaC activity in Xenopus oocytes. Oocytes were injected with 0.11ng cRNA of each rENaC 
subunit and CAP1, CAP3 and Spint2 cRNA as indicated. A, Inhibition of CAP3 by Spint2wt and Spint2FLAG. 
B, Inhibition of CAP1 by Spint2wt and Spint2GFP. n≥6 measured oocytes. ENaC-mediated sodium currents INa
+
 
are measured without (grey bars) and with trypsin (5μg/ml) perfused extracellularly (black bars) as a positive 
control for ENaC activation. *** P<0.001 compared to oocytes injected with rENaC and CAP3 or CAP1.  
 
 
Figure 15: Spint2-FLAG and Spint2-GFP protein expression in Caco-2 cells. Caco-2 cells grown on plastic 
were transfected using Lipofectamine (=L) or FuGene (=F) with hSpint2-FLAG (left panel) or hSpint2-GFP 
(right panel). A membrane preparation was performed 18h after transfection (Mb=membrane fraction, Cyt= 
cytosolic fraction). Left panel: immunoblot with the anti-FLAG antibody. Right panel: immunoblot with the 
anti-GFP antibody. GFP was transfected as a positive control. 
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3.3. Knocking down Spint2 in Caco-cells 
In addition to overexpressing Spint2 in Caco-2 cells, we had also planned to knock-
down endogenous expression of Spint2 and ordered 5 different shRNA constructs that target 
the Spint2 gene. After transfection into Caco-2 cells, a 50% reduction in Spint2 mRNA levels 
(figure 16). Since Caco-2 cells are known to be difficult to transfect and are usually 
transduced using lentiviruses, the reduction observed here suggests that all shRNA construct 
potently knock down Spint2 expression in cells that are readily transfected. 
The efficiency of the shRNA construct 1 (shRNA 1 in figure 16) is further demonstrated 
in figure 17, where Spint2-FLAG protein levels are strongly decreased in Caco-2 cells 
transiently transfected with Spint2-FLAG cDNA and shRNA construct 1. We could not assess 
endogenous protein expression levels of Spint2, because we do not have any anti-Spint2 
antibody.  
 
3.4. Stably transfection of Caco-2 cells 
Caco-2 cells grown on filter require 3 weeks to form monolayers of well-differentiated 
and polarized cells. The effect of transient transfection performed before culturing the cells on 
filter is therefore lost when monolayers are formed. A second issue is that Caco-2 cells on 
filter are even more difficult to transfect than Caco-2 cells grown on plastic. One solution 
would be to use a retroviral-based transduction system to infect monolayers. Another 
possibility would be to generate stably transfected clones.  
To do so, Caco-2 cells were transfected with Spint2-FLAG, Spint2-GFP or shRNA 1 
and 2 against Spint2 and cells were then selected by adding puromycin in the culture medium. 
In a first attempt, serial dilution was done to get single stably transfected clones. 
Unfortunately, no clone could be obtained. In a second try, no serial dilution was performed 
in order to get a polyclonal population of cells. This time, transfected cells grew in the 
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presence of puromycin, albeit slowly. However, neither any overexpression of Spint2-FLAG 
and Spint2-GFP nor any reduction in endogenous Spint2 mRNA expression levels could be 
detected in cells transfected with Spint2-FLAG, Spint2-GFP or shRNA-1 respectively (data 
not shown). 
 
Figure 16: Effects of shRNA constructs on Spint2 mRNA expression in Caco-2 cells. Caco-2 cells were 
transiently transfected with 5 shRNA constructs that targets Spint2. 48 hours after transfection, Spint2 mRNA 
expression levels were assessed by qRT-PCR. Each condition was analyzed in duplicate. 
 
 
Figure 17: Effect of shRNA construct 1 on Spint2-FLAG protein expression in Caco-2 cells. Caco-2 cells 
were transiently transfected with Spint2-FLAG, shRNA 1 against Spint2, or shRNA against AKAP (unrelated 
protein used here as a negative control) as indicated. Immunoblot using the Anti-FLAG antibody (in red) was 
performed on membrane preparation. 
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4. THE NA-H-EXCHANGER NHE3 AND MEMBRANE-BOUND 
SERINE PROTEASES 
 
4.1. Cleavage of NHE3 by Tmprss3 
As mentioned in the introduction, the Na-H-exchanger NHE3 represents an interesting 
ion transporter potentially involved in the pathogenesis of the congenital sodium diarrhea. We 
showed that Spint2 is a powerful inhibitor of membrane-bound serine proteases (see 
introduction and functional assay in Xenopus oocytes). Based on this, we made the hypothesis 
that NHE3 might be regulated by membrane-bound serine proteases that can then be blocked 
by Spint2. To address this hypothesis, we also used Xenopus laevis oocytes, because we 
succeed to express functional intestinal membrane-bound serine proteases in this heterologous 
expression system (see functional assay in Xenopus oocytes).  
The α and γ subunits of the epithelial sodium channel ENaC are known to be cleaved in 
the presence of several serine proteases (234). Similarly, we first used a biochemical approach 
to look for the presence of any cleaved fragment of NHE3 when co-expressed with serine 
proteases. cRNA of human NHE3 with a HA-tag in its C-terminal part was co-injected in 
Xenopus oocytes with cRNAs of all intestinal membrane-bound serine proteases used in our 
functional assay with Spint2 (see functional assay in Xenopus oocytes). Figure 18 shows that 
NHE3 can be expressed in oocytes and detected at the protein level via the HA-tag as a 
monomer around 90kDa and as a dimer around 200kDa as expected. The significance of the 
dimer is unknown (36,204). 24 hours after injection, no cleaved form of NHE3 or any change 
in its expression could be seen when co-injected with membrane-bound serine proteases 
except in the presence of Tmprss3 where a faint band of lower molecular weight (around 
65kDa) could be observed. This band is better seen when NHE3 expression is increased by 
incubating the oocytes for 48 hours as seen in a second experiment (figure 19). 
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Figure 18: Effect of membrane-bound serine proteases on NHE3 protein expression (24 hours after 
injection). Xenopus oocytes were co-injected with 5ng of hNHE3-HA-tag cRNA and 5ng of membrane-bound 
serine proteases cRNAs as indicated. 24 hours after injection, oocytes were lysed and western blot were 
performed using anti-HA antibody (in green).Blue arrow indicates the putative cleaved form of NHE3. Actin 
control is in red. 
 
Figure 19: Effect of membrane-bound serine proteases on NHE3 protein expression (48 hours after 
injection). Xenopus oocytes were co-injected with 5ng of hNHE3-HA-tag cRNA and 5ng of membrane-bound 
serine proteases cRNAs as indicated. 48 hours after injection, oocytes were lysed and western blot were 
performed using anti-HA antibody (in green).Blue arrow indicates the putative cleaved form of NHE3. Actin 
control is in red. 
 
This extra band, which can be easily detected in every experiment we performed (n>7), 
was not observed in oocytes injected with Tmprss3 alone, but only in the presence of NHE3, 
strongly suggesting that this signal represent a cleaved form a NHE3 as seen in figure 20. 
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Figure 20: NHE3 protein expression in Xenopus oocytes. Xenopus oocytes were injected with 5ng of hNHE3-
HA-tag cRNA and 5ng of Tmprss3 or Tmprss13 cRNAs as indicated. 48 hours after injection, oocytes were 
lysed and western blot were performed using anti-HA antibody (in green). Actin control is in red. 
 
These experiments were performed using a human construct of NHE3. We were also 
able to detect this cleaved form of NHE3 using a rat form of NHE3 (figure 21). In this 
particular experiment, two extra bands were seen for the rat construct but also for the human 
construct, although the signal is weaker for the human construct. 
For all these experiments, 5ng of Tmprss3 cRNA were used. Since it represents a rather 
high amount of cRNA and this might lead to non-specific and toxic effect on NHE3, we 
tested whether it was possible to observe the cleaved fragment of NHE3 with lower amounts 
of Tmprss3 cRNA. Indeed, in oocytes injected with 3ng of NHE3 cRNA, an effect of 
Tmprss3 was still seen when Tmprss3 cRNA amounts as low as 0.375ng were injected (figure 
22). No clear dose-dependent effect was identified; it seems rather that Tmprss3 acts in an all-
or-nothing manner because the cleaved form was abruptly lost in another experiment when 
using Tmprss3 cRNA amount lower than 0.4ng (figure 23). Similarly, very low Spint2 cRNA 
amounts (0.01ng!) should be injected to prevent the effect of Tmprss3 (figure 23). 
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Figure 21: Effect of Tmprss3 on rat NHE3. Xenopus oocytes were injected with 5ng of rat or human NHE3-
HA-tag cRNA and 5ng of as indicated. 48 hours after injection, oocytes were lysed and western blot were 
performed using anti-HA antibody (in green). Actin control is in red. 
 
 
Figure 22: Effect of injecting decreasing amounts of Tmprss3 on NHE3 expression pattern. Xenopus 
oocytes were injected with 3ng hNHE3-HA-tag cRNA and decreasing amounts of Tmprss3 cRNA as indicated. 
48 hours after injection, oocytes were lysed and western blot were performed using anti-HA antibody (in green). 
Actin control is in red. 
 
 
Figure 23: Inhibition by Spint2 of the Tmprss3-dependent cleavage of NHE3. Xenopus oocytes were 
injected with 3ng hNHE3-HA-tag cRNA and decreasing amount of Tmprss3 and Spint2 cRNA as indicated. 48 
hours after injection, oocytes were lysed and western blot were performed using anti-HA antibody (in green). 
Actin control is in red. 
 
To assess whether the putative Tmprss3-mediated cleavage of NHE3 occurs at the cell 
surface, we co-injected oocytes with NHE3 and Tmprss3 and incubate them with extracellular 
aprotinin, a serine protease inhibitor of Kunitz-type. The cleaved fragment of NHE3 was still 
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detected even in the presence of extracellular aprotinin (figure 24). This suggests that the 
effect of Tmprss3 on NHE3 does not occur at the cell surface. However, it is also possible 
that aprotinin does not inhibit Tmprss3. To address this question, we observed the capacity of 
extracellulary added aprotinin to block the activating effect of Tmprss3 and CAP1 on the 
epithelial sodium channel ENaC in Xenopus oocytes. Although the activation of ENaC by 
CAP1 could be fully prevented by extracellular aprotinin, Tmprss3 was only slightly inhibited 
by aprotinin, whereas full inhibition could be achieved with Spint2 (Figure 25). Thus no clear 
conclusion can be drawn from these experiments. 
 
Figure 24: Effect of aprotinin on Tmprss3-dependent cleavage of NHE3. Xenopus oocytes were injected 
with 3ng hNHE3-HA-tag cRNA and 0.75ng Tmprss3 cRNA as indicated and then incubated in 100µg/ml 
aprotinin. 48 hours after injection, oocytes were lysed and western blot were performed using anti-HA antibody 
(in green). Actin control is in red. 
 
 
Figure 25: Inhibitory activity of extracellular aprotinin on CAP1 and Tmprss3. Xenopus oocytes were 
injected with 0.11ng cRNA of each rENaC subunit and CAP1, Tmprss3 and Spint2 cRNA as indicated and 
incubated with 100µg/ml aprotinin. A, effect of aprotinin on CAP1. B, effect of aprotinin on Tmprss3. n≥8 
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measured oocytes. ENaC-mediated sodium currents INa
+
 are measured without (grey bars) and with trypsin 
(5μg/ml) perfused extracellularly (black bars) as a positive control for ENaC activation. 
 
4.2. Functional consequence of the Tmprss3-dependent cleavage of NHE3 
The putative cleavage of NHE3 by Tmprss3 was only examined using a biochemical 
approach. We thus assessed the potential consequences of such cleavage on the function of 
NHE3. Since biochemical data were obtained in Xenopus oocytes, we used the same 
heterologous expression system to study the function of Spint2. Na
+
 fluxes using 
22
Na were 
measured as done in the laboratory of O.W. Moe and R.J. Alpern (235,236). Briefly, oocytes 
are incubated in a Na-free solution pH 6.8 for 30 minutes, then 
22
Na uptake is performed by 
transferring the oocytes into a 
22
Na-containing solution pH 7.4 for 30 minutes and uptake is 
terminated using an excess volume of ice-cold stop solution (50mM NaCl). 
A first experiment was done with non-injected oocytes. Figure 26 shows that some 
22
Na 
transport occurs in non-injected oocytes, which can be inhibited by high dose of amiloride 
(10
-5
M). This amiloride-sensitive 
22
Na uptake suggests that the protocol used here works and 
that some endogenous NHE activity is present, probably mediated by the ubiquitous NHE1.  
 
Figure 26: Amiloride-sensitive 
22
Na uptake in non-injected Xenopus oocytes. Non-injected oocytes were 
incubated in 
22
Na uptake solution to measure NHE activity in the absence or presence of amiloride. n=3 groups 
of 5 oocytes per condition.  
 
The inhibition constant (IC50) of NHE1 and NHE3 for amiloride is around 1µM and 100µM 
respectively (237). We thus determined in another experiment that a concentration of 5x10
-6
M 
amiloride might be high enough to block any NHE1 endogenous activity but not exogenous 
activity of NHE3 (figure 27). 
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Figure 27: Inhibition by amiloride of 
22
Na uptake in non-injected Xenopus oocytes. Non-injected oocytes 
were incubated in 
22
Na uptake solution to measure NHE activity in the absence or presence of amiloride. n=3 
groups of 5 oocytes per condition.  
 
Having set good conditions, 
22
Na uptake was next assessed in oocytes injected with 
human NHE3 cDNA. Surprisingly, we did not observe any increase in 
22
Na uptake in NHE3-
injected oocytes compared to water-injected oocytes (figure 28), even though 
22
Na uptake 
could be blocked in both condition by amiloride.  
 
Figure 28: human NHE3 activity in Xenopus oocytes. Oocytes injected with H2O or 10ng human NHE3 
cRNA were incubated (3 days after injection) in 
22
Na uptake solution to measure NHE3 activity in the absence 
or presence of 5x10
-6
M amiloride (in grey). n=3 groups of 5 oocytes per condition.  
 
It is possible that the concentration of amiloride used here inhibits exogenous NHE3 
activity. To overcome this issue, we decided to block endogenous NHE activity with ethyl-
isopropyl-amiloride (EIPA), which blocks Na-H exchangers more specifically. The IC50 of 
human NHE3 for EIPA is around 6 µM, whereas the IC50 of the putative endogenous NHE in 
Xenopus oocytes (a homolog of NHE1) is 25 nM (237,238). A dose-response experiment 
done in non-injected oocytes showed that endogenous NHE activity was inhibited by EIPA 
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with an IC50 of 4X10
-7
M (figure 29), a value which is between the expected IC50 of the 
endogenous NHE and the human NHE3, suggesting the possibility that more than one type of 
NHE is expressed in Xenopus oocytes.  
 
 
Figure 29: Inhibition of endogenous NHE activity in non-injected oocytes. Non-injected were incubated in 
22
Na uptake solution to measure NHE3 activity in the absence or presence EIPA. n=3 groups of 5 oocytes per 
condition. 
 
We first used 10
-6
M of EIPA, because it is supposed to inhibit most of the endogenous NHE 
activity while blocking only half of the human NHE3 activity. Despite this new protocol, 
similar results were obtained, namely no difference between water-injected oocytes and 
NHE3-injected oocytes in the presence or absence of 10
-6
M EIPA (figure 30). EIPA 
efficiently inhibited endogenous NHE activity as seen by the decrease in 
22
Na uptake in every 
condition.  
 
Figure 30: human NHE3 activity in Xenopus oocytes. Oocytes injected with H2O or human NHE3 cRNA 
(3ng or 10ng) were incubated (2 days after injection) in 
22
Na uptake solution to measure NHE3 activity in the 
absence or presence of 10
-6
M EIPA (in black). n=4 groups of 5 oocytes per condition.  
 
One explanation for this absence of exogenous human NHE3 activity could be that our 
construct is for some reason not functional. In another experience, we used a rat NHE3 cDNA 
94 
 
construct known to be functional (cDNA kindly provided by Daniel Fuster from the 
University of Bern). Oocytes were also injected with one mutant form of rat NHE3, which 
does not transport Na
+
 (NHE3 E213I). In addition, we also block any endogenous NKCC 
(Na-K-Cl-cotransporter) activity with 100µM furosemide and the activity of the Na-K-
ATPase pump with 10µM ouabain. Unfortunately, there was again no difference in 
22
Na 
uptake in wild-type NHE3 and non-functional NHE3 E213I-injected oocytes, in the presence 
or absence of Tmprss3 (figure 31A). However, 10
-6
M EIPA was able to block to decrease 
22
Na uptake in both conditions (figure 31B).  
 
 
Figure 31: rat NHE3 activity in Xenopus oocytes. A) Oocytes injected with rat NHE3 cRNA (wild-type or 
mutant E213I) with or without hTmprss3 cRNA as indicated were incubated (4 days after injection) in 
22
Na 
uptake solution to measure NHE3 activity. B) Same protocol in the absence or presence of 10
-6
M EIPA. n=6-8 
oocytes per condition measured individually.  
 
The failure to measure any activity of exogenous rat NHE3 may be due to the fact that 
NHE3 proteins are not express at the cell surface in Xenopus oocytes. To answer this 
question, cell-surface biotinylation was performed. No conclusion could be drawn from this 
experiment since a lot of non-specific binding of NHE3 to the streptavidin beads as seen in 
lane 3 and 4 of the bound fraction where oocytes were not biotinylated (figure 32). Such 
binding could not be prevented by extensive washing steps (3 washes in Lysis Buffer, 2 in 
high salt buffer and 1 in low salt buffer). 
95 
 
 
Figure 32: Cell surface expression of NHE3 in Xenopus oocytes. Oocytes were injected with human NHE3 
HA-tag and human Tmprss3 cRNAs as indicated. 48 hours after injection, oocytes were biotinylated (except lane 
3 and 4) and total lysate were mixed with streptavidin beads to purify cell surface protein (bound fraction). Anti-
HA antibody (in green) is used to detect NHE3 and anti-actin (in red) antibody as negative control for 
intracellular protein. 
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DISCUSSION 
1. FUNCTIONAL ASSAY IN XENOPUS OOCYTES 
 
This discussion is a complement to the discussion that can be found in the manuscript 
submitted to the Journal of Biological Chemistry. The focus is specifically related to the 
complementary data presented in the results section of this thesis manuscript. 
 
1.1. The R48L and R143L Spint2 mutations 
The canonical mechanism for serine protease inhibition involves a key and lock 
mechanism, where the inhibitor acts as a substrate of the protease that is only very slowly 
cleaved. In this aspect, the P1 residue in the reactive site of the inhibitor is of particular 
importance (see intro). We therefore tested functional consequences of mutations in the P1 
residue involved in the reactive site of both Kunitz domains of Spint2. As done in two 
previous studies using a cell-free in vitro approach, we mutated the arginine residues at 
position 48 and 143 into a leucine residue (90,93). When tested for their inhibitory effect on 
CAP3, the mutant Spint2 R48L showed a partial loss of function, whereas the Spint2 R143L 
maintained its full inhibitory activity. A stronger loss of function was observed for the double 
mutant Spint2 R48L/R143L.  
These results suggest that the first inhibitory domain of Spint2 plays an important role 
in the inhibition of CAP3, confirming the results obtained by Larsen et al in MDCK cells, 
although the loss of function observed in Xenopus oocytes is less dramatic (93). This 
discrepancy could be explained by the different heterologous expression system used (MDCK 
cells / Xenopus oocytes) and the different readouts used to monitor CAP3 activity; we used 
the epithelial sodium channel ENaC as reporter gene whereas Larsen et al assessed 
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biochemically the function of Spint2 as a “protector” of CAP3 from (auto-?) proteolytic 
activation and degradation. In both cases, an indirect mechanism where Spint2 in fact blocks 
another protease than CAP3 cannot be excluded. Qin et al have showed in a cell-free in vitro 
assay using soluble recombinant proteins and the proteolytic processing of HGF as a readout 
that Spint2 R48L have a strongly reduced capacity to inhibit HGFA compared to Spint2 
R143L and wild-type, suggesting again an important role of the first Kunitz domain (90). 
Interestingly, both mutants were fully functional when assessed with Tmprss2, although this 
protease has an important homology with CAP3. 
The P1 residue is highly conserved among Kunitz inhibitors. Inhibitors that have an 
arginine or a lysine residue in the P1 position usually inhibit trypsin, whereas a tyrosine, 
phenylalanine, tryptophane, leucine or methionine residue confers inhibition towards 
chymotrypsin (148). This highlights a very particular characteristic of serine protease 
inhibitors; mutating the conserved P1 residue of the reactive site usually does not abolish its 
function but rather change its capacity to block other types of substrates. Furthermore, 
residues other than the P1 residue in the inhibitory domain make contacts with the substrate. 
For these reasons, mutational approaches should be interpreted with caution and it is probably 
not possible to conclude that the first inhibitory domain is responsible for the inhibition of 
CAP3, HGFA or other protease based on the sole R to L mutation in the P1 position. 
In addition, we showed that the loss of function of Spint2 R48L (first Kunitz domain) 
and Spint2 Y163C (second Kunitz domain) results in a similar reduced capacity of Spint2 to 
inhibit CAP3. The double mutant Spint2 R48L/Y163C displays even a larger loss of function 
than the single mutants. All these results suggest a complex interaction of both Kunitz 
domains of Spint2 in serine protease inhibition. 
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1.2. Dipeptidyl peptidase IV as putative partner of Spint2 
We also tested in our functional assay the hypothesis that Spint2 could be an inhibitor 
of the dipeptidyl peptidase IV, DPPIV, a putative regulator of NHE3. DPPIV did not activate 
ENaC. This might be expected since ENaC is very sensitive to trypsin- or chymotrypsin-like 
serine protease of the S1 family. DPPIV belongs to the S9 family and is known to cleave 
proline-containing small peptides, hence its name (161). Despite this issue, we still tried to 
use ENaC as a reporter gene by co-expressing CAP3 and DPPIV together with ENaC and 
Spint2. We did not observe any competition between CAP3 and DPPIV for the binding to 
Spint2 in the competition experiment, suggesting that Spint2 does not inhibit DPPIV. To 
support this result, no interaction could be detected at the protein level between Spint2 and 
DPPIV in a pull-down assay. It is thus unlikely that DPPIV plays a role in the pathogenesis of 
the congenital sodium diarrhea. Moreover, inhibition of DPPIV has been shown to reduce 
NHE3 activity in rat (210). If we assume that mutations of Spint2 associated with the 
congenital sodium diarrhea are loss-of-function mutations, increased Na
+
 absorption mediated 
by NHE3 should occurs. For all these reasons, we can reasonably rule out DPPIV as a 
candidate protease in the congenital sodium diarrhea.  
 
 
2.  GENERATION OF A SPINT2 KNOCKOUT MOUSE MODEL 
 
A Spint2 knockout mouse model has already been generated, but display an embryonic 
lethal phenotype (116,117). To solve this problem, we tried in this work to generate a gut-
specific and a tamoxifen-inducible Spint2 knockout mouse model. A gene-trap approach 
combined with the Cre/lox technology was used here.  
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In its initial configuration (mutation is active), the conditional gene trap vector construct 
used in this project reproduced the embryonic lethal phenotype of the constitutive Spint2 
knockout mouse model already known from the literature (116,117). We were then able to 
rescue this embryonic lethality with the overexpression of the FLPe recombinase driven by a 
ubiquitous promoter that invert the orientation of the construct and thus inactivate the lethal 
mutation. Reactivation of the mutation was done with the overexpression of the Cre 
recombinase, either specifically in intestinal cells using the vilin promoter or in a tamoxifen-
inducible manner in all cells. However, our strategy did not result in the generation of a gut-
specific knockout or a tamoxifen-inducible knockout.  
No decrease in Spint2 mRNA expression was observed in the gut-specific Villin-Cre 
model. Absence of Cre expression might explain this very low or even absent recombination 
rate with the Cre. However, other members of our department have used these Villin-cre 
expressing mice successfully, suggesting that Cre is correctly expressed in our mice. 
Regarding the tamoxifen-inducible model, we observed a maximal reduction in Spint2 
mRNA expression of only 50% using two different protocols. This indicates that the system 
works, namely recombination occurs within the gene trap vector construct and reactivation of 
the mutation is possible. However, this was not sufficient to completely abolish Spint2 
expression. In both models, no clear phenotype could be observed as expected with this 
modest (or absent) decrease in Spint2 expression. 
Assuming that the Cre expressing mice used in this project are functional, the failure of 
generation of conditional Spint2 knockout mice could be due to the inefficiency of the gene-
trap system as designed by Schnutgen et al to abolish Spint2 expression in conditional manner 
(226). The reasons of this lack of efficiency are multiple. 
First, the Cre recombinase may have a limited access to the Spint2 locus resulting in a 
low recombination rate. To address this hypothesis, it would be necessary to generate a 
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conditional Spint2 knockout using the classical gene-targeting method. A failure of such an 
approach would strongly suggest intrinsic problems of the Spint2 locus, while the successful 
generation a conditional Spint2 knockout mouse model would exclude that the Spint2 locus is 
somehow “inaccessible” to the Cre.  
Second, Cre- or FLPe- mediated recombination is supposed to occur only once since the 
recognition sites for both recombinases are present as two pairs of sites for each recombinase 
that cannot recombine together. For example, both LoxP and Lox511 sites are recognized by 
the Cre but one LoxP site cannot recombine with one Lox511. In addition, sites are arranged 
in a specific manner so that the system is blocked once the orientation of the gene trap 
construct has been changed after successful Cre- or FLPe-mediated recombination. However, 
heterotypic (between LoxP and Lox511 sites for example) recombination has been reported, 
albeit at low but significant levels (239,240). Thus, if the system cannot block itself as 
described above, the gene trap construct can recover its initial configuration after one single 
recombination because of heterotypic recombination. This might easily cause a decrease in 
efficiency of this conditional gene-trap approach. 
Third, the capacity of the gene trap vector construct to recombine in the presence of the 
FLPe and the Cre recombinases as reported in the original paper was only demonstrated in 
cell culture. In that study, embryonic stem cells that have one gene trapped by the gene trap 
vector construct were electroporated with plasmids encoding the Cre or FLPe recombinases 
and treated with antibiotics to select sublines with strong recombinase expression or very 
high/very low (depending on the configuration of the gene trap construct) reporter gene 
cassette expression. In addition to this drastic selection step, they provide data for only two 
genes. Both genes are localized on the X chromosome. Male derived ES cells were thus used 
so that analyses were performed on a haploid background, where only one allele has to 
recombine. Even with these strategies aimed to get maximal efficiency of the system, trapped 
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gene expression was not completely abolished in one case. Finally, no experimental evidence 
demonstrated that the system works in mice. To our knowledge, no published article has 
reported the successful recombination of this conditional gene trap vector construct in vivo, 
particularly in mice since 2005. Only one group showed in September 2012 that this 
mechanism was efficient in zebrafish, however (241). This group used a different construct 
but Cre and FLPe-mediated recombination was based on the same strategy. 
Since all these explanations are not mutually exclusive, it becomes likely that the 
conditional gene trap approach used in our work results in a lack of efficiency to generate a 
conditional Spint2 knockout mouse model, although it seemed at first to be promising with 
the rescue of the embryonic lethality with the FLPe recombinase. 
It is also important to mention that a classical gene trap-vector construct without Cre/lox 
technology-based conditional potential may be “leaky”. Indeed, to fully abolish Spint2 normal 
expression, the gene trap construct requires two important properties. It should have a strong 
polyadenylation signal leading to premature termination of transcription so that exons of 
Spint2 located downstream of the construct are not transcribed. Second, the gene trap vector 
is present in an intronic sequence and contains a splice acceptor site. In our case, the construct 
was present within the first intron of Spint2. Thus, correct splicing within the first intron is 
necessary to incorporate the gene trap transcript into the final mRNA. When the mutation is 
active, correct splicing and premature transcription termination downstream of the gene-trap 
construct result in the production of a truncated mRNA made of the first intron of Spint2 and 
the gene-trap reporter cassette. If one of these two properties is not 100% efficient, it may 
lead to the production of a “normal” mRNA containing all exons of Spint2 without the 
reporter cassette. To support the relative inefficiency of the gene-trap system, the group of 
Thomas Bugge generated two KO mouse models of CAP3, one using a classical gene 
targeting approach and one using a gene trap approach. The “gene-targeting” model was 
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lethal two days after birth whereas the gene trapping” model was viable and showed a milder 
phenotype (176,242) suggesting that the “gene trapping” model is not a constitutive KO with 
a completely abolished expression of CAP3 but a hypomorphic model with some residual 
expression of CAP3. For example, the authors observed that the newborn mice still have 1% 
CAP3 mRNA expression in skin compared to wild-type controls and adult mice have up to 
12% CAP3 mRNA expression. Kidney and lung of newborn mice already showed a residual 
mRNA expression of around 10%. Other groups have reported this hypomorphic state of 
mouse models (243-246). In some situations, a hypomorphic and thus viable mouse model 
might be an advantage when for example embryonic or early postnatal lethality of the 
constitutive knockout model hinder biological analyses or experiments. However, expression 
should be low enough to still observe a phenotype as it is the case for CAP3 but not for 
Spint2. 
Finally, a last problem related to this gene-trap approach is the fact that alternative 
splicing might interfere with the splicing event that is supposed to integrate the transcript of 
the reporter cassette to produce a final truncated mRNA molecule. Two isoforms of Spint2 
have been described: a full-length isoform with both Kunitz domains and a shorter isoform 
that lacks the first inhibitory domain (91). The latter is thought to be the major form in mouse, 
the opposite occurring in human. Since the first Kunitz domain is encoded in the second exon 
and the gene trap vector construct is found in the first intron (between exon 1 and exon 2), it 
is possible that alternative splicing may skip the transcription of the gene trap reporter cassette 
so that transcription of the short isoform occurs and not of a truncated mRNA as expected 
(247). This provides another explanation for the low efficiency of the gene trap approach used 
in this work. 
In conclusion, based on what has been said above, we recommend avoiding using a 
gene trap approach for the generation of knockout mouse models. This is particularly true for 
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gene trap vector constructs with conditional potential based on the Cre-lox technology, for 
which a successful use in mice still requires a well-demonstrated validation. Classical gene-
targeting approaches, although more time-consuming, are more efficient and should be 
therefore preferred. 
 
 
3. AN EPITHELIAL CELL MODEL FOR SPINT2 
 
In order to study the physiological role of Spint2 in epithelia, we used the Caco-2 cell 
line. These cells spontaneously form a monolayer of polarized cells showing enterocytic 
characteristics when grown on filter. Such monolayers have been widely used as a model for 
intestinal epithelial barrier either for pharmacological studies or for physiological experiments 
(248,249).  
We showed here that transcripts of Spint2 as well as its homolog Spint1 can be 
amplified from Caco-2 cells total RNA. These cells also express at the mRNA level several 
membrane-bound proteases such as CAP1, CAP3 and Tmprss2. Tmprss13, a potential partner 
of Spint2, is apparently not expressed in Caco-2 cells. But Tmprss13 transcripts have already 
been detected in small intestine and colon of mice and humans (250). Caco-2 cells also 
express the sodium-hydrogen exchanger NHE3 and the chloride channel CFTR. Endogenous 
NHE3 and CFTR activity can be measured in Caco-2 cells (251,252). We also observed a 
stronger signal of NHE3 expression in polarized cells grown on filter. But CFTR expression 
was decreased in the same cells. In vivo, NHE3 expression is more abundant in the villous 
cells, whereas CFTR expression is mainly detected in crypts (37). It is probable that Caco-2 
cells, when grown on filter, differentiate into cells that are more similar to villous cells than 
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cryptic cells, thus explaining the opposite findings about NHE3 and CFTR expression 
observed in this study.  
We have also generated two tagged constructs of Spint2 for protein detection in 
overexpression studies: one with a FLAG-tag (in the putative extracellular part) and another 
with a GFP-tag (in the cytosolic region). Both constructs are functional and can be detected at 
the protein level in Caco-2 cells. Finally, 5 Spint2 shRNA constructs can be used to 
efficiently knock-down Spint2 in Caco-2 cells.  
It is unfortunately difficult to use transfection for experiments with monolayers since 
effect of transfection is surely lost during the three weeks required for the differentiation of 
Caco-2 cells. To circumvent this issue, one approach would consist in transfecting the cells 
just before plating them on filter. Such approach was used to study the formation of tight 
junctions (253), in particular by Buzza et al to assess the consequence of knocking down the 
CAP3 gene in the formation of intestinal barrier (179). In such studies, experiments were 
carried out up to 7 days after transfection. However, this approach is inefficient for 
physiological experiments done after three weeks of differentiation.  
Another approach is to generate stably transfected clones and let them grow on filter 
in the presence of the selection medium. Our strategy using the transfection reagent 
Lipofectamine2000 and puromycin for the selection failed to generate either monoclonal or 
polyclonal populations of stably transfected cells. This could be due to low amounts of 
transfected cells when starting the selection, the long doubling time of the Caco-2 cells (~ 60 
hours) or altered proliferation/differentiation mediated by Spint2 overexpression or 
knockdown. 
To overcome these problems, introduction of foreign cDNA material into caco-2 cells 
should be done using lentiviral-based transduction system (232). This approach is very 
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efficient and results in a high proportion of transduced cells so that selection done on cells 
that are in the majority of cases transduced is much easier.  
A last possibility, which seems to be very efficient and relevant for the study of Spint2 
in the regulation of ion transport in intestinal tissues is reported by the group of Mark 
Donowitz (254). In that study, Caco-2 cells are infected with lentiviral particules aimed to 
knock-down NHERF1, a regulator of the Na-H-exchanger NHE3. Transduced cells are 
selected with puromycin for 2 or 3 passages. Cells are then plated on filter and during 
differentiation an adenoviral-based approach is used to transduce polarized cells with NHE3 
cDNA, so that the effect of knocking-down NHERF1 on NHE3 activity can be assessed in 
monolayers of Caco-2 cells. 
We cannot exclude that the difficulties we had to get stably transfected clones are a 
consequence of an efficient knock-down or overexpression of Spint2. Spint2 is thought to 
play a role in cell proliferation and differentiation. It is thus possible that altering Spint2 
expression in Caco2-cells might for example decrease cell proliferation and/or increase cell 
differentiation so that the culture of such cells becomes very tricky. 
 
 
4. THE NA-H-EXCHANGER NHE3 AND MEMBRANE-BOUND 
SERINE PROTEASES 
 
The Na-H-exchanger NHE3 is a particularly interesting candidate that could be 
involved in the pathogenesis of the congenital sodium diarrhea. Since, we showed using our 
functional assay in Xenopus oocytes that Spint2 is a potent inhibitor of several intestinal 
membrane-bound serine proteases, we tested whether theses proteases might regulate the 
activity of NHE3.  
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In biochemical experiments, we observed on western blot a specific band that could 
potentially correspond to a cleaved form of NHE3 that appears when co-expressed with the 
serine protease Tmprss3. This cleaved form of NHE3 was observed using both the rat and the 
human form of NHE3 and was not seen with all other proteases used in this assay suggesting 
a specific Tmprss3-mediated cleavage of NHE3. This is also highlighted by the fact that very 
small amounts of Tmprss3 cRNA were sufficient to generate the cleaved fragment.  
It is still not clear whether this cleavage occurs at the cell surface since both the 
experiments with extracellular aprotinin and the cell surface biotinylation were non-
conclusive. One reason is that NHE3 proteins extracted from non-biotinylated oocytes bind in 
a non-specific manner to the strepatividin beads even when extensive washing steps are done. 
This is surprising since there is an abundant literature reporting the successful study of cell 
surface expression of NHE3 using cell surface biotinylation. It is important to note in every 
case that cell surface biotinylation was performed in fresh tissues or heterologous expression 
system other than Xenopus oocytes. This raises the possibility that NHE3 expressed in 
Xenopus oocytes can show non-specific binding to the streptavidin beads because of different 
post-translational modifications occurring in oocytes for example. Such non-specific binding 
to the streptavidin beads has already been observed for the alpha subunit of ENaC (255,256). 
The HA-tag used to reveal NHE3 protein expression in injected oocytes is located at 
the C-terminal end of NHE3 composed of a large cytosolic region. The cleaved fragment has 
a molecular weight that is only 10-15kDa lower than the full length NHE3. This indicates that 
the cleavage occurs in the N-terminal part of NHE3, a region containing the 12 
transmembrane segments involved in Na-H-exchange, suggesting that this cleavage could 
alter the transporting activity of NHE3.  
Unfortunately, NHE3 activity could not be detected in Xenopus oocytes. We faithfully 
followed a protocol reported by the laboratories of Moe and Alpern (235,236), which 
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successfully allows them to observe a significant increase (5 fold in average) in 
22
Na uptake 
in NHE3-injected oocytes compared to water-injected oocytes. Furthermore, these 
experiments were carried out without the pharmacological inhibition of endogenous Na-H-
exchange by EIPA or other blockers. We did not detect any increase in 
22
Na uptake in NHE3-
injected oocytes likely because of the very high endogenous Na-H-exchange mediated by 
NHE1 in Xenopus oocytes (238). No improvement could be obtained even when using 
carefully defined concentrations of amiloride and EIPA. We made the observation that 
endogenous NHE activity varied from batch to batch. The laboratories of Moe and Alpern 
reported only individual experiments and not pooled data from several independent 
experiments, raising the possibility that some batches, although rare, might have endogenous 
NHE activity sufficiently low to measure activity of exogenous NHE3. To avoid issues due to 
endogenous NHE activity, NHE-deficient cell lines, such as AP1 cells or PS120 cells, are 
usually used to study the activity of NHE3 (257,258). 
Another explanation for this lack of detectable activity of exogenous NHE3 in oocytes 
could be that only a very small fraction of NHE3 proteins do insert into the plasma 
membrane. For example, in fibroblast cell lines such as AP1 cells and PS120 cells, only 15%-
20% of NHE3 proteins are found at the cell surface (11,259,260). Thus, very low exogenous 
NHE3 expression at the plasma membrane in the presence of high endogenous NHE activity 
might easily explain the problems encountered in this project. 
Tmprss3 is a membrane-bound serine protease for which loss of function mutations 
that lead in deafness in humans have been reported (183,184). Tmprss3 is expressed at low 
levels in stomach, kidney, lung, small intestine, colon and thymus (181,183). Our qPCR data 
on mouse gastro-intestinal tissues confirmed a low but significant expression of Tmprss3 in 
the gut with an increased expression in stomach and jejunum (see functional assay in Xenopus 
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oocytes). Interestingly, the role of NHE3 in Na
+
 absorption in the gut occurs throughout the 
gastro-intestinal tract but is particularly important in jejunum.  
Proteolytic regulation of NHE3 has never been described so far. The significance of 
the cleavage of NHE3 observed in Xenopus oocytes in the presence of Tmprss3, although 
consistant, remains elusive. NHE3 has been intensively studied, notably during diarrheal 
states where its activity is inhibited. In spite of this, a cleaved fragment of NHE3 as seen in 
our experiments has never been reported so far. Given that we do not know the functional 
repercussions, if any, of such cleavage, it is difficult to speculate about its physiological role. 
Although Spint2 is able to potently inhibit Tmprss3 (see functional assay in Xenopus 
oocytes), the mutant associated with the congenital sodium diarrhea Spint2 Y163C still 
conserve an inhibitory activity on Tmprss3 of about 50% compared to the wild-type form of 
Spint2. It seems thus unlikely that Tmprss3 plays a role in the congenital sodium diarrhea, 
even though we cannot rule out any involvement of Tmprss3 solely on these findings. One 
hypothesis would be that Tmprss3 and Spint2 appear as members of a novel pathway that 
regulates NHE3 activity in the gut. Alternatively, the physiological role of Tmprss3 in 
intestinal tissues might not be related to ion transport at all and it is only when Tmprss3 is no 
longer efficiently inhibited by Spint2, possibly indirectly via a Spint2-CAP1/Tmprss13-
Tmprss3 cascade, that uncontrolled proteolytic activity could result in off-targets toxicity such 
as undesired cleavage of NHE3 leading to a decrease Na-H-exchange in the gut. Such a toxic 
effect of unopposed proteolytic activity is suggested in our functional assay in Xenopus 
oocytes, where high amounts of membrane-bound serine protease cRNA led to a paradoxical 
decrease in ENaC-mediated sodium currents (see the case of Tmprss13 for example). All 
these ideas are pure speculations and work done in Spint2 knockout mouse models and 
epithelial cell lines are clearly necessary.  
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GENERAL CONCLUSIONS AND 
PERSPECTIVES 
 
In this work, we established a functional assay in Xenopus oocytes that allows us to 
study interactions between Spint2 and gastro-intestinal membrane-bound serine proteases. 
With this approach, we identified Tmprss13 and CAP1 as potential partners of Spint2 because 
there were no longer inhibited by the congenital sodium diarrhea mutant Spint2 Y163C. We 
propose that the highly conserved tyrosine at position 68 and 163 in the first and second 
Kunitz domains respectively may play a role in the regulation of the binding of Spint 2 to the 
target protease whereas the mutation of this residue into a cysteine may alter the scaffold of 
the Kunitz domain. Depending on the serine protease to be blocked, this reduces the 
inhibitory activity of Spint2 to different extent. How both Kunitz domains of Spint2 
participate in membrane-bound serine protease inhibition remains elusive. To better 
understand how Spint2 inhibits serine proteases, crystallographic studies on Spint2-target 
complexes could be particularly interesting. In our assay, the expression of the Spint2-
Tmprss13 complex was quite abundant. It would be therefore possible to use this data as a 
basis to elaborate a strategy for a crystallographic approach. Crystals of complex formed by 
intact membrane-bound serine proteases and inhibitors have never been solved. Only 
complexes with truncated proteins (catalytic domain of the protease bound to one Kunitz 
domain) have been studied (164,165). Consequently, crystallographic data of full-length 
Tmprss13 bound to full-length Spint2 wild-type and mutants (Y68C and Y163C) would be 
unique and would provide a lot of useful data regarding various aspects such as the interaction 
between both Kunitz domains and their involvement in Tmprss13 inhibition, the effects of 
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mutations on the structure of Kunitz domains and the binding to Tmprss13 or the role of the 
accessory domains of membrane-bound serine proteases that may play a role in protein-
protein interaction (261,262). In addition, it may give explanations about how the mutant 
Spint2 Y163C shows an almost complete loss of inhibitory activity on Tmprss13 in spite of 
increased binding to the protease. 
In this work, we also showed that a gene trap approach combined with the Cre/lox 
technology was inefficient to generate a conditional Spint2 knockout mouse model. An 
animal model deficient of Spint2 expression and activity constitutes the best tool to decipher 
the physiological role of Spint2, provided that Spint2 plays a significant role in mice. In 
particular, Spint2-deficient animals could be used to identify the ion transporter that is 
defective in the congenital sodium diarrhea.  
A last attempt that should be performed with our gene trap model is to cross Spint2 
TRAP mice (homozygous are embryonic lethal) with Frizzy mice (loss-of-function point 
mutation in the CAP1 gene), since Szabo et al demonstrated that the Frizzy background 
enables to rescue the embryonic lethality of Spint2 knockout mice and allows postnatal 
survival (at least up to one day after birth as indicated in their publication) (119). As an 
alternative to the gene trap approach described in this project, a classical gene-targeting 
approach should be preferred to generate such animals. Although more time-consuming, 
gene-targeting has been widely and successfully used to generate knockout mouse models. 
The Spint2 gene is 28kb long, but critical exons (exon 2 and exon 6) coding for both Kunitz 
domains are found in region of around 6kb. Thus, it seems feasible to flank this region with 
lox sites in order to remove almost all exons of Spint2 upon Cre-mediated recombination. 
Alternatively, it would be also interesting to flank the first exon of Spint2 with lox sites to 
remove the start codon and the peptide signal, but this approach predicts the putative 
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existence of an open reading frame encoding a protein truncated in the N-terminal part 
containing the second Kunitz domain and the transmembrane domain.  
New technologies for the generation of genetically modified animal models have arisen 
recently. Among them, the TALEN (for transcription activator-like effector nucleases) 
technology looks promising, in particular because it avoids manipulation of embryonic stem 
cells and thus allows genetic modifications in animals other than mouse such as rats 
(263,264). Regarding Spint2, several differences exist between mouse and human: 1) 
constitutive Spint2 knockout mice display embryonic lethality, whereas Spint2 is probably 
dispensable for human development in utero, 2) the major isoform of Spint2 in mouse lacks 
the first Kunitz domain, while the major isoform in human has both Kunitz domains. In 
addition, knockout mouse model do not always recapitulate human genetic diseases, for 
example CFTR knockout mice do not develop any pulmonary phenotype as seen in patients 
with cystic fibrosis (216,265). Knockout rats appear therefore as very interesting models. 
Generating mouse models that overexpress in the gut membrane-bound serine proteases such 
as Tmprss13 or CAP1 that have been identified in the functional assay in Xenopus oocytes as 
potential targets of Spint2 could also be of great interest. 
We started to use Caco-2 cells as an epithelial cell model for Spint2 and showed 
endogenous expression of Spint2, overexpression of tagged constructs of Spint2 (FLAG and 
GFP tags) and efficient knock down of Spint2. Because these cells are rather resistant to 
transfection, a lentiviral-based approach should be used to overcome this problem. The 
possibility to study the activity of NHE3 and thus its putative regulation by Spint2 in 
monolayers of polarized and differentiated Caco-2 cells makes this model very useful as an 
alternative to animal models. Other ion transporters such as the CFTR could be tested in this 
model, as could be assessed paracellular transport and transepithelial resistance.  
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We also studied the potential involvement of membrane-bound serine proteases in the 
regulation of NHE3 in Xenopus oocytes and identified a putative cleavage of NHE3 in the 
presence of Tmprss3. The functional repercussion and physiological relevance of this 
cleavage is unknown. Since it seems difficult to measure the activity of NHE3 in Xenopus 
oocytes because of high endogenous Na-H-exchange, NHE-deficient cells such AP1 cells or 
PS120 cells could be used as an alternative model. Finally, it would be interesting to verify 
whether this cleavage also occur in more physiological models such as Caco-2 cells. 
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RÉSUMÉ DESTINÉ À UN LARGE PUBLIC 
 
La diarrhée est un problème de santé très fréquent dans le monde. Heureusement, la 
plupart des cas se résolvent spontanément. Cependant, une diarrhée peut parfois provoquer 
une déshydratation suffisamment importante pour mener à la mort ou persister pendant des 
semaines, mois ou années et diminuer considérablement la qualité de vie.  
Il est donc impératif de mettre au point de nouveaux médicaments pour traiter ce 
problème et ceci implique notamment une bonne compréhension des mécanismes permettant 
l’absorption d’eau et de sels minéraux dans l’intestin. Dans ce but, les maladies génétiques, 
bien que rares, sont d’une grande aide dans la mesure où elles indiquent aux chercheurs un 
gène d’intérêt et donc une cible de potentiels nouveaux médicaments.  
La diarrhée congénitale de sodium est l’une de ces maladies. Cette pathologie est 
caractérisée chez les enfants qui en sont atteints par une diarrhée très sévère et le plus souvent 
mortelle. Cette diarrhée entraîne la perte spécifique de sodium qui est un sel minéral 
particulièrement important de notre organisme. Des mutations dans le gène Spint2 ont été 
identifiées chez des malades.  
Le gène Spint2 code pour un inhibiteur de protéase. Une protéase est une protéine 
capable de couper ou « digérer » en des points précis une autre protéine. Spint2 empêche donc 
cette « digestion ». Le rôle de Spint2 dans l’intestin, ainsi que la protéase bloquée par Spint2 
nous sont totalement inconnus. 
Durant ce travail, des expériences effectuées dans un modèle cellulaire ont permis 
d’identifier deux nouvelles cibles potentielles de Spint2, à savoir les sérines protéases 
transmembranaires CAP1 et Tmprss13. Un effet de la sérine protéase Tmprss3 sur NHE3, une 
protéine responsable de l’absorption de sodium dans l’intestin, a pu être mis en évidence. 
Cependant, ces résultats n’ont malheureusement pas pu être vérifiés dans un organisme 
vivant. 
Ces données représentent une première étape vers une meilleure compréhension de la 
diarrhée congénitale de sodium et permettent d’établir de nouvelles hypothèses quant au rôle 
de Spint2. Des expériences supplémentaires sont nécessaires en vue d’élucider les 
mécanismes causant la diarrhée congénitale de sodium.  
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Background: Mutations in the serine protease 
inhibitor Spint2 are linked to congenital sodium 
diarrhea. 
Results: The Spint2 Y163C mutant no longer 
inhibited the intestinal membrane-bound serine 
proteases CAP1 and Tmprss13 in Xenopus 
oocytes. 
Conclusion: CAP1 and Tmprss13 are putative 
physiological partners of Spint2 in the intestine. 
Significance: Our functional assay identifies 
targets of membrane-bound serine protease 
inhibitors and may help in deciphering the 
physiological role of Spint2.  
 
SUMMARY 
Membrane-bound serine proteases play 
important roles in different biological 
processes. Their regulation by endogenous 
inhibitors is poorly understood. A Y163C 
mutation in the Spint2 gene encoding a serine 
protease inhibitor has been associated with 
congenital sodium diarrhea, suggesting a role 
of serine proteases in water/electrolyte balance 
in intestinal tissues. However, physiological 
targets of Spint2 remain to be identified. We 
established a novel cellular assay in Xenopus 
laevis oocytes to study functional interactions 
between Spint2 and candidate membrane-
bound serine proteases expressed in the gastro-
intestinal tract. We found that the wild-type 
form of Spint2 was a potent inhibitor of nine 
gastro-intestinal serine proteases. The Y163C 
mutation in the second Kunitz domain of 
Spint2 induced a complete loss of inhibitory 
activity on only two proteases, CAP1/prostasin 
and Tmprss13. Parallel analysis of the 
homologous mutation Y68C in the first Kunitz 
domain of Spint2 revealed differential 
involvement of the Kunitz domains in serine 
protease inhibition. Finally, the loss of function 
of the Y163C mutant was not due to an 
impaired binding interaction between 
Tmprss13 and Spint2. Based on these 
observations, we propose that CAP1/prostasin 
and Tmprss13 represent potential targets for 
Spint2 in controlling Na
+
 absorption in the 
intestine.  
Membrane-bound or membrane-anchored serine 
proteases have lately emerged as a subfamily of 20 
serine proteases that all share a conserved catalytic 
domain and a transmembrane domain (1). Diverse 
physiological and pathophysiological roles of 
some members of this family have been identified 
such as skin and intestinal barrier integrity (2-5), 
processing of atrial natriuretic peptide (6), iron 
homeostasis (7-9), trophoblastic development 
(10), hearing (11,12) and ion homeostasis (13,14). 
More elusive is the identity and the role of their 
potential physiological inhibitors such as Spint1 
and Spint2 (also known as HAI-1 and HAI-2), two 
Kunitz-type serine protease inhibitors that have a 
transmembrane domain. Spint1, first purified from 
a stomach cancer cell line (15), has been shown to 
form a complex in human milk with the 
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membrane-bound serine protease 
CAP3/Matriptase (16). Furthermore, genetic 
evidence supports an interaction between Spint1 
and CAP3 in mouse skin (17).  
Spint2, with its two inhibitory domains of 
Kunitz-type and a transmembrane domain, is 
highly homologous to Spint1 except that it lacks 
the LDL-receptor class A domain. Spint2 was 
cloned from three different sources: placental 
tissue, a gastric and a pancreas cancer cell line 
(18-20). In cell-free in vitro systems, it is a potent 
inhibitor of the membrane-bound serine proteases 
Tmprss1/hepsin, CAP1/prostasin, CAP3 and 
Tmprss13 (21-24).  
The physiological role of Spint2 is 
unknown. In mice, it contributes to the correct 
development of the embryo (25-27). In humans, 
mutations in the Spint2 gene have been linked to a 
syndromic form of congenital sodium diarrhea, 
indicating that Spint2 likely plays a role in 
intestinal ionic homeostasis (28). Among the 
mutations associated with the disease that 
predominantly involve intronic mutations, a 
unique missense mutation substitutes a conserved 
tyrosine in the second Kunitz domain for a 
cysteine (Spint2 Y163C). The functional 
consequence of this mutation has not yet been 
determined. Furthermore, the physiological 
partners of Spint2 remain unknown. 
In this study, we investigated the inhibitory 
function of wild-type Spint2 and its mutant 
Y163C on different serine proteases that were 
chosen according to the following hypothesis. 
Since Spint2 has a putative transmembrane 
domain and given that Spint1 is considered as 
physiological inhibitor of CAP3, we selected 
members of the membrane-bound serine proteases 
family as potential targets for Spint2. Considering 
the role of Spint2 in intestinal ionic homeostasis, 
we focused our interest on membrane-bound 
serine proteases reported in the literature to be 
expressed in the gastro-intestinal (GI) tract. 
Functional interactions between serine proteases 
and protease inhibitors are frequently studied in 
cell-free in vitro systems. Here, we established a 
cellular assay using Xenopus laevis oocytes as a 
heterologous expression system to functionally 
assess the activity of the candidate serine 
proteases and their inhibition by Spint2 and Spint2 
mutants. We took advantage of the high sensitivity 
of the epithelial sodium channel ENaC to 
stimulation by a wide variety of serine proteases 
and used it as a reporter gene to quantify the 
inhibitory activity of Spint2 by 
electrophysiological methods (29).  
We found that Spint2 is a powerful inhibitor 
of several membrane-bound serine proteases 
expressed in the GI tract. The Spint2 Y163C 
mutation associated with congenital sodium 
diarrhea induced a loss of inhibitory activity 
towards a limited number of serine proteases such 
as CAP1 and Tmprss13. Biochemical analysis 
shows that the Y163C mutation results in a loss of 
Spint2 activity despite a conserved ability to bind 
the serine protease. 
 
EXPERIMENTAL PROCEDURES 
Expression of human Spint2 and human 
membrane-bound serine proteases in Xenopus 
oocytes - cDNA clones of human CAP1, CAP2, 
CAP3, Tmprss1, Tmprss2, Tmprss11a, Tmprss13, 
Tmprss15 and Spint2 were obtained from the 
Mammalian Gene Collection (MGC). Human 
Tmprss3 is a kind gift of Bernard Rossier 
(University of Lausanne). Membrane-bound serine 
proteases were selected based on their gastro-
intestinal expression, as reported in the literature 
(see results). The other members of the 
membrane-bound serine proteases family were not 
tested because of a reported expression that 
appears to be restricted to specific tissues, even 
though we cannot rule out that they might display 
any gastro-intestinal expression. All cDNAs were 
subcloned into the pSD(BS)easy vector for 
expression in Xenopus laevis oocytes. A FLAG-
tag sequence was added to Spint2 using a single 
BstEII restriction site located in the sequence 
encoding the region between both Kunitz domains 
of Spint2. PCR amplification was performed to 
add a tag of 8 histidines in the N-terminal part of 
Tmprss13. Point mutations in Spint2 cDNA were 
introduced by site–directed mutagenesis 
(Stratagene's QuickChange ) to generate Spint2 
mutants Y68C, Y163C, Y68S, Y163S and double 
mutant Y68C/Y163C.  
Stage V and VI healthy oocytes were 
isolated from ovarian tissue of Xenopus laevis and 
pressure–injected with 100nl of cRNA solution. 
For the functional assay, oocytes were injected 
with α, β and γ subunits of rat ENaC cRNAs 
(0,11ng of each subunit per oocyte) and with 
cRNAs of membrane-bound serine proteases and 
Serine protease inhibition by Spint2 in Xenopus oocytes 
3 
 
Spint2 wild-type or mutants as indicated in the 
results section. In this heterologous expression 
system, we found that the effects of the serine 
proteases on ENaC as well as the effects of Spint2 
on the serine proteases were dose-dependent. To 
minimize artifacts due to overexpression, we 
determined for each serine protease the amount of 
cRNA to be injected for a robust proteolytic 
activation of ENaC similar to the activation by 
trypsin (Fig.2B). We also determined the minimal 
amount of Spint2 cRNA necessary to completely 
inhibit the effect of the protease (Fig.2C). For the 
biochemical assay, oocytes were injected with 
cRNAs of His-tagged hTmprss13 (1.7ng) and 
FLAG-tagged hSpint2 (8.3ng). This ratio 
Tmprss13/Spint2 is similar to the ratio used in the 
functional assay. Oocytes were kept at 19° C in a 
low Na
+
 (for the functional experiments with 
ENaC) modified Barth solution (MBS) containing 
(in mM): 10 NaCl, 0.82 MgSO4, 0.41 CaCl2, 0.33 
Ca(NO3)2, 80 N-methyl-D-glucamine (NMDG), 2 
KCl and 5 HEPES or a normal Na
+
 (for the 
biochemical experiments done without ENaC) 
modified Barth solution (MBS) containing (in 
mM): 85 NaCl, 1 KCl, 2.4 NaHCO3, 0.82 MgSO4, 
0.41 CaCl2, 0.33 Ca(NO3)2, and 10 HEPES, 4.08 
NaOH. 
Electrophysiology - Electrophysiological 
measurements were made 12 hours after injection 
except for experiments with Tmprss3 and 
Tmprss15 which were performed 30 hours after 
injection. ENaC-mediated Na
+
 currents were 
measured in oocytes using the standard
 
two-
electrodes voltage clamp technique using a Dagan 
TEV voltage
 
clamp amplifier (Dagan, 
Minneapolis, MN), the Digidata 1322
 
digitizer, 
and the PClamp 9 data-acquisition and analysis 
package
 
(Axon Instruments, Molecular Devices, 
Sunnyvale, CA).
 
The two electrodes contained 1M 
KCl solution. All electrophysiological 
measurements were performed at room 
temperature (22 °C) in a perfusion solution 
containing (in
 
mM) 120 NaCl, 2.5 KCl, 1.8 CaCl2-
2H2O, and 10 HEPES-H
+
. The holding potential 
inside the oocytes was -100 mV.  
Data analysis - The epithelial sodium 
channel (ENaC) is highly sensitive to amiloride 
with an IC50 of 0.1 μM. ENaC activity was 
measured by the amiloride-sensitive Na
+
 current 
(INa
+
), defined as the difference between Na
+
 
current obtained in the presence (10 μM) and in 
the absence of amiloride. ENaC activity is 
increased by a variety of serine proteases as well 
as by trypsin (13,29,30), making ENaC an ideal 
tool for measuring serine protease activity. We 
used trypsin (Sigma-Aldrich Chemie) 5 µg/ml in 
the perfusion solution for 2-3 minutes to define a 
maximal proteolytic stimulation on ENaC activity 
as measured by the increase in INa
+
. In each 
condition, sensitivity of ENaC to trypsin (defined 
as the relative trypsin-mediated increase in INa
+
) 
can vary depending on whether proteases with or 
without Spint2 wt/mutants are co-expressed with 
ENaC and was quantified by dividing, for each 
oocyte, INa
+
 after trypsin treatment by INa
+
 before 
trypsin treatment. A relative trypsin-mediated 
increase in INa
+
 close to one reflects resistance of 
ENaC to trypsin because of the presence of an 
activating co-expressed protease. When Spint2 
fully inhibits the co-expressed protease, relative 
trypsin-mediated increase in INa
+
 has a value (>1) 
similar to control oocytes injected with ENaC 
alone. 
Biochemistry – The Spint2 – Tmprss13 
complex was isolated by affinity purification on 
nickel-beads. 24 hours after injection, 60 
oocytes/condition were lysed in lysis buffer (1 % 
triton X-100, 100 mM NaCl, 20 mM Tris-HCl pH 
7.5, 10mM Imidazole, 1 mM PMSF and 10 μg/ml 
of each Leupeptin, Pepstatin and Aprotinin). 
Lysates were then vortexed and centrifuged for 10 
minutes at 12’000rpm. The intermediate phase 
was withdrawn and a sample of each lysate was 
kept as a control of “total lysate fraction”. The rest 
of the lysate was incubated overnight with 50μl of 
nickel-beads (Ni-NTA Agarose, Quiagen). Elution 
was performed with 50μl of 2x SDS-PAGE 
sample buffer (containing 25mM DTT and 50mM 
EDTA). All samples were heated at 95°C for 10 
minutes before loading on the SDS-PAGE (5-
15%). Blots were probed with the anti-FLAG 
mouse antibody (Sigma) at a 1:500 dilution and 
with the anti-His rabbit antibody (Rockland) at a 
1:1000 dilution. The latter antibody is conjugated 
to an infrared dye IRdye800 (green color) that 
allows protein detection using the Li-Cor® 
technology. The anti-FLAG antibody was detected 
with an anti-mouse IRdye680 (red color) antibody. 
Co-purification of Spint2 with Tmprss13 was 
quantified by densitometric analysis normalized 
with Spint2 signal in total lysates and Tmprss13 
signal in total lysates and nickel-beads fraction. 
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Quantitative PCR analysis – Tissues were 
removed from three C57/B6 8 week-old mice. 
Duodenal, jejunal, ileal, caecal and colonic 
(proximal and distal) tissues were longitudinally 
opened and mucosal side was scrapped with a 
razorblade to obtain a fraction enriched in mucosal 
cells. Total RNA was extracted from mouse 
tissues using the RNeasy kit from Qiagen 
according to the manufacturer's protocol. 500g 
RNA (RNA from the 3 mice was pooled together) 
was reverse transcribed into cDNA using the 
PrimeScript RTreagent kit (TaKaRa). RNA was 
treated with DNAse I (Promega) to remove any 
possible traces of genomic DNA before the cDNA 
synthesis. The primers used in this study are 
reported in the supplementary table S1. qRT-PCR 
experiments were carried out on an ABI PRISM 
7500 equipment (Applied Biosystems). PCR was 
performed in 96-well plates (Applied Biosystems) 
in 20-μl reactions that contained 10 μl of 
FastSYBR Green Master Mix (Applied 
Biosystems), 125 nM of each primer and 4 μl of 
cDNA (diluted 30 times). For each gene, standard 
curves were obtained using tissues with the 
highest abundance and 1/1, 1/5, 1/25, 1/625 and 
1/3125 dilutions. The analysis of the slope of the 
standard curves showed a PCR efficiency between 
1.70 and 2. These values were used for absolute 
quantification. Relative quantification using 
reference genes such as actin or GAPDH was not 
used because detection levels of those genes 
varied up to a difference of 4 cycles between 
different mouse tissues. Each gene was assessed in 
duplicates in two independent experiments. 
Statistical analysis – All data are 
represented as means ± SEM. Statistical 
significance was determined with one-way/two 
way ANOVA followed by Dunnett or Tukey’s 
multiple comparison test and indicated in the 
legend of the figures. 
 
RESULTS 
mRNA expression of Spint2 and candidate 
membrane-bound serine protease in gastro-
intestinal tissues – We selected, as putative 
partners of Spint2, 9 membrane-bound serine 
proteases reported in the literature to be expressed 
in gastro-intestinal tissues namely CAP1, 
CAP2/Tmprss4, CAP3, Tmprss1/hepsin, Tmprss2, 
Tmprss3, Tmprss11a/ECRG1, Tmprss13 and 
Tmprss15/enterokinase (11,21,31-43). Detailed 
mRNA expression levels of Spint2 and these 
candidate proteases were assessed in mouse GI 
tissues, and compared to heart, lung and kidney. 
Since Spint2 is known to be mainly expressed in 
epithelial cells (21), we took intestinal tissue 
fractions enriched in mucosal cells. Fig.1 shows 
that Spint2 mRNA was found along the entire GI 
tract, but its expression increased in the distal part. 
As already reported, the short isoform of Spint2 
that lacks the first Kunitz domain appeared more 
abundant than the long (full-length) isoform in 
mouse (opposite findings are known in human) 
(44). CAP3 had an expression pattern similar to 
Spint2. CAP1, CAP2 and Tmprss2 could be easily 
detected in the small and large intestines with a 
higher abundance in the distal part. The other 
candidates showed a more restricted expression 
along the GI tract (in oesophagus for Tmprss11a, 
in oesophagus and colon for Tmprss13, in 
duodenum and jejunum for Tmprss15). Although 
Tmprss1 was very abundant in the kidney, low 
expression levels could be observed in the colon. 
Finally, Tmprss3 mRNA was detected at very low 
levels in all tissues, with a higher expression in 
stomach and jejunum. 
Functional assay in Xenopus laevis oocytes 
– In order to test whether Spint2 can inhibit these 
candidate serine proteases in a cellular assay, we 
injected Xenopus laevis oocytes with Spint2 and 
protease cRNAs. The activity of the co-injected 
protease was monitored using the epithelial 
sodium channel ENaC because of its sensitivity to 
stimulation by serine proteases (29). ENaC is a 
Na
+
 selective ion channel that is constitutively 
open at the cell surface, and can be selectively 
inhibited with submicromolar concentrations of 
amiloride. Proteolytic activation of ENaC was 
used as the readout for the activity of the 
expressed serine protease; the ENaC activation by 
the serine protease was compared with maximal 
ENaC activity obtained in the presence of trypsin. 
Typical tracings of ENaC-mediated currents (INa
+
) 
in the presence or absence of trypsin are shown in 
Fig.2A. In an oocyte injected with ENaC alone, 
the amiloride-sensitive current dramatically 
increased in the presence of trypsin (left tracing); 
co-injection of ENaC with Tmprss13 increased 
INa
+
 to the level of INa
+ 
recorded in the presence of 
trypsin (middle tracing); finally, co-injection of 
ENaC, Tmprss13 and Spint2 completely abolished 
the effect of Tmprss13 on INa
+
 (right tracing). In 
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other words, an active serine protease such as 
Tmprss13 nearly abolishes the trypsin effect on 
ENaC-mediated current, and Spint2, as inhibitor 
of Tmprss13, allows the recovery of the trypsin 
effect on ENaC. 
We noticed an additional effect when 
Tmprss13 is overexpressed by injecting increasing 
amounts of cRNA; under these conditions ENaC-
mediated INa
+
 decreased together with the 
suppression of the trypsin effect on ENaC (Fig.2B, 
left panel). This effect was interpreted as a non 
specific proteolytic effect (toxic effect) of the 
protease that kills the channel activity. In the case 
of Tmprss15, a robust activation of ENaC was 
obtained at higher doses of cRNA encoding the 
protease (Fig.2B, right panel). Due to the 
complexity of the dose-related effect of the serine 
proteases on ENaC activity, we systematically 
determined for each serine protease the 
appropriate amount of protease cRNA needed for 
a stimulation comparable to that of trypsin, as 
shown in Fig.2B for Tmprss13 (left) and 
Tmprss15 (right): co-injection of ENaC with 
0.5ng of Tmprss13 cRNA increased INa
+
 to the 
level obtained with trypsin but higher amounts 
paradoxically decreased INa
+
, whereas robust 
activation of ENaC could be obtained only with 
6ng of Tmprss15. All candidate serine proteases 
tested were functional on ENaC as shown by the 
robust increase in INa
+
 (Table 1 and Fig.3). This 
effect varied from a 2 to 5 fold increase in ENaC 
activity depending on the protease and on the 
batch of oocytes used for the experiment.  
Inhibition of serine proteases by Spint2 - 
We then evaluated the ability of Spint2 to inhibit 
the different serine proteases by determining the 
minimal amount of Spint2 cRNA needed to 
completely reverse the effect of each protease 
tested on the magnitude of ENaC current and the 
effect of trypsin. The inhibition of Tmprss13 and 
15 by Spint2 is given as examples. Experiments in 
Fig.2C show that 1ng and 1.5ng of Spint2 cRNA 
were sufficient to obtain a full inhibition of 
Tmprss13 and Tmprss15 respectively as seen by a 
return of INa
+
 to baseline and the recovery of the 
effect of trypsin. Similar preliminary experiments 
were performed with each protease. We also 
verified that Spint2 per se did not directly alter 
INa
+
, neither the effect of trypsin on ENaC 
(Fig.2D). For all proteases tested in figure 3, the 
co-expression of Spint2 with the serine protease 
reversed the stimulating effect of the protease on 
INa
+
 and restored the trypsin effect, indicating that 
Spint2 is a powerful inhibitor of membrane-bound 
serine proteases (Fig.3).  
Effect of the congenital sodium diarrhea-
associated mutation of Spint2 – We tested the 
effect of the Spint2 Y163C mutation in the 2
nd
 
Kunitz domain associated with the congenital 
sodium diarrhea, together with its homologous 
Y68C mutation in the 1
st
 Kunitz domain (this 
mutation has not been linked to the disease). 
These mutations were tested on the capacity of 
Spint2 to inhibit membrane-bound serine 
proteases. Although the wild type form of Spint2 
efficiently inhibited all membrane-bound serine 
proteases tested in this study, differential effects of 
the Spint2 Y68C and Y163C mutants were 
observed on serine protease activity. For instance, 
the Y68C or Y163C did not change the ability 
Spint2 to inhibit Tmprss15, whereas these same 
mutations resulted in a loss of function Spint2 on 
Tmprss13. In figure 3B, in order to compensate 
for oocyte variability in ENaC expression and 
protease activation, we inferred the inhibitory 
effect of Spint2 on the serine protease by 
calculating for each oocyte the relative trypsin-
mediated increase in INa
+
 (ratio INa
+
 after trypsin 
treatment/INa
+
 before trypsin treatment).When 
equal to one, this ratio indicates resistance of 
ENaC to trypsin due to the full effect of the serine 
protease, whereas a ratio ≥ 3 (value similar to that 
obtained for oocytes injected with ENaC alone) 
indicates a sensitivity of ENaC to trypsin and a 
lack of effect of the serine protease due to 
inhibition by Spint2. Fig.3B shows that both 
Spint2 mutants were still able to inhibit Tmprss15, 
but showed a strong reduction in inhibitory 
activity on CAP1 and Tmprss13 proteases. Spint2 
Y163C inhibited Tmprss2, Tmprss11a and 
Tmprss1, whereas Spint2 Y68C lost its inhibitory 
activity on these specific proteases. The opposite 
pattern was seen with Tmprss3 and CAP3, namely 
Spint2 Y68C being fully functional and Spint2 
Y163C showing a partial loss of its inhibitory 
activity (although not statistically significant). 
Finally a partial loss of function was seen in both 
mutants when co-injected with CAP2. Briefly, a 
strong loss of function of the congenital sodium 
diarrhea mutant Spint2 Y163C was seen only with 
CAP1 and Tmprss13 proteases. These latter 
proteases appear thus as interesting potential 
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partners of Spint2 in the regulation of Na
+
 
transport in the intestine. 
Effect of the double mutant Spint2 
Y68C/Y163C – Four candidate proteases 
(Tmprss15, Tmprss3, CAP2 and CAP3) were still, 
at least partially, blocked by either Spint2 Y68C 
or Y163C. Therefore, we assessed the effect of the 
double mutation Spint2 Y68C/Y163C on these 
proteases. As shown in Fig.4, the double mutation 
in both Kunitz domains of Spint2 decreased its 
inhibitory activity on Tmprss15, Tmprss3, CAP2 
and CAP3. Values of relative-trypsin-mediated 
increase in INa
+
 shown in Fig.4B indicate that the 
Y68C/Y163C double mutation results in an almost 
complete loss of function of Spint2 consistent with 
an additive effect of these two homologous 
mutations in either Kunitz domains. 
Effect of the serine mutants Spint2 Y68S and 
Spint2 Y163S – To further understand the 
molecular basis of Spint2 Y163C loss of function 
mutation for Tmprss13 inhibition, we asked 
whether it was due to the loss of the tyrosine, 
which is highly conserved among Spint2 orthologs 
from different species, or to the addition of a 
sulfhydryl group (via the substitution of the 
tyrosine by a cysteine residue). We mutated this 
tyrosine into a serine and assessed the inhibitory 
effect of Spint2 Y68S and Spint2 Y163S on 
Tmprss13. In contrast to the cysteine mutants, the 
serine mutants Spint2 Y68S and Spint2 Y163S 
retained their activity and were able to fully inhibit 
the effect of Tmprss13 on ENaC (Fig.5), 
suggesting that the presence of a new cysteine 
rather than the loss of the conserved tyrosine 
abolishes the inhibitory activity of Spint2 on 
Tmprss13. 
Biochemical interaction between Spint2 and 
Tmprss13 – To ascertain that Spint2 WT and 
mutants are equally expressed in the oocytes and 
to investigate the binding interaction between 
Tmprss13 and the Y68C and Y163C Spint2 
mutants, we affinity purified Tmprss13 onto 
nickel beads using a Histidine-tag on the N-
terminal part of Tmprss13 and assessed the co-
purification of a FLAG-tagged construct of 
Spint2. The presence of a His-tag in Tmprss13 and 
a FLAG-tag in Spint2 did not alter their function 
(Fig.6A). When oocytes were injected with 
Tmprss13 alone (Fig.6B, lane 2), we detected a 
specific signal with a very low molecular weight 
that probably represents a fully processed cleaved 
form of Tmprss13. Fig.6B shows that Spint2WT 
could be co-purified with Tmprss13 as shown by a 
specific 35kDa band corresponding to Spint2 (lane 
3).The absence of a non-specific binding of Spint2 
to the nickel-beads was verified (Fig.6C). 
Surprisingly, all mutants, including the non-
functional mutants Y68C and Y163C, are still able 
to interact with Tmprss13, (lanes 3 to 7). The 
intensity of the specific 35kDa band 
corresponding to Spint2 WT and mutants was 
quantified and showed even an increase for Spint2 
Y163C and Y163S (lanes 5 and 7) (Fig.6B right 
panel). Furthermore, when Spint2 WT or mutants 
were co-injected with Tmprss13 (lanes 3 to 7), a 
specific 70kDa band was detected corresponding 
to the full-length form of Tmprss13. An 
intermediary cleaved form of around 45kDa was 
also present in oocytes co-injected with non-
functional mutants of Spint2 (Y68C and Y163C in 
lanes 4 and 5). These experiments suggest that the 
Tmprss13 injected alone is rapidly processed, and 
that co-injection with Spint2 WT or mutants 
stabilizes its full-length form. The Y68C and 
Y163C mutations do not disrupt the formation of a 
Spint2-Tmprss13 complex indicating that the loss 
of function of Spint2 mutants is not due to 
changes in their ability to bind the protease. These 
inactive Spint2 mutants seem to increase the 
abundance of Tmprss13 forms of intermediate 
molecular weight that might include the active 
form of Tmprss13 (24). 
 
DISCUSSION 
In this study, we used a cellular assay in 
Xenopus laevis oocytes to assess the functional 
interactions between Spint2 wild type or mutants 
and different membrane-bound serine proteases 
expressed in the gastro-intestinal tract.  
ENaC and serine-proteases – ENaC, a Na+ 
selective ion channel that mediates transepithelial 
Na
+
 transport in renal distal tubules, distal colon 
and lung, was used in this assay as a reporter gene 
to monitor serine protease activity (45,46). ENaC 
has already been shown to be activated by CAP1, 
CAP2, CAP3 and Tmprss3 by cleavage of the α 
and the γ subunits of the channel complex 
(13,33,39). Here, we report the activation of ENaC 
by Tmprss1, Tmprss11a, Tmprss13 and Tmprss15. 
All proteases tested activate ENaC by two- to 
fivefold; this range is similar to the four- to 
sevenfold effect of CAP1, CAP2 and CAP3 
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reported in the literature (29). The proteases 
presented in this study increase the list of serine 
proteases that activate ENaC and provide further 
evidence that ENaC is a relatively unspecific 
target for a large number of membrane-bound 
serine-proteases. We also observed an activating 
effect of Tmprss2 in contrary to a previous study 
showing a decrease in ENaC activity and protein 
levels when co-expressed with Tmprss2 (47). We 
observed that the effects of serine proteases on 
ENaC are dose-dependent, and as for Tmprss13 
(see Fig.2) we noticed that an overexpression or 
activity of the protease can decrease ENaC-
mediated currents. The decrease in ENaC-
mediated currents might reflect an extensive 
proteolytic effect of the protease on ENaC channel 
complex leading to a loss of function.  
The specificity and the physiological 
relevance of the modulation of ENaC activity by 
serine proteases is not yet firmly established, but 
in vivo ENaC activity at the cell surface can be 
correlated with the proteolytic cleavage of its 
subunits (48). Considering the ENaC sensitivity to 
a large number of serine proteases, it is likely that 
the protease-dependent regulation of ENaC is 
tissue-specific. The expression of Tmprss15 (also 
called enterokinase/enteropeptidase) is restricted 
to the small intestine where ENaC is not present. 
An interaction ENaC-Tmprss15 is therefore of 
little physiological relevance. Independently of the 
relevance of this regulation, we would like to 
emphasize that ENaC was used in this study 
essentially as a reporter gene for serine protease 
activity, without any consideration of its 
implication in the pathogenesis of the congenital 
sodium diarrhea.  
Spint2 and congenital sodium diarrhea - 
Spint2 efficiently inhibits all candidate proteases 
tested in our assay. The inhibition of Tmprss1, 
CAP1, CAP3 and Tmprss13 has already been 
described (21-24) but experiments were performed 
in cell-free assays. Here we confirmed this 
inhibition in a cellular assay. In addition, we also 
showed that Spint2 inhibits CAP2, Tmprss2, 
Tmprss3, Tmprss11a and Tmprss15.  
In spite of the broad inhibitory capacity of 
Spint2, the congenital sodium diarrhea mutant 
Y163C (2
nd
 Kunitz domain) and its homologous 
mutant Y68C (1
st
 Kunitz domain) have different 
effects depending on the target protease. However, 
both mutations strongly reduced the inhibitory 
activity of Spint2 only towards CAP1 and 
Tmprss13. Thus, these two proteases appear as 
interesting targets of Spint2 in regulating Na
+
 
transport in the intestine. Na-H-exchange has been 
shown to be defective in jejunal biopsies of 
patients affected by congenital sodium diarrhea 
and mice deficient for the Na-H-exchanger NHE3 
display a phenotype resembling to the disease, 
suggesting that NHE3 plays an important role in 
the pathogenesis of congenital sodium diarrhea 
(49-51). CAP1 shows significant mRNA levels in 
small intestine and colon like Spint2 and NHE3, 
and recent genetic evidence shows that disruption 
of the CAP1 gene rescues the embryonic lethality 
of Spint2 deficient mice (27). Regulation of NHE3 
by membrane-bound serine proteases such as 
CAP1 has never been tested. Only the serine 
protease dipeptidyl peptidase IV (DPPIV, a 
membrane-bound serine protease unrelated to the 
family tested in this study) has been proposed so 
far as regulator of NHE3 in rat renal proximal 
tubule (52). However, DPPIV inhibition has been 
shown to downregulate NHE3 activity and loss of 
function mutations in Spint2 would thus be 
expected to result in an increase in Na
+
-absorption 
mediated by NHE3. CAP1 could also be a target 
of Spint2 during embryonic development since 
children with the syndromic form of congenital 
sodium diarrhea also have dysmorphic features 
(28). It should be mentioned that CAP1 has been 
proposed to be an activator of ENaC in vivo (14) 
and notably in colon (53). However, it is unlikely 
that ENaC, used in this study as a reporter gene, is 
the target of CAP1 in the pathogenesis of 
congenital sodium diarrhea. If we assume a loss of 
function of Spint2 in congenital sodium diarrhea, 
unopposed CAP1 would lead to an activation of 
ENaC and thus an increase in sodium 
(re)absorption in colon. On the other hand, too 
strong expression or activity of the serine protease 
as seen with Tmprss13 for instance (See Fig.2B) 
might lead to a toxic effect on ENaC or other 
transporter resulting in decrease in Na
+
 transport. 
Thus, unopposed CAP1 activity in the distal colon 
would result in decreased ENaC expression and 
Na
+
 absorption.  
Tmprss13, whose physiological role is 
totally unknown, is also an interesting candidate 
since it is no longer inhibited by Spint2 mutants 
Y68C and Y163C. Furthermore, Tmprss13 is 
significantly expressed at the mRNA level in the 
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distal colon. Although, congenital sodium diarrhea 
is likely due to Na-H-exchange defect in the small 
intestine and/or proximal colon, involvement of 
ENaC in the distal colon via toxic proteolysis, as 
described above, is not excluded.  
Other proteases were only partially 
inhibited by Spint2 Y163C mutant. They cannot 
be totally excluded as targets of Spint2 in the 
congenital sodium diarrhea and remain potential 
targets of Spint2 in other tissues since Spint2 has a 
very broad tissue distribution. The Spint2 
expression pattern is for instance particularly 
similar to CAP3 (as shown in this study and in 
(21).  
The functional target(s) of Spint2 and the 
pathophysiological basis for the intestinal loss of 
Na
+
 ions in congenital sodium diarrhea remain to 
be identified. Work done in Spint2 knockout 
mouse models would be of great interest in order 
to decipher the physiological and 
pathophysiological role of Spint2.  
Interactions of Spint2 with Tmprss13 - 
Spint2 mutants Y68C and Y163C, which lose their 
inhibitory capacity on Tmprss13, provide an 
opportunity to study the role of the tyrosines at 
position 68 and 163 that are well conserved in 
Spint2 protein among several species and also in 
Kunitz domains of Spint1 and other Kunitz 
inhibitors (28). Our biochemical data support that 
substitutions of the tyrosine in the first and second 
Kunitz domains by cysteine or serine residues do 
not disrupt the binding interaction between Spint2 
and Tmprss13; it seems rather that substitution of 
tyrosine 163, but not tyrosine 68, stabilizes the 
Spint2-Tmprss13 complex as shown by a higher 
abundance of Spint2 co-purified with Tmprss13 
(Fig.6B). The loss of Spint2 activity observed for 
the Y68C and Y163C mutants, but not for the 
corresponding serine substitutions, supports the 
notion that the presence of a sulfhydryl side chain 
at position 68 and 163 is responsible for this 
effect. Kunitz domains contain 60 amino acids 
including 6 conserved cysteines involved in the 
formation of specific disulfide bonds (54). The 
cysteine at positions Y163 and Y68 may disrupt 
the canonical structure of the Kunitz domains by 
changing the pattern of the three disulfide bonds 
resulting in a Spint2 loss of function.  
Kunitz inhibitors belong to the so-called 
canonical inhibitors, which block serine proteases 
via an interaction where the Kunitz domain binds 
to the catalytic site of the protease in a substrate-
like manner (55). Our results indicate that the loss 
of a serine protease inhibition by Spint2 mutations 
can occur despite a conserved binding interaction 
between inhibitor and its substrate. This suggests 
two separate functional regions in Spint2: one 
involved in the binding to the target protease, the 
other responsible for the inhibition of the catalytic 
side of the protease. According to this view, the 
loss of the conserved tyrosines 68 and 163 of 
Spint2 may alter the binding interaction with the 
substrate (see the functional serine mutant Y163S 
in the case of Tmprss13). In addition to this effect, 
the substitution of these tyrosines into cysteines 
specifically alters the inhibitory function of Spint2 
depending on the target protease. Interestingly, the 
tyrosines 68 and 163 in each Kunitz domains are 
very close to the putative secondary binding 
segment of the Kunitz domain, which is distinct 
from the reactive site that binds to the catalytic 
site of the protease (21,56).  
In vivo substrates of serine proteases and 
targets of serine protease inhibitors are known 
only in a few cases. Thus, our understanding on 
the detailed mechanisms of serine protease 
inhibition is scarce, and is based on experiments 
done with less or even non-specific proteases or 
substrates. Here, we used ENaC to monitor 
protease activity. CAP2 and CAP3, but not CAP1, 
require an active catalytic site to activate ENaC 
(57). Therefore, we cannot exclude that Tmprss13 
activates ENaC via interaction with another 
protease or through its catalytic site. Similarly, we 
cannot be sure whether Spint2 prevents the effect 
of Tmprss13 on ENaC by inhibiting the catalytic 
site of Tmprss13 or not. In spite of this issue, the 
differential functional effects of the cysteine and 
the serine mutations, which show a similar binding 
pattern to Tmprss13, strongly suggest a loss of the 
inhibitory function of Spint2 on the catalytic 
activity of Tmprss13; this of Spint2 function is 
likely due to the introduction of the sulfhydryl 
group and alterations in binding due to loss of the 
conserved tyrosine. It should also be noted that 
membrane-bound serine proteases have accessory 
domains potentially involved in protein-protein 
interaction that makes the mechanism of 
interaction with their inhibitor difficult to interpret 
(58,59).  
The molecular basis of the inhibitory 
activity of Spint2 on serine proteases appears even 
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more complex when we take into account that 
Spint2 has two inhibitory domains that may work 
synergistically. Our data suggest that the 2 Kunitz 
domains are differentially involved in the 
inhibition of specific serine proteases. For 
instance, the Y68C mutation specifically disrupts 
the inhibitory activity of Spint2 on Tmprss1, 
Tmprss2 and Tmprss11a in contrast to the Y163C 
mutation that abolishes the function of Spint2 on 
CAP1 and Tmprss13. In other cases, the 
contribution of each Kunitz domain appears 
synergistic. How each domain contributes to the 
binding and to the inhibition respectively remains 
poorly known.  
Proteomics approaches are of great interest 
for the identification of physiological partners of 
serine protease inhibitors, that could then be 
studied in a functional assay as ours. In addition, 
cystallographic studies performed with intact 
proteins might provide new insights into the 
mechanisms that regulate interactions between 
membrane-bound serine proteases and their 
inhibitors 
In summary, we developed a cellular assay 
in Xenopus oocytes to study functional and 
biochemical interactions between membrane-
bound serine proteases and inhibitors using ENaC 
as a reporter gene. Spint2, whose mutations have 
been linked to congenital sodium diarrhea, appears 
to be a potent inhibitor. Being no longer blocked 
by the Y68C and Y163C Spint2 mutants, CAP1 
and Tmprss13 are interesting candidate partners of 
Spint2 for maintaining Na
+
 homeostasis in the 
intestine. Moreover, our assay provides the 
possibility to study in further details the complex 
interaction between membrane-bound serine 
proteases and inhibitors in a cellular context and 
with native proteins. 
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FIGURE LEGENDS 
 
FIGURE 1. Tissue distribution of mRNA expression of Spint2 and membrane-bound serine 
proteases. Quantitative RT-PCRs were performed on selected organs from three wild-type adult mice. 
From stomach to distal colon, tissues were scrapped to get fractions enriched in mucosal cells. Each gene 
was assessed in duplicates in two independent experiments. Results are expressed as arbitrary units (A.U.) 
based on standard dilution curves (see Experimental Procedures). 
 
FIGURE 2: Validation of the functional assay using ENaC as a reporter gene. A, Representative 
recordings of amiloride-sensitive current (INa
+
) in the presence (filled bars) or absence of trypsin (5μg/ml), 
in Xenopus oocytes injected with 0.11ng/subunit rENaC alone (left panel), with rENaC and 0.25ng 
hTmprss13 (middle panel) and with rENaC, hTmprss13 and 1.5ng hSpint2 cRNA (right panel). 10 μM 
amiloride was used to block the ENaC-mediated current. B, Effects of increasing the amounts of injected 
Tmprss13 and Tmprss15 cRNAs on INa
+
. INa
+
 was measured in oocytes injected with rat ENaC 
with/without of Tmprss13 or Tmprss15 as indicated. INa
+ 
was measured without (black bars) or with 
trypsin (5μg/ml) perfused extracellularly (white bars) as a positive control for ENaC activation. C, Effects 
of increasing the amounts of injected Spint2 cRNA to prevent the Tmprss13- or Tmprss15-mediated 
increase in INa
+ 
(left and right panels, respectively). D, Effect of Spint2 on INa
+
. INa
+
 was measured 12, 24 
and 30 hours after injection (left, middle and right panels, respectively) performed in three independent 
experiments. n= 6 -9 measured oocytes per condition from 2 different batches for each experiment. Data 
are means ± SEM; *, p<0.05 / **, p<0.01 compared to rENaC alone or rENaC + protease (as indicated) 
after two-way repeated measure ANOVA followed by Dunnett’s multiple comparisons test. 
 
FIGURE 3. Functional analysis of interactions between Spint2 (wt and mutants) and membrane-
bound serine proteases. A, ENaC-mediated sodium currents (INa
+
) were measured in Xenopus oocytes 
injected with rat ENaC with/without candidate serine protease and Spint2 (wild-type or mutants Y68C and 
Y163C) as indicated. INa
+ 
was measured without (black bars) or with trypsin (5μg/ml) perfused 
extracellularly (white bars) as a positive control for ENaC activation. n≥15 measured oocytes per 
condition from at least 2 different animals. Each protease was tested in at least two independent 
experiments. Data are means ± SEM. B, Relative trypsin-mediated increase in INa
+
 was calculated by 
dividing, for each oocyte from experiments of panel A, INa
+ 
after treatment with trypsin by INa
+ 
before 
treatment with trypsin. Data are means ± SEM. */#/°, p<0.05, **/##/°°, p<0.01, ***/###/°°°, p<0.001, 
compared to ENaC alone, {ENaC + protease} or {ENaC + protease + Spint2 WT} respectively after One-
way ANOVA followed by Tukey’s multiple comparisons test. 
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FIGURE 4. Effect of the double mutant Spint2 Y68C/Y163C on Tmprss15, Tmprss2, CAP2 and 
CAP3 proteases. A, ENaC-mediated sodium currents (INa
+
), were measured in Xenopus oocytes injected 
with rat ENaC with or without serine protease and Spint2 (wild-type or double mutant Y68C/Y163C) as 
indicated. INa
+ 
was measured without (black bars) and with trypsin (5μg/ml) perfused extracellularly 
(white bars) as a positive control for ENaC activation. n≥11 measured oocytes from 4 different animals. 
Each protease was tested in two independent experiments. Data are means ± SEM. B, Relative trypsin-
mediated increase in INa
+
 was calculated by dividing, for each oocyte from experiments of panel A, INa
+ 
after treatment with trypsin by INa
+ 
before treatment with trypsin. Data are means ± SEM. **/##/°°, 
p<0.01, ***/###/°°°, p<0.001, compared to ENaC alone, {ENaC + protease} or {ENaC + protease + 
Spint2 WT} respectively after One-way ANOVA followed by Tukey’s multiple comparisons test. 
 
FIGURE 5. Effect of Spint2 Y68S and Y163S mutation on Tmprss13 activity. A, ENaC-mediated 
sodium currents (INa
+
), were measured in Xenopus oocytes injected with rat ENaC, Tmprss13 and Spint2 
(wild-type or mutant). INa
+ 
was measured without (black bars) and with trypsin (5μg/ml) perfused 
extracellularly (white bars) as a positive control for ENaC activation. n≥14 measured oocytes from 4 
different batches performed in two independent experiments. Data are means ± SEM. B, Relative trypsin-
mediated increase in INa
+
 was calculated by dividing, for each oocyte from experiments of panel A, INa
+ 
after treatment with trypsin by INa
+ 
before treatment with trpysin. Data are means ± SEM. ***, p<0.001, 
compared to ENaC alone, after One-way ANOVA followed by Tukey’s multiple comparisons test. 
 
FIGURE 6. Biochemical interaction between Spint2 and Tmprss13. A, Left panel: typical western blot 
performed using Xenopus oocytes coexpressing tagged His-Tmprss13 and FLAG-Spint2 as indicated. Cell 
lysates are shown in the lower part and the elution fraction from the Nickel beads in the upper part. 
Membranes were blotted with anti-FLAG (red) and anti-His (green) antibodies. Right panel: quantification 
of the 35kDa band of Spint2 wild-type and mutants co-purified with Tmprss3. n=4 experiments, *,p<0.05; 
**,p<0.01 compared to Spint2 WT after One-way ANOVA, followed by Dunnett’s multiple comparison 
test. B, Control western blot. Xenopus oocytes were injected with FLAG-Spint2 WT with or without 
Tmprss13 (without His-Tag). Cell lysate were loaded onto nickel-beads for purification. Membranes were 
blotted with Anti-FLAG (red) and anti-His (green) antibodies. C, Effect of a His-tag and a FLAG-tag on 
the function of Tmprss13 and Spint2 in Xenopus oocytes. ENaC-mediated sodium currents (INa
+
), were 
measured in Xenopus oocytes injected with rat ENaC, Tmprss13 (+/- HIS-tag=H8) and Spint2 (+/- FLAG-
tag=FLAG). INa
+ 
was measured without (black bars) and with trypsin (5μg/ml) perfused extracellularly 
(white bars) as a positive control for ENaC activation. n=8 measured oocytes from 2 different batches. 
Data are means ± SEM. 
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Table 1 
 
 
protease (ng of cRNA) 
Fold increase in ENaC-mediated 
current  
  
hTmprss2 (5ng) 2.6 ± 0.2 (trypsin: 3.5 ± 0.3) 
hTmprss11a (0.25ng) 2.1 ± 0.2 (trypsin: 3.7 ± 0.3) 
hTmprss15 (6ng) 2.6 ± 0.3 (trypsin: 3.7 ± 0.3)  
hTmprss1 (0.05ng) 2.5 ± 0.3 (trypsin: 3.7 ± 0.4) 
hTmprss3 (2.5ng) 2.6 ± 0.3 (trypsin: 3.9 ± 0.3) 
hCAP3 (1.5ng) 2.6 ± 0.3 (trypsin: 3.1 ± 0.3) 
hCAP2 (2ng) 2.4 ± 0.4 (trypsin: 3 ± 0.2) 
hCAP1 (1ng) 3.6 ± 0.4 (trypsin: 3.8 ± 0.5) 
hTmprss13 (0.25ng) 5.2 ± 0.8 (trypsin: 4.4 ± 0.3 
 
Table 1. Increase in ENaC activity by membrane-bound serine proteases. Values were obtained from 
experiments in figure 3. Effect of trypsin is indicated in parentheses. Data are means ± SEM.   
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Figure 1 
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Figure 4 
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Figure 5 
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Figure 6 
 
Supplemental Data 
 
Functional analysis of a missense mutation in the serine protease inhibitor Spint2/HAI-2 associated 
with the congenital sodium diarrhea 
Faller N, Gautschi I and Schild L 
 
 
Supplemental Table S1 
 
Gene Forward Primer Reverse Primer 
   
Actb ggctcctagcaccatgaaga agctcagtaacagtccgcc 
Gapdh catggccttccgtgttccta cctgcttcaccaccttcttga 
Spint2 (long isoform) tttatggaggctgtgaaggca aagagtcggctccattcctg 
Spint2 (short isoform) tagacgtccacgagaacacca actcaggacagaagagtcgg 
Prss8 (=CAP1) agaaccgcacactatccagc ccaagtaccagatgccctcc 
Tmprss4 (=CAP2) cattcagaggggccagttgt cagggtggatctgtccttgg 
St14 (=CAP3) tccgaagctttgatgtcgct agcgtgacaaggaagacgtt 
Hpn (=Tmprss1) ctgacatggcgaaggaggg cttggtacagtggctcctgg 
Tmprss2 aaagcctggtatcccgtgtg ctggtctggtatcccttggc 
Tmprss3 tcagatgacaaggtgacggc cgaggacatgtttccaccca 
Tmprss11a ggcgaagaaccgtagggaaa gctcgcttgccacaatcttt 
Tmprss13 gatggagtggtggactgcaa tcgccagaagacccagagta 
Entk (=Tmprss15) gtggctgcaacaacttcagg ggcacatagcccagtgtctt 
 
SUPPLEMENTAL TABLE S1. Sequences of the primers used for the quantitative PCR experiments on 
mouse tissues. 
 
